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Abstract 
Chronic lymphocytic leukaemia is a mature B cell neoplasm which, despite 
recent focused research attention, remains incurable. It is the commonest 
leukaemia in the Western world and affects around 3,500 patients per annum in 
the UK and with the median age of those diagnosed at around 70 years it poses a 
specific challenge in disease management with standard chemoimmunotherapy 
being potentially too toxic for many patients. Treatments targeting the B cell 
receptor (BCR)-mediated signals including ibrutinib and idelalisib which target 
BTK and PI3K respectively, have pronounced clinical effects with improvement in 
progression-free and overall survival for significant patient numbers and are 
becoming more widely available. However, issues of disease resistance 
mutations and clonal evolution leave scope for novel targets of BCR and related 
signalling pathways. My hypothesis is that the serine/threonine protein kinase 
mechanistic target of rapamycin (mTOR) signalling which is located downstream 
of BTK and PI3K and downstream of BCR signalling offers a promising therapeutic 
target in CLL and may complement existing therapies that have proven clinical 
efficacy. Furthermore, dual mTORC1/2 inhibition offers a potential mechanism 
for overcoming the negative feedback loop which internally regulates mTOR 
kinase thus may offer potential for an improvement on the mTORC1 inhibitors 
already tested in clinical trial.  
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Project Aims 
 
1. To explore the molecular effects of mTOR inhibition on CLL cell migration in 
vitro.  
 
 
2. To investigate the functional effects of mTOR kinase inhibition on CLL cell 
migration. 
 
3. To examine the regulation of CLL cell migration by small GTPases and the 
effects of mTOR inhibition.  
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Chapter 1 Introduction  
1.1 CLL epidemiology 
 Disease incidence and prevalence 
Chronic lymphocytic leukaemia (1) is the most frequently occurring leukaemia in 
the Western world, with an incidence of 4-5/100000 each year in countries such 
as the UK, USA, Ireland and Australia and with around 3500 new cases in the UK 
alone (2, 3). Also, with reference to the UK’s data on CLL, the disease accounts 
for around 1% of all new cancer cases however less than 1% of all cancer deaths 
are attributable to CLL. Each year there are around 1000 deaths from the 
disease in the UK alone. CLL is a disease which shows a male predominance; 
there is a lifetime risk of the disease of 1/155 for men and around 1 in 260 for 
women (3). CLL rates have increased by 14% since the 1990s which represents an 
increase for male and female patients and for both genders together (4). As with 
other cancers, CLL incidence increases with age and this is most likely due to the 
associated acquisition of DNA damage and cumulative exposure to disease risk 
factors. It is of note that age-specific incidence increases markedly from age 45-
49 with the gender differences in incidence being most marked in this age 
category. Some families display multiple members with the CLL or with related 
lymphomas therefore CLL has been attributed as one of the most heritable 
cancers (5). There do not appear to be any significant differences in clinical 
features of so-called “familial CLL” from sporadic cases and the search is 
underway for specific predisposing germline mutations (6). It seems that the risk 
of solid tumours is not increased in association with CLL from the original cohort 
of study of familial CLL cases however it has since been concluded that CLL does 
increase the risk of a second malignancy and of skin tumours in particular (5, 7). 
 Demographic distribution of CLL patients 
CLL rates show a strong age correlation with 4 in 10 cases being diagnosed in 
people aged 75 or older. Of interest, 5-11% of affected individuals are <55 years 
of age and this patient population were historically believed to have a poorer 
prognosis although this was derived from early studies predating many advances 
in CLL care (2). It is now known that CLL in younger patients carries a 
preponderance of high-risk features which may explain the poorer outcome, 
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based on a large-scale study of biomarkers (8). Furthermore, CLL median 
survival is in the order of 5 to 10 years, dependent upon risk factor status, and 
comorbid disease incidence increases with age, such that younger patients are 
significantly more likely to die of their disease (4). Of recent new UK cases 
diagnosed in 2014, 63% were in male patients as opposed to 37% in female 
patients and the mortality rates do not differ significantly for gender. The 
mainstay of CLL patients are from countries such as the UK, USA, Ireland and 
Australia and the disease displays a predilection for people of Caucasian origin. 
There is a paucity of cases in people of Asian descent; rates are 5 to 10-fold 
lower than those of Caucasians, which suggests that the disease is a product of 
both genetic and environmental risk factors. However, it is notable that the 
relative lower disease incidence in Asians is not affected by geographical 
migration of individuals to higher-risk regions (9). 
1.2 Clinical features of CLL 
CLL is defined as a malignant B cell neoplasm which differs from its counterpart, 
small lymphocytic lymphoma (SLL), due to the circulating lymphocyte population 
in the peripheral blood (PB). The patient’s clinical history is an important 
feature for evaluation at diagnosis and at clinical review which, which may 
comprise frequent infections and which may indicate the existence of 
lymphadenopathy or splenomegaly which may be confirmed upon clinical 
examination. In addition to clinical history-taking and physical examination, the 
diagnostic procedure commonly involves the evaluation of the lymphocyte 
count, PB smear and immunophenotyping characterisation of the aberrant 
lymphoid population.  
 Lymphocytosis: immunophenotypic and morphological 
features 
The clinical diagnosis of CLL requires the presence of monoclonal B cell 
populations at >5 X 109/l in the PB with characteristic immunophenotypic 
features which consists of CD5, CD19, CD22 and CD23 positivity, FMC7 negativity 
and weak expression (+/-) of surface immunoglobulin (SmIg). A diagnostic score 
has been developed to incorporate 5 of these markers with high sensitivity for 
the diagnosis of CLL. The diagnostic score is based on the probability of a PB 
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specimen conforming to the diagnostic entity of CLL, to aid distinction of CLL 
from conditions such as mantle cell or marginal zone lymphoma. The features of 
the CLL score are described in Table 1-1 and a score of at least 4/5 is found to 
be a feature of 87% of cases of CLL. A high CLL score has been shown to 
correlate strongly with the typical morphological features of CLL and where 3/5 
of the listed conditions are present an alternative diagnosis should be sought 
(10). A range of alternative markers have been proposed as providing an 
alternative diagnostic score however none to date have superseded the Matutes 
score (11, 12). 
Table 1-1 Scoring system for CLL 
An immunophenotypic score based on flow cytometric analysis of peripheral blood 
whereby a score of >/= 4/5 is indicative of a diagnosis of CLL and a score of </= 3/5 should 
encourage consideration of an alternative diagnosis (10).  
Cell surface marker 1 point 0 point 
Surface immunoglobulin Weak moderate/strong 
CD5 Positive Negative 
CD22 /CD79b Negative Positive 
CD23 Positive Negative 
FMC7 Negative Positive 
 
In cases of atypical CLL there may be modifications to the immunophenotype 
and in practice 92% of CLL cases score 4 or 5, 6% score 3 and 2% score 1 or 2 
(13). 
CLL displays characteristic features on examination of PB smear: a population of 
lymphoid cells is visible; these are small and monotypic with a dense nucleus 
containing visible nucleoli and some chromatin aggregation, with a small border 
of cytoplasm. CLL cells are more fragile than the non-malignant lymphocyte 
population and on preparation of PB films for examination there may be the 
pathognomonic finding of “smudge” or “smear cells” whose appearance is 
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attributable to the cytoplasmic fragments which are breakdown products of CLL 
cells. 
 Hypogammaglobulinaemia and immune deficit 
Mature B cell malignancies such as CLL share clinical features of immune system 
compromise which are mainly attributable to the associated loss of g-globulin 
production. The process of CLL cell malignant transformation requires subversion 
of normal cellular functions such as production of immunoglobulin. As the 
malignant B cell population gradually out-competes the healthy B cell population 
with and through immune dysregulation by mechanisms that are not yet clearly 
defined, there is immune paresis. One consequence of the malignant clonal 
progression in CLL is the reduction in serum g-globulin levels, sufficient to 
impair humoral immunity.  
 Autoimmune features and associations 
There are widely recognised associations between CLL and autoimmune disease, 
in particular, autoimmune haemolytic anaemia (AIHA) and immune 
thrombocytopenic purpura (14). The biological basis for the association is 
complex and not yet fully understood but is believed to be based upon the 
ability of CLL cells to promote the production of polyclonal autoantibody. CLL 
cells may interact with T cells in the disease microenvironment by presenting 
autologous red blood cell antigens; the T cell population expands and interacts 
with normal B cells to provoke the production of antibody (15). Despite some 
CLL cells retaining the ability to produce immunoglobulin, it is rare that an 
autoreactive clone produces sufficient autoantibody to cause clinical disease; 
although limited in repertoire it is more usual for CLL cells to secrete polyclonal 
antibody; the biological basis for the majority of immune manifestations of CLL 
(16). CLL therapy with fludarabine may be complicated by AIHA and fludarabine 
is avoided as a therapeutic strategy in patients with AIHA as the drug may 
worsen the haemolysis. It is not fully understood as to how fludarabine may 
worsen haemolysis in CLL however it may be that fludarabine acts to remove the 
suppression of a pre-existing red cell autoantibody (17). The finding of a low 
platelet count in untreated CLL patients requires further investigation to 
delineate ITP from bone marrow infiltration as the latter carries a significantly 
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poorer prognosis and will require monitoring and follow up (18). Although 
patients with autoimmune cytopenias are typically believed to have a worse 
prognosis than those without, there are conflicting reports as to the impact on 
overall patient prognosis and association with other risk factors (14, 19). AIHA 
has been found in association with an unmutated immunoglobulin heavy chain 
(IgVH) and with a positive direct antiglobulin test, but as only patients requiring 
CLL therapy are likely to have had screening for prognostic markers, there may 
have been bias introduced with this finding (20). Furthermore, the same 
population studied for ITP associations found no association between ITP and 
IgVH mutational status (21). Hypothetically, the basis for AIHA as a cause of 
worse overall outcomes in CLL is that the individual likelihood of CLL cell 
exposure to red cell antigen increases, for example in the shared environment of 
the spleen, which may be enlarged. The presence of AIHA may therefore 
correlate with advanced disease stage in CLL which in turn confers a poorer 
prognosis. All cytopenias in CLL require careful consideration in their diagnosis 
and management to promote the overall health of the patient and to permit safe 
and successful completion of CLL therapy.  
 Richter’s syndrome 
In around 5% of patients affected by CLL, their clinical course includes the 
potential for high-grade transformation of disease known as Richter’s syndrome 
(RS) (22). This, rare and often intractable condition, manifests most commonly 
as non-Hodgkin Diffuse Large B Cell Lymphoma (DLBCL) (90%) but may 
alternatively be similar in pathology to Hodgkin lymphoma (HL) in 10% of cases 
(23). Investigation for RS is indicated in response to clinical presentation of the 
patient with “night sweats” or weight loss, known as “B symptoms”, a rapid 
increase in palpable lymph node (LN) number and/or size and a marked increase 
in serum Lactate Dehydrogenase (LDH) on PB sampling. Patients are investigated 
further by PET CT where available and positive findings include a demonstrable 
increase in 18Fluorodeoxyglucose (18FDG)-avidity in regions of disease 
transformation, relative to the background activity of CLL-affected nodes (24). 
Histopathological findings on LN biopsy in affected nodes typically include 
effacement of LN architecture by a monomorphic B cell population which carries 
a high Ki67% on immunohistochemistry with concomitant background of the 
original CLL which differs by its largely low Ki67% index and by CD5 positivity. 
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Management of RS is dependent upon histological subtype and clinical trial entry 
should be sought where suitable trials are available. Median survival of patients 
with RS is currently <1 year therefore this remains an area in need of directed 
research effort (25). For patients able to achieve a remission with 
chemoimmunotherapy for Richter’s syndrome, salvage with allogeneic stem cell 
transplantation (AlloSCT) may be an option. 
1.3 Disease monitoring and identification of relapse 
 Disease staging and prognostication 
There is a spectrum of disease presentation in CLL from disease which is mainly 
confined to the PB, to that which manifests as bulky lymphadenopathy. 
Associations between CLL immunophenotype and cytogenetic subset have been 
identified in relation to LN involvement. Moderate splenomegaly is a common 
clinical feature but medical imaging may be required to identify subtle 
enlargement. The underlying aetiology of splenomegaly may be uncertain in the 
context of an AIHA, also splenomegaly may be associated with splenic pooling of 
platelets which in turn causes thrombocytopenia. SLL requires histopathological 
assessment of LN biopsy. Clinical features of lymphadenopathy and splenomegaly 
are present in SLL but the PB lymphocyte count should not reach measurement 
levels of >5 x 109/l (26). Because investigation, management and monitoring of 
SLL is equivalent to CLL, these diagnostic entities shall be regarded as 
synonymous hereinafter.  
The clinical course of CLL varies widely from an almost indolent disorder to a 
rapidly progressive condition which leads to an early death. In general, CLL is a 
disease which follows a relapsing and remitting course; it is largely an incurable 
disease, except for the intervention of AlloSCT, an intensive therapy restricted 
to patients with a low level of comorbidity. The overwhelming majority of 
patients with CLL are therefore ineligible for curative therapy, thus the aim of 
their treatment is to prolong their progression-free (PFS) or overall survival (OS). 
Individual patient prognosis may be classified using a disease-based risk score 
derived from either of the Rai and Binet scoring systems (27, 28). The Binet 
staging system is in more widespread use in the UK and it integrates clinical 
features as described in Table 1-2.  
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Table 1-2 Binet staging system. 
Disease stage relates to survival with stage A median patient survival duration at >10 years, 
stage B at >8 years and with stage C at approximately 6.5 years. 
Stage Clinical features 
A Lymphocytosis, does not meet criteria 
for stages B and C 
B >/= 3 areas of lymphadenopathy, does 
not meet criteria for stage C 
C Anaemia (Hb <10 g/dL) or 
thrombocytopenia (platelets <100 x 
109/L) 
 
Patients of Binet stage A CLL may be characterised as having greater longevity, 
fewer relapses and are less likely to require CLL therapy. Negative outcomes 
increase in frequency from stage A to B with stage C disease conferring the 
poorest prognosis in terms of PFS and OS. In addition to disease-specific 
markers, the presence or absence of which define patient prognosis and shall be 
discussed in section 1.6, clinical trials are in progress to create and refine 
prognostic tools and markers and this shall be discussed. Evaluation of the 
patient with CLL at the time of diagnosis is performed with attention to 
available national guidelines with the aim of establishing the timing and 
indication for therapy. In addition to the armamentarium of investigational tests 
below, the patient’s clinical condition may dictate the necessity for treatment 
in the absence of any other indication. Terms used to describe responses to 
therapy find their origin in clinical trial protocols but their use may be extended 
to routine clinical practice, such terms include partial (PR) or complete (CR) 
response. Estimation of prognostic markers such as Zeta-associated-protein 
kinase 70 (ZAP-70) and Fluorescence In Situ Hybridisation studies do not 
represent an indication for therapy so shall be dealt with separately (29). 
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 Physical examination 
Once a diagnosis of CLL has been established, patients should be evaluated for 
cervical, axillary and inguinal lymphadenopathy with measurement of maximal 
LN size in each region in 2 dimensions, and the presence and extent of hepato- 
or splenomegaly should be recorded.  
 Peripheral Blood sampling and Bone Marrow biopsy  
After diagnostic blood counts and evaluation of prognostic parameters, serial PB 
sampling is performed to monitor disease progression. Disease progression in 
need of treatment may not always be discernible from the absolute lymphocyte 
count however lymphocyte doubling time of </= 1 yr may be indicative of a need 
to start CLL therapy (30). BM aspirate and biopsy sampling is recommended prior 
to the initiation of myelosuppressive therapy and either to monitor treatment 
response, in the context of clinical trials, as per protocol, or in the investigation 
of cytopenias. 
 Minimal residual disease monitoring by flow cytometry and 
PCR 
Recent advances in the understanding of CLL biology have contributed to the 
development of techniques to monitor low levels of disease which remain after 
completion of therapy; these levels are referred to as “minimal residual disease” 
or MRD. The monitoring of MRD requires the existence of a disease-specific 
marker and requires the ready availability of an assay to permit routine clinical 
testing at pre-specified time-points in line with clinical trial protocols. The 
benefits of MRD negativity were demonstrated first with the use of alemtuzumab 
which showed an improved survival with MRD eradication (31). The assays for 
monitoring MRD were developed further for use in monitoring of response to 
chemoimmunotherapy regimens (32). Some of the earliest trial data on MRD 
arose from the CLL8 study which established the superiority of 
chemoimmunotherapy over chemotherapy alone (33). MRD was found to predict 
OS and PFS independently of other parameters and MRD negativity associated 
more strongly with the chemoimmunotherapy arm (33). Monitoring may be 
performed to establish MRD status in CR or it may be employed as a tool to 
detect relapse at an early stage. Optimal schedules of monitoring for MRD and 
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clinical implications are the subject of current clinical trials to enable a 
schedule for testing that may be applied universally. Flow cytometry (FC) may 
be used to determine the presence of cells with a disease-specific 
immunophenotype. Allele-specific primers may facilitate disease monitoring by 
polymerase chain reaction (PCR) and markers may be screened for using either 
PB or BM sampling and the site of MRD testing and test positivity has implications 
for patient prognosis. In general, a threshold of 104 is used as the limit of 
detection however this may be lowered as the sensitivity of assays are improved. 
Recent study has confirmed an association between MRD negativity and 
improved PFS in CLL, incorporating data from a number recent trials including 
CLL8, CLL10 and CLL11 to establish MRD as a primary end point in randomised 
clinical trials (34).  
 CT/ PET-CT scanning 
Clinical staging of CLL is not reliant upon CT scan findings however CT scanning 
is often utilised by clinical trials as a means of assessing disease response. Where 
CT scans are in use, one scan is to be performed prior to the initiation of therapy 
and a subsequent scan is indicated at the end of therapy if abnormalities were 
detected at the outset. PET CT scanning is not routinely indicated in CLL except 
as part of the diagnostic workup for suspected cases of Richter’s syndrome (RS).  
1.4 CLL disease management  
Individual cases and their relative eligibility for therapy are assessed using 
parameters such as the CLL International Prognostic Index (CLL-IPI) in Table 1-3 
which aid clinical decision-making relation to timing and intensity of therapy.  
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Table 1-3 The CLL International Prognostic Index (CLL-IPI). 
A risk score may be calculated for each patient, based upon integrated CLL-IPI parameters 
to aid prediction of time to first treatment in CLL (35). 
Variable                                       Adverse factor                             Grading 
(17p)/TP53 Deleted and/or mutated 4 
IGHV mutation status Unmutated 2 
B2M, mg/L >3.5 2 
Clinical stage Binet B/C or Rai I-IV 1 
Age >65 years 1 
                                                  Prognostic score                        0-10 
 
 Chemoimmunotherapy 
The current standard of care in CLL first-line regimen for “fit” patients is a 
combination of purine analogue fludarabine, alkylating agent cyclophosphamide 
and monoclonal anti-CD20 antibody, rituximab (FCR). The original study which 
established fludarabine as first-line alkylating agent contrasted the PFS of CLL 
patients on fludarabine as a single agent with that of chlorambucil-treated 
patients (36). Later, as reported by the CLL4 trial, fludarabine in combination 
with cyclophosphamide was found to have greater PFS than either fludarabine or 
cyclophosphamide alone (37). The development of chimeric monoclonal 
antibodies directed at the CD20 changed the landscape of combination therapy 
for all types of B cell malignancy. CLL has a relatively low CD20 expression and 
high lymphocyte counts compared with other B cell malignancies such that 
responses to a single agent rituximab regimen were poor, but when introduced 
in addition to FC demonstrated superior PFS and OS to the chemotherapy-only 
regimen as part of the CLL8 trial (38, 39).  
Limitations to FCR as a treatment approach include its toxicity; median age of 
patients in the CLL8 trial was 61 years which is relatively young as a CLL 
population and current UK guidance no longer recommend FCR for use in 
patients of >70 years in age. As mentioned previously, patients with a 17p 
deletion as part of their disease phenotype fare particularly poorly. 
Furthermore, in the context of early disease relapse (i.e. <3 years from first-line 
FCR) patients receiving repeat FCR have poorer OS than those who achieve a 
greater initial response duration (40). For those younger patients with few 
comorbid diseases assessed to be unfit for FCR the regimen of bendamustine in 
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combination with rituximab is offered (BR). Bendamustine is an alkylating agent 
with properties shared with those of purine analogues. The original study 
contrasted its impact with that of chlorambucil to demonstrate a significant 
improvement in PFS (41). The use of BR as a combination yielded significant 
responses in the first-line and relapsed/refractory settings (42) however under 
comparison with FCR in the CLL10 study it gave a significantly lower PFS overall 
and in the patient age group >65 years there was no significant benefit of FCR 
over BR, most likely due to the increased toxicity associated with the regimen 
often experienced by this patient group.  
Chlorambucil is largely reserved for those patients unfit for either of the above 
regimens and has been trialled in combination both with rituximab (R-Clb) and 
with an alternative anti-CD20 antibody: obinutuzumab (G-Clb). Obinutuzumab 
differs from rituximab in that it maps its CD20 epitope in 3 dimensions with a 
glyco-engineered Fc region with enhanced antibody-dependent cellular 
cytotoxicity and apoptosis in relation to rituximab. G-Clb resulted in more 
partial and complete responses than R-Clb, with both superior to chlorambucil 
alone, and PFS of G-Clb was greatest (43). Obinutuzumab therapy tends to result 
in a greater frequency and severity of infusion-related reactions than rituximab, 
which may influence treatment decisions in some patients (43). 
 Treatment algorithm 
The optimal sequencing of therapies in CLL has been altered greatly by the 
introduction of novel agents as described below, and numerous alternative 
therapeutic algorithms have been proposed. The results of ongoing clinical trials 
including CLARITY, FLAIR and the planned successor trials which have already 
been planned will alter the therapeutic order of established 
chemoimmunotherapeutic regimens as will the introduction of novel 
combinations as more information is acquired from such trials. At present, it is 
considered as good clinical practice for patients requiring therapy to be entered 
into a clinical trial where a suitable trial is available.  
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 Novel agents in clinical practice 
BTK inhibitors have been in widespread clinical use since the development of 
ibrutinib and second-generation acalabrutinib and others (GS-4059, BGB-3111, 
CC-292). The phase 1b demonstration of safety and efficacy with this orally-
administered irreversible BTK-binding agent established ibrutinib’s tolerability 
and its ability to produce durable remissions that transcend prognostic sub-
classification (44). At three years’ follow up ibrutinib demonstrated high 
response rates as a single agent in both treatment-naïve and relapsed/refractory 
settings (45). Since this study, an increase in the incidence of atrial fibrillation 
and the development of minor haemorrhagic complications have been reported 
in recipients of ibrutinib; bleeding diatheses have been attributable to an off-
target platelet function defect (46). Only modest toxicity featured in this 
patient group with grade 3 cytopenias, infections and fatigue observed. The 
kinetics of treatment-related lymphocytosis was observed in some patients at >1 
yr with no adverse effect on those patients experiencing such an elevation (45). 
Ibrutinib is being compared with ofatumumab in the phase 3 RESONATE trial and 
interim results are available with 74% of patients on ibrutinib being progression-
free at 24 months. PFS appears to be consistent across patient subgroups except 
for a reduction in PFS with those carrying both 17p deletion and TP53 mutation 
and so far RESONATE reports ongoing safety and efficacy consistent with the 
earlier evidence (47).  
Another, irreversible but more selective, BTK inhibitor has been developed 
which has no effect on epidermal growth factor receptor (EGFR), tyrosine kinase 
expressed in hepatocellular carcinoma (TEC) and interleukin-2-inducible T-cell 
kinase (48). Acalabrutinib (ACP-196) offers greater selectivity which may 
accommodate a greater dose range and has been trialled in relapsed CLL in a 
phase I/II study with evidence of safety and efficacy in patient groups including 
the 17p deletion subset (49).  
Idelalisib, the first-in-class PI3Kd inhibitor was first evaluated in combination 
with rituximab in the relapsed/refractory setting. This heavily pre-treated 
patient group experienced significant responses in comparison with the 
rituximab and placebo combination with an impact on PFS and OS (50, 51). 
Idelalisib has also been compared with ofatumumab in a phase 3 trial but as a 
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combination with ofatumumab compared with ofatumumab alone (52). The 
relapsed/refractory nature of those cases enrolled in the trial were amenable to 
the drug combination and displayed improved PFS independently of prognostic 
risk categories. Idelalisib has also been used in the treatment-naïve setting in 
combination with rituximab. Durable responses were observed in this phase II 
study in all prognostic categories with the main side effect of diarrhoea/colitis 
observed at grade 3 with some patients requiring cessation of therapy as a result 
(53). Phase III study of idelalisib in combination with rituximab in 
relapsed/refractory patients demonstrated improvement in PFS, Overall 
Response Rates (ORR) and OS across the risk categories at interim analysis (51), 
with long-term results awaited. Second-generation duvelisib (IPI-145) which 
targets both PI3Kg and PI3Kd holds promise in the targeting of additional 
microenvironmental signals as PI3Kg is expressed not only by malignant B cells 
but by T cells and other aspects of the innate immune system (54). There appear 
to be apoptotic effects in vitro in addition to anti-migratory and chemotaxis 
effects and the drug is in phase I study (55). 
Direct targeting of the BCL-2 protein was first explored as a therapeutic strategy 
in CLL with the development of BH3 mimetics such as ABT-737 and ABT-263 
(navitoclax). Prior to this, the only mode of BCL-2 inhibition was with the use of 
antisense molecules such as Oblimersen and SPC2996 (56, 57). BH3 mimetics are 
thus named as they share an ability to bind the hydrophobic groove on anti-
apoptotic BCL-2 proteins directly. As non-specific BCL-2 inhibitors target both 
BCL-2 and BCL2L1 effectively with significant apoptotic effects in vitro on 
primary CLL samples, they were first investigated as potential agents for 
combination use in CLL. However ABT-737 did not graduate to clinical studies 
and ABT-263 did not progress beyond phase I in CLL trials due to the impact of 
off-target platelet effects on drug tolerability, mediated by BCL-XL (58). 
Fortuitously, an agent with capacity to directly target BCL-2 whilst sparing 
platelet number was developed in the same year and was progressed quickly to 
clinical trial evaluation (59). Venetoclax phase I studies were able to 
demonstrate 79% ORR as a single agent and with a maximal dose of 400mg and 
CR in 20% of cases confirmed with MRD negativity. Even as monotherapy 
venetoclax can achieve 16 months’ PFS in the 17p deletion subgroup. Phase 1b 
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studies are maturing with 24 months’ PFS at 82% in combination with rituximab 
(60).  
Safety and tolerability concerns were raised over the development of tumour 
lysis syndrome (TLS) relating to the exquisite sensitivity of CLL to BCL-2 
inhibition. Two fatalities were recorded and three cases of acute renal failure 
were recorded, leading to the introduction of a sub-therapeutic dose escalation 
phase prior to a plateau at the therapeutic level to permit gradual disease 
debulking. Other adverse reactions recorded which limit therapeutic utility of 
venetoclax include neutropenia and there are concerns as to the degree of the 
depletion of innate immune cells, given the ubiquity of BCL-2 in normal cells. 
Challenges to BCL-2 inhibition as a therapeutic strategy include the functional 
redundancy of BCL-2 family members such that multiple family members may 
need to be targeted concurrently for long-term response, also the occasional 
upregulation of myeloid cell leukaemia 1 (MCL-1) and other anti-apoptotic 
proteins as a consequence of BCL-2 inhibition.  
Combination therapy with the eagerly-anticipated MCL-1 inhibitors may provide 
a fail-safe in circumstances of venetoclax resistance. Microenvironment 
modification has been targeted as a means of therapy and knowledge of the role 
of the Programmed Death-1 (PD-1) and Programmed Death Ligand-1 (PD-L1) axis 
in interactions between CLL cells and immune effector cells has been exploited 
with the development of PD-1/PD-L1 pathway inhibitors (48). Patients have been 
treated for relapsed CLL using PD-1 blockade as a therapeutic strategy after 
progression on ibrutinib and in the context of Richter transformation, showing 
promise in setting of RS.  
 Role of allogeneic stem cell transplantation 
AlloSCT remains the only known cure for CLL and its application is limited to 
those with an available donor who are without significant comorbidity and in 
general, <70 years old. A recent European Society for Blood and Marrow 
Transplantation (EBMT) multicentre study confirmed long-term survival (OS) in 
35% of patients at 10 years with an even contribution from disease relapse and 
other causes in impact on survival (61). There was a sharp gradient in treatment-
related mortality (NRM) in older patients (>65) with an increase from 14% to 47% 
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in 5-year survival with age-matched controls as anticipated with such an 
intensive procedure. In another study, individual centre experience of 
supporting allogeneic procedures varied widely however the event-free survival 
was found to be 37% at 5 years (1). Ten year follow-up data for AlloSCT in CLL 
was published from the CLL3X trial by the German Lymphoma Study Group 
(GCLLSG) with PFS of 34% in a study of 90 patients, indicating that AlloSCT does 
not always offer a cure for those patients that are eligible (62). Non-
myeloablative is the preferred option for transplant conditioning, lending 
support to the procedure as a reduced-intensity version. In this patient cohort 
above many others, patient selection is key to optimising outcome in allogeneic 
stem cell transplantation. Work is ongoing to optimise the procedure and to find 
its position in the CLL treatment algorithm in the era of novel agents, as the role 
of ibrutinib is explored as an alternative and as a bridge to transplantation. 
1.5 Normal B cell lymphopoiesis 
Normal B cell development involves transition through stages of cellular 
maturation, each of which may be distinguished by cell surface receptor profile 
and by the maturation status of the B cell Receptor (BCR). B cell development is 
tightly regulated both temporally and anatomically to create a magnitude of 
diversity in immune responses to pathogens without error which may lead to 
neoplastic changes. B cell antigen specificity and diversity is created by the BCR; 
these steps are highly regulated to permit a sufficient diversity of BCR and to 
eliminate autoreactive cells. B cell diversity is created in one of three ways: by 
the negative selection of B cells with initiation of cell death, by inactivation of B 
cells to induce anergy, and by BCR editing. 
 B Cell Receptor: structure and function 
The BCR is a multivalent transmembrane molecule which displays affinity to a 
range of antigenic molecules which it may bind reversibly with varying avidity, 
according to its specificity. The cell surface structure depends upon the class of 
antibody being expressed, which on mature B cells is either IgD or IgM. The cell 
surface structure consists of two heavy chain immunoglobulin (IgVH) molecules 
which are associated each with a light chain molecule (IgVL). The structure may 
be further subdivided into a fragment crystallisable (Fc) region which is 
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associated with the plasma membrane and the portion responsible for antigen-
binding, known as the fragment antigen binding (Fab). The antibody isotype is 
largely dictated by the Fc region and the Fab fragment has both constant and 
variable regions with the antigen-binding specificity determined by the variable 
region. The identical arms of the Fab fragment and their variable regions on 
both heavy chain molecules possess areas which provide additional antigen 
specificity, known as heavy chain complementarity regions (HCDR1,2,3) (63). 
Membrane-bound immunoglobulin (Ig) molecules do not transmit signals directly 
but are linked to transmembrane CD79A/CD79B heterodimers which signal via 
their Immunoreceptor Tyrosine-based Activation Motif (ITAM) (see Figure 1-1 B 
cell receptor structure).  
The BCR exists as a discrete oligomeric structure which differs according to the 
specific class of IgVH molecule (64). The BCR exerts its function in the regulation 
of B cell development to mediate cell fate decisions, and in antigen processing 
to confer cellular immunity. Upon BCR ligation by antigen, either a cascade of 
signal transduction is commenced, resulting in receptor oligomerisation, with 
BCR internalisation of the bound antigen to permit antigen processing and 
antigen presentation to T cells. The various mechanisms of BCR activation and 
their subversion in CLL will be discussed.  
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Figure 1-1 B cell receptor structure 
The BCR molecule consists of antigen-binding heavy chains (VH, CH1-4) containing heavy 
chain complementarity determining region 3 (HCDR3) and light chains (VL, CL). The 
transmembrane molecules Iga and b transmit the BCR signal via phosphorylation of 
immunoreceptor tyrosine activation motifs (ITAM).  
 B cell development and regulation 
Our understanding of B cell development and differentiation has progressed 
significantly since the earliest, almost linear representations of the B cell 
hierarchy (65). We now know that there are multiple well-defined stages which 
have transition phases, tightly-regulated by chemokine-ligand interactions with 
persistence of fluidity in developmental potential at all stages to mediate 
response to infection and to populate the growing organism as shown in Figure 
1-2 (66). The first class of antibody to appear on the cell surface is IgM; the 
formation of pre-B cells requires the rearrangement of the immunoglobulin 
molecule at both variable- and joining-regions to form a primitive BCR 
constructed from µ chain molecules. Pre-B cells have a pre-BCR which is formed 
from 2 light chains attached to 2 µ chains which then insert into the plasma 
membrane. As the diagram in Figure 1-3 illustrates, the mature BCR defines the 
immature B cell stage, the latest stage which is confined to the BM which then 
emigrate to the spleen or LN to become transitional or marginal zone B cells. 
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Figure 1-2 Stages of B cell development 
Maturation initiates in the bone marrow microenvironment with the most primitive 
precursor, the haematopoietic stem cell (HSC), followed by common lymphoid precursor 
(CLP) to progenitor B cell (Pro-B). At this point there is a divergence into B-1 and B-2 
subtypes; B-1 transitional cells may populate the spleen but have terminal differentiation 
stages in the body serous cavities. Cells move through from marginal zone (MZ) to germinal 
centre (GC) in the secondary lymphoid organs to terminal stages of differentiation which 
circulate in the peripheral blood. Mature B cells which populate B cell follicles are thought 
to have different cellular origins to MZ and B-1 phenotyped cells (66). 
 
Figure 1-3 Stages of BCR maturation 
The diagram above illustrates the stages of B cell maturation with a specific focus on BCR 
maturation and with delineation of stages of heavy and light chain recombination which 
demarcate maturation stages. The stages of maturation are also delineated by cell marker 
surface expression. Regulation of VDJ recombination is by RAG gene expression which 
occurs at all stages up to the immature B cell stage. B cell development is tightly regulated 
by transcription factors, including IKAROS family transcription factors, followed by STAT5, 
E2A and EBF1. There is an underlying dependence upon RUNX1 function in early B cell 
development (67). Later, PAX5 and BLNK are pivotal regulators of B cell development. 
Overexpression of developmental regulatory factors such as RUNX1 are frequently 
implicated in developing leukaemias of immature B cell origin (68).  
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B cells are categorised as B-1 or B-2 cells which is a phenotypic characterisation 
largely based upon the presence or absence of surface expression of CD5. They 
may be further subdivided into B-1a (CD5+) and B-1b (CD5-) cells which share 
other phenotypic features (69). B-2 cells are largely negative for CD5 expression 
although surface expression on these cells may be induced and as there is some 
surface phenotype overlap of B-1 cells and activated B cells therefore cell 
surface phenotype-based definitions should be applied with caution (69). The 
major B cell subset responsible for populating the spleen and LN is known as the 
B-2 cell stage and these cells may progress from transitional stages T1 to T2, 
reliant upon basal BCR signals, with maintenance of T2 cells receiving a 
contribution from external signals. A third transitional phase from T2 to the 
mature Follicular stage is responsible for the generation of the anergic B cell 
population (70). The transition from T2 to follicular/marginal zone B cells is 
regulated both by BAFF and NF-kB2 and by a stronger BCR signal at this stage. B 
cell development is critically dependent upon BCR signalling as where there is 
disruption of the BCR signal this results in a differentiation block. The BCR is 
required for mature B cell development even before the stage of antigenic 
exposure. The B-1 cell stage transitions independently of BAFF but with greatest 
reliance upon the BCR signal and other signals; B-1 cells are responsible for 
populating the body’s serous cavities. Localisation of B lymphocytes plays a part 
in regulation of cellular development by means of microenvironmental variations 
in factors such as BAFF signalling (66). Regulation of B cell development appears 
also to be influenced by features of the BCR such as its antigen specificity and 
density of cell surface distribution (71). 
 Immunoglobulin gene rearrangement 
As stated previously, BCR comprises both heavy and light chain Ig molecules, 
these are encoded on chromosome 14 in the case of the heavy chain molecule or 
chromosomes 2 and 22 for kappa (k) and lambda (l) chains respectively. Each 
heavy and light chain gene is split into constant segments (Cµ,Cd) with variable 
(V) and joining (J) segments, and only at the IgVH locus, diversity (D) segments. 
In early B cell differentiation in the BM, there is reorganisation of the gene 
segments to create a wide array of Ig molecules; with D and J regions 
recombining before V and DJ. Initiation of somatic recombination is performed 
by protein products of the recombinase-activating gene (RAG) family (72). RAG1 
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and RAG2 proteins exist in a complex which creates DNA double-strand breaks 
which are then repaired by non-homologous end joining (NHEJ) by enzymes 
including terminal deoxynucleotidyl transferase (TdT). Once a functional IgVH 
molecule has been created there is elimination of the alternate allele from 
recombination attempts by a process known as allelic exclusion. The IgVH 
molecule undergoes the described recombination process before the light 
chains, which are restricted to either k or l in any given B cell.  
 Somatic hypermutation and class switch recombination 
Once a functional IgVH molecule has been created, the cell may proceed to 
maturation and migrates into the germinal centre (GC) of the spleen and LN to 
undergo affinity maturation by a process known as somatic hypermutation (73) 
(74, 75). As B cells respond to pathogens via antigen-presenting cells, the V 
regions accumulate point mutations at 106 –fold increased frequency than the 
background DNA mutation rate. Although SHM generates mutations at random 
and may not even generate coding sequences, the selection of mutated 
molecules which bind antigen with greater affinity occurs later in the GC. Also in 
response to antigen-binding, B cells engage in isotype switching known as class 
switch recombination (CSR), from production of low affinity IgM to high affinity 
IgG, IgA and IgE antibodies. In CLL, cells express a similar class of 
immunoglobulin molecule to naïve B cells, both IgM and IgD however some cases 
may undergo isotype class switching and may express terminally differentiated 
isotypes (76, 77). The mechanism of CSR is one of DNA deletion and 
recombination in the IgVH gene at the switch regions which results in exchange of 
Cµ/Cd regions for Cg, Ca and Ce regions (78). Activation-induced cytidine 
deaminase (AID), a single-strand DNA cytidine deaminase, exhibits increased 
levels of expression in activated germinal centre B cells and is key to the 
mechanistic basis for B cell diversity, playing a role in both SHM and CSR (79). 
Both SHM and CSR require transcription to occur and at this point the DNA helix 
is opened up and single strand DNA is generated which may be deaminated by 
AID to form mismatched base pairs. The processes of SHM and CSR harness the 
normal cellular processes of base excision repair and mismatch repair to convert 
deaminated sites to mutations and/or double-strand breaks. In SHM, there is an 
increased occurrence of mutations in the complementarity-determining regions 
of the immunoglobulin molecule; the regions which bind antigen directly. The 
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mutation rate is amplified by regions where AID is more active, relative to other 
areas of the V genes (80). In CSR, transcription occurring upstream of the switch 
region of the first constant domain opens the DNA helix to facilitate AID activity. 
The normal functioning of the processes of SHM and CSR are essential to create a 
diversity of B cells which can respond to a wide range of pathogens, with fail-
safe mechanisms to reduce autoreactivity and prevent the unregulated 
proliferation of a clonal population. Both SHM and CSR may be subverted in CLL 
and have implications for disease features and heterogeneity and response to 
therapy (81, 82).  
1.6 CLL pathogenesis 
 Monoclonal B cell lymphocytosis 
It is now recognised that individual cases of CLL typically begin with a precursor 
syndrome known as monoclonal B cell lymphopoiesis (MBL)(83). MBL is a 
diagnostic entity which comprises <5 X 109/l circulating clonal lymphocytes, 
often with a CLL-specific immunophenotyped, and no evidence of 
extramedullary disease (26). Study of peripheral blood samples using flow 
cytometry or molecular analysis confirmed the existence of a pre-diagnostic 
clone in 44/45 CLL cases, leading to the understanding of MBL as a precursor 
condition of CLL (84).There is a distinction to be made between low count (LC) 
and high count (HC) as these conditions carry differing risk of progression to CLL. 
HC-MBL is regarded as indistinguishable from CLL and many of the CLL-specific 
mutations may be seen in this condition as found in CLL. 
Hypogammaglobulinaemia is a feature of HC but not LC-MBL, consequently 
patients with HC-MCL are more vulnerable to infections such as Epstein-Barr 
virus (EBV) and Cytomegalovirus (CMV), or infection by encapsulated organisms 
such as streptococcus pneumoniae.  
It is known that T cells are increased overall in CLL, with a greater number of T 
cells which are phenotypically activated; there is an increased activated 
phenotype compartment correlates with advanced disease stage in CLL (85). T 
cell compartment differences also exist between MBL and CLL with T regs being 
reduced in HC-MBL in relation to CLL. LC-MBL was also found to have the 
cytogenetic abnormalities as seen in CLL although progression rates are low, 
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therefore the rate of LC-MBL in the general population remains fairly constant 
over time (86). T cell clones have been found in association with LC-MBL (86). 
Interestingly, recent work has shown an increase in T cell exhaustion relative to 
age-matched controls with a reduction in immune synapse function as B cell 
clone expands, whereas this capacity of T cells remains unchanged in stable LC-
MBL. The pathogenesis of MBL is of interest in the efforts to elucidate the 
mechanisms of CLL, and debate is ongoing as to the role of infection in its 
aetiology. Up to 50% of patients with MBL experience significant infections and 
these infections may predate the incidence of CLL (87). Large-scale association 
studies have shown a link between pneumonia and subsequent CLL but whether 
this is a function or basis of the disease remains unknown (88). There appears to 
be no increased risk of hospitalisation with infection in HC-MBL in contrast with 
LC-MBL when correction is applied for patient age. Studies have also shown the 
risk of non-haematological malignancies with HC-MBL is increased relative to 
their inherent risk of CLL, indicating the importance of immune surveillance as 
mechanism of protection against oncogenesis (89). 
 Immunoglobulin heavy chain mutation in CLL 
The delineation of prognostic subgroups based on patient immunoglobulin heavy 
chain mutational status not only provided the basis for an awareness of the role 
of SHM in CLL pathogenesis but also gave elucidation to theories on the cell of 
origin in CLL (90). Further exploration of the phenomenon of SHM led 
researchers to hypothesise that cases of CLL where the original malignant cell 
has passed through the GC have mutated immunoglobulin genes, therefore arise 
from a more mature B cell than those which have IgVH that are yet to undergo 
SHM.  
Theories regarding populations with differential IgVH mutational status have been 
investigated, first by using gene expression microarray data which displayed only 
minor differences between IgVH mutational subgroups (91). An appreciation of 
the contribution of epigenetic regulation to cancer pathogenesis has provided an 
alternative approach to disease theories. In general, it appears that CLL is a 
disease of widespread DNA hypomethylation and although overall DNA 
methylation does not appear to relate to gene expression levels, specific gene 
body CpG dinucleotide methylation status was found to correlate more strongly 
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with gene expression (92). On analysis of the epigenetic signature of each 
subpopulation it was discovered that unmutated CLL DNA methylation patterns 
resemble those of naïve B cells whereas mutated CLL bears more similarity to 
that of memory B cells. These data suggest that unmutated CLL is derived from a 
pre-germinal centre origin, with a germinal centre-experienced cell as the basis 
for mutated CLL (92). 
The original study which identified IgVH  mutational status as an independent risk 
factor compared IgVH genes with the nearest germline gene and found 2 subsets; 
45.2% of patients each possessing >/= 98% sequence homology to the nearest 
germline gene and a subset comprising 54.8% of patients, each of whom 
displayed somatic mutations in their IgVH gene. These populations showed 
distinct differences in CLL disease stage, atypical CLL morphology, between use 
of specific variable regions in the IgVH molecule and with prognostic measures 
such as OS to conclude that an unmutated IgVH confers a worse prognosis by all 
of these measures, independently of known effects of disease karyotype on 
prognosis (90). Recent evidence has clarified that it is the absolute percent 
deviation from germ-line sequence rather than the previously assigned threshold 
of 98% which is the indicator of prognosis and response to chemoimmunotherapy 
(93). Furthermore, IgVH mutational status was found to have a surrogate marker 
in ZAP70, as high levels correlate with unmutated status. This finding had 
positive implications for disease risk stratification of CLL populations, given the 
practical difficulties with IgVH sequencing in routine clinical laboratories. From 
gene expression profiling studies, expression of ZAP-70, a tyrosine kinase with 
increased expression in a diversity of lymphoid populations was increased at the 
messenger RNA (mRNA) level in those patients with unmutated IgVH genes in 93% 
of cases (94). 
The role of AID in determination of CLL IgVH mutational status has been explored 
(95). It is known that the AID regulation of processes of SHM and CSR are 
dissociated in unmutated CLL, in which the disease retains the capacity to 
switch class of immunoglobulin. However, CLL unmutated IgVH is known to have 
increased levels of AID. It is hypothesised that build-up of an AID splice variant 
leads to functional inactivation of AID but there may other, as yet 
undetermined, mechanisms at play (95). 
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 IgVH gene stereotypy and HCDR3 
Understanding of CLL disease biology has been enhanced by an awareness of the 
presence and function of stereotyped IgVH sequences, which may be found in up 
to a third of cases of CLL (13). Stereotypy in immunoglobulin gene sequence may 
co-segregate with properties ranging from patient characteristics and disease 
biological properties, discernible at the clonal level. The shared characteristics 
of stereotyped IgVHs have contributed to an understanding of CLL biology with 
the applications extending to and beyond those cases which have stereotyped 
clones. Theories of CLL pathogenesis which incorporate immunological response 
to foreign and self-antigens are supported by the finding of IgVH stereotypy as 
CLL cells use a restricted range of IgVHs (96, 97), some of which are specific to 
CLL but there are others which are non-specific (98). Indeed, 9/19 major CLL-
like sequences have been discovered at different stages of B cell development in 
normal precursor cells (13). Presence of stereotyped IgVH rearrangements are 
thought to be linked to B cell tolerance, as mechanisms such as deletion and 
receptor editing are employed by the CLL pathogenic processes to limit diversity 
of the IgVH. Infection-based theories of CLL are supported by the presence of IgVH 
stereotypy as the frequency of a limited range of sequences which are described 
as stereotyped in CLL may have originated as an individual’s response to a 
particular infectious agent, for example streptococcus pneumoniae or 
haemophilus influenza (99).  
Stereotyped IgVH rearrangements have been studied in normal B cell populations 
by ultra-deep next generation sequencing in an attempt to map CLL ontogeny 
with some evidence of restriction of stereotype subset restriction to 
developmental stages and with some light chain restriction in individual subsets. 
It also appears that CLL-like stereotyped sequences are present at their highest 
frequency in young adults, with frequency declining over time, linking diversity 
of IgVH to the ageing process (100). In addition to a predilection for use of 
specific IgVH subsets there is a restricted range of HCDR3 sequences deployed by 
the pathogenic process in CLL. Findings in relation to HCDR3 specificity give 
additional credence to antigenic exposure theories of CLL as these are the main 
determinants of antigen recognition by the BCR. As it seems that neither HCDR3 
nor IgVH are sufficient to confer an adequate range of diversity in the antigenic 
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response process, it seems unsurprising that both immune mechanisms may be 
hijacked in CLL pathogenesis (101). 
 CD38 and cell surface abnormalities 
With the advent of IgVH mutational status subclassification was another of the 
earliest discoveries in relation to prognostic delineation of CLL, that of CD38 and 
its role (102). The role of specific cell surface immunophenotypic markers in CLL 
pathogenesis, in particular, that of the single-chain type II transmembrane 
glycoprotein CD38, was found to vary in its cellular expression by cell 
differentiation and activation status. Patients with high CD38 expression share 
features of a more aggressive disease and have associated bulk LN disease, low 
haemoglobin, hepatomegaly and high beta-2 microglobulin levels (103). As a 
result, patient population outcomes such as OS are poorer where CD38 
expression features in individuals with CLL (104). Investigation for the basis of 
the differential outcomes by CD38 expression have uncovered an increased 
migratory potential for CD38+ CLL cells and with the discovery of CD49d as an 
independent negative prognostic determinant, the mechanism of migration 
control was partially elucidated. CD49d plays a role in adhesion to fibronectin, 
part of the extracellular matrix with its binding of vascular cell adhesion 
molecule 1 (VCAM-1) influencing cellular binding in the CLL microenvironment. 
CD49d promotes CLL cell survival by allowing CLL cells to evade apoptosis and its 
expression is associated with that of CD38 (105). 
 Cytogenetic aberrations 
A large proportion (~80%) of CLL cases are defined by one of a small group of 
frequently recurring cytogenetic anomalies, each with their own biological and 
phenotypic associations. The most prevalent defect is a loss of genetic material 
at the 13q14 locus, occurring in 55% of all CLL cases, which confers a better 
outcome in terms of disease progression and survival (PFS and OS) in comparison 
to those cases where no cytogenetic abnormality may be identified. The next 
most frequently occurring defect is of a deletion at the 11q23 region, which is 
notable as the site of genes responsible for the regulation of lymphocyte 
development e.g. ATM, KMT2A. First discovered as a distinct subgroup in the 
late 1990s, CLL patients harbouring the 11q deletion were defined as having 
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poor prognostic parameters such as low OS and PFS and with the characteristic 
clinical finding of extensive bulky nodal disease (106). Specific morphological 
abnormalities are present in CLL affected by trisomy of chromosome 12; these 
patients have an indeterminate prognosis in comparison with cases which have a 
normal karyotype, but share an association with NOTCH1 mutation and CD49d 
positivity, the implications of which shall be discussed (107). Although its 
impairment or disruption is ubiquitous in cancer, in CLL, the genomic guardian 
TP53 along with additional chromosome 17p material is commonly deleted to 
confer the poorest prognosis of all chromosomal subgroups with low PFS, OS and 
resistance to fludarabine chemotherapy; a key component of current standard 
chemoimmunotherapy regimens (108). Other cytogenetic abnormalities are less 
commonly observed, e.g. 6q del., 2p gain, but may confer additional cellular 
phenotypic and clinical properties. Complex karyotype profiles incorporating at 
least three cytogenetic defects confer a particularly poor outlook independently 
of CLL International Prognostic Index (CLL-IPI) scores underlining the importance 
of identifying all detectable abnormalities (109). 
 Somatic mutations contributing to CLL 
As well as loss of chromosomal loci, CLL may be stratified by alterations which 
are limited to the level of a single transcript, conferring characteristic clinical 
properties to mutational subgroups. Mutations in the gene affected in ataxia 
telangiectasia, ATM, were one of the first to be discovered in CLL and may be 
found in isolation or in association with loss of the corresponding chromosomal 
region on the opposite chromosome; locus 11q23 (110, 111). Mutations in the 
ATM gene tend to result in a partial or complete loss of protein function with 
consequent impairment in DNA damage response and appears to form part of the 
pathogenic mechanism of affected CLL cases, occurring at the pre-germinal 
centre phase of differentiation (112). Cases affected by ATM mutations may 
have more aggressive disease with poorer PFS, similar to those affected by 11q 
deletion as a sole abnormality.  
The tumour suppressor TP53, a DNA damage repair pathway gene encoded on 
chromosome 17p13 and is recurrently implicated in CLL, as it is in many other 
cancers and cancer syndromes. Of all frequently occurring mutations in CLL it 
confers the poorest outcomes with demonstrable resistance to standard 
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chemoimmunotherapy inherent to affected cases (108). TP53 mutation is an 
independent prognostic risk factor in CLL and European recommendations apply 
the requirement for a minimum of Sanger sequencing of exons 4-9 of the gene in 
all cases of CLL prior to therapy (113).  
Mutations in the BIRC3 gene provide a biological explanation for the chemo-
refractoriness of a subset of CLL patients and may be present as an isolated 
anomaly or in association with TP53 disruption (114). The protein BIRC3, a 
member of the inhibitors of apoptosis family (IAP), acts as an E3 ubiquitin-
protein ligase to regulate both canonical and non-canonical signalling of the NF-
kappa-b signalling pathway. The 10-year survival of those harbouring a BIRC3 
lesion is estimated at 29%, equivalent to that of TP53 mutation carriers.  
Other recurrent abnormalities which confer a poor prognosis independently of all 
other abnormalities are those lesions which target the spliceosome function and 
its catalytic component, SF3B1. Cases of mutated SF3B1 may be considered to 
have an indeterminate prognosis and investigative strategies have employed 
integrated transcriptome and functional analysis (115). Mutational changes may 
be activating coding or non-coding mutations and are found in association with 
subtle changes in DNA telomerase, with inhibitory effects on NOTCH signalling. It 
appears that SF3B1 is mainly a subclonal event with somatic mutations which 
lead to the progression of an affected subclone which then leads to overall 
disease progression.  
Mutations in NOTCH1 play a role independently of spliceosome responses in that 
NOTCH1, NOTCH2 and their ligands are constitutively activated as part of the 
pathogenesis of CLL (116). NOTCH PEST-domain activating mutations are a 
source of upregulated NOTCH activity and such mutations were found to be 
present in a subset of CLL cases and were found to cluster with cases displaying 
trisomy 12. The trisomy 12-associated NOTCH–mutated population have 
demonstrable increases in integrin signalling via upregulated expression of CD38 
and CD49d (107). The increased migratory capacity of the described subset shall 
be discussed later; it appears that the increased capacity for tissue homing 
associated with the trisomy 12 subgroup relays a more aggressive disease 
phenotype. The contribution of NOTCH1-mutation to CLL cases carried 
prognostic significance, independent of other risk factors for CLL progression and 
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these mutations did not co-segregate with TP53 mutations (117). Known 
pathways for inhibition of the NOTCH signal including g-secretase inhibitors have 
been exploited with therapeutic efficacy in CLL (118). Other recurrent somatic 
mutations have been observed at a lower frequency and shall not be discussed 
here as their prognostic value is less clearly established.  
 Germline mutations contributing to CLL 
Large scale genome-wide association studies (GWAS) aimed at elucidating 
inherited traits which render individuals as susceptible to CLL are in progress to 
decipher the genetic basis of the disease. Based upon the observation that there 
is a relative 7.52-fold increase in risk of CLL for first degree relatives of affected 
patients (5), a single-nucleotide polymorphism study was conducted by 
candidate gene studies and with the use of Sanger sequencing, enlisting 206 
families with no discernible associations found. Susceptibility loci were then 
determined using GWAS with p-value set at <10-8 for novel loci. Individual alleles 
predisposing to CLL were found to have weak association in isolation but acting 
in concert there were strong associations with an enrichment for genes 
associated with open chromatin (119). GWAS findings were progressed to 
techniques such as chromatin immunoprecipitation sequencing (ChIP-seq) to 
develop an understanding of associations with gene function which led to the 
discovery of a causal variant at 15q15.1 in the RelA gene associated with 
decreased B cell lymphoma 2- modifying factor (BMF) binding (120). 
Furthermore, whole exome sequencing was used to identify familial CLL genes 
and led to the discovery of loss of function mutations in POT1; 3.5% of CLL has 
somatic mutations in POT1, part of the shelterin gene complex responsible for 
maintaining DNA integrity (121). The POT1 findings are supported by the finding 
that mutations are associated with other cancers including malignant melanoma 
and glioma and TERF2IP shelterin genes are mutated in other CLL families, 
providing direct evidence for inherited susceptibility towards CLL (122).  
Studies are ongoing to find overlap between susceptibility loci and genes with 
functions known to be implicated in oncogenesis. Information from whole 
genome sequencing has also contributed to our understanding of CLL heritability 
in the study of an individual with the congenital autoimmune disease Aicardi-
Goutieres syndrome (123). It is known for SAMHD1 to be mutated in AGS; it is 
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the gene which codes for deoxynucleoside triphosphate triphosphohydrolase, a 
protein involved in DNA damage repair pathways. A patient with germ-line 
mutated SAMHD1 developed CLL at the early age of 24, commencing the 
retrospective screening of CLL samples for SAMDH1 expression and variant allele 
frequency, found to be at around 11% in CLL patients requiring therapy (124). 
Whilst not directly implicating SAMHD1 in the heritability of CLL, this case serves 
to describe a predisposing factor thought to be one of the early events in CLL 
development and to illustrate the discovery of clinically significant mutations 
with a low frequency of occurrence.  
 BCL-2 and apoptotic regulators 
The discovery of B cell lymphoma-2 (BCL-2) was grounded in the study of the 
recurrent t(14;18) chromosomal translocations which are integral to the 
development of follicular lymphoma (FL). Using recombinant DNA probes to 
characterise the breakpoint from patients affected by FL it was established that 
rearrangements in chromosome 18 were limited to a short region of the 
chromosome (125, 126). Northern blotting was used to generate multiple variant 
transcripts with subsequent determination of the DNA sequence of BCL-2 and the 
protein sequence of the encoded BCL-2 product (127). Multiple protein members 
of the BCL-2 family have since been discovered, some of which are anti-
apoptotic and some structurally similar proteins which have pro-apoptotic 
actions. BCL-2-family proteins play central roles in regulation of CLL cell death 
and may be categorised structurally based on the presence or absence of single 
or multiple domains with homology to BCL-2 (BH domains).  
The original family-member, BCL-2, measuring at around 26 kDa, resides in the 
mitochondrial membrane and participates in oncogenesis by the prevention of 
apoptosis, facilitating the accumulation of malignant cells; oncogenes were 
hitherto known as pro-proliferative in mechanism of action. A range of pro-
survival molecules known to act similarly to BCL-2 include MCL-1, BCL2L1 (also 
known as BCL-XL) and BCL2A1 (BFL1) and knowledge of these proteins with 
overlapping functions has informed the drug development process. The unique 
importance of BCL-2 to CLL pathogenesis is corroborated by the fact that it is 
overexpressed in CLL cells, and by the evidence that potent and selective BCL-2 
inhibitor ABT-199 leads to MRD negativity and spares patient platelet counts 
  30 
unlike the BCL-2 inhibitors which were developed earlier and which also inhibit 
BCL-XL. The first identified regulator of BCL-2, the pro-apoptotic BAX, exists 
together with BCL-2 in homeostatic equilibrium until the event of cellular injury 
at which point BAX undergoes conformational change and oligomerisation, 
thereby creating a channel in the mitochondrial membrane. The next step is the 
initiation of caspase cascade and apoptotic processes via the escape of 
cytochrome c from the mitochondria and into the cytoplasm. Pro-apoptotic 
functions are shared by BCL-2 family members BAX and BAK, however a third 
group of BH3 domain-only members (BID, BAD, BIK, BIM, BMF, HRK, NOXA, and 
PUMA) act as a ligand between other BCL-2 family-members and may be 
targeted in cancer therapy by BH3-mimetic agents (128).  
 miRNAs in CLL pathogenesis 
The discovery that genetic alteration in noncoding genomic regions can be 
initiating events in malignant transformation led to a paradigm shift in cancer 
biology. MicroRNAs (miRNAs) are regulatory RNAs implicated in a range of 
cellular processes including DNA methylation, cellular growth, differentiation 
and programmed cell death. These small noncoding sequences have been 
associated with several types of cancer and much of the original surrounding 
data were derived from familial studies, from studies using solid organ tumours 
and from the biology of mouse models with deletion of the 13q14 region which 
encodes DLEU2/miR-15a/16-1 (129-131).  
Prior to any CLL-specific study, understanding of the functions of were miR15a 
and 16-1 limited to transcriptional processing with responsibility for activation of 
apoptosis in tumour cells. Their proximity on 13q14.3, which is also commonly 
disrupted in cancer, led to suspicions that these miRNAs were the target of 
events in the process of cellular transformation. Hypotheses involving miR-15a 
and miR-16-1 as tumour suppressors were augmented by the rare finding that 
the loss of miR-16-1 function via an inactivating mutation leads to CLL (132). 
These discoveries were confirmed as integral to CLL biology by the finding that 
BCL-2 expression inversely correlated with miR-15a and miR-16-1. The role of 
miR-15a and miR-16-1 in regulation of homeostatic levels of BCL-2 may be key to 
their loss in oncogenic processes but also may be required for cancer drug 
response to DNA damaging agents such as fludarabine (133).  
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Receptor tyrosine kinase-like orphan receptor 1 (ROR1) positive CLL cells differ 
from ROR1 negative with respect to miR-15a/miR-16-1 positivity. It was found 
that miR-15a/miR-16-1 and miR365-3p target 3’ untranslated (UTR) region of 
ROR1 which was predicted by nanoscan software and confirmed by luciferase 
assay with the co-transfection of HEK-203 cells (134). In support of the 
contribution of ROR1 to CLL progression, ROR1 is low or deficient in cases of CLL 
with chromosomal deletion of 13q; this and earlier findings lay the foundations 
for the therapeutic targeting of ROR-1 in combination with BCL-2, the 
therapeutic implications of which shall be discussed in (1.13.2). The second most 
common alteration in miRNA found in CLL targets the activation of TCL-1. 
MicroRNA miR3676 targets 28 bp repeats in the Tcl-1 3’UTR and its 17p13 
localisation means that it is co-deleted with TP53 (135). It was later found 
miR3676 is not a microRNA as originally believed but is a short transfer RNA, 
cleaved by RNAse Z and with IL-2 binding capacity, however its role in histone-
binding is to silence gene expression; functioning as micro-RNA (136).  
 CLL clonal evolution 
The existence of clonal proliferation was established in the heavy water 
labelling study of CLL birth and death rates which formed the biological basis for 
the existence of clonal evolution. With the advent of Next Generation 
Sequencing (NGS) it became possible to study a variety of abnormalities 
simultaneously and to track their progression within clones and subclones of CLL. 
These studies provided the information on the properties of genomic 
abnormalities commonly observed in CLL; as to whether they exist as “driver” or 
“passenger” mutations in an individual (137, 138). It has been realised that 
subclonal mutations are worthy of study and their response to CLL therapies is of 
relevance to disease prognosis. In particular, clonal and subclonal TP53 
mutations are of equal importance and carry similar negative prognostic value to 
mutations affecting whole clones of CLL. Patients with subclonal NOTCH1 
mutations also carry similar outcomes as to clonal mutations (139, 140). 
Subclonal architecture in the context of disease relapse may inform the choice 
of second or subsequent-line therapy and the disease profile at relapse of 
patient treated with novel agents in CLL may help to characterise the mutations 
that promote disease resistance and relapse. With recent studies we have a 
greater understanding of the complexity of CLL; reflective of the contribution of 
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several clones and subclones, each with differing properties. Therapeutic 
strategies may be tailored in light of the above knowledge to prevent the 
unchecked proliferation of a single clone or subclone.  
1.7 B cell migration 
 CLL microenvironment 
The significant contribution of both LN and BM microenvironments has given rise 
to investigation of disease pathogenesis. Dameshek first described CLL in 1967 as 
an “accumulative disease of immunologically incompetent lymphocytes” (141) 
however we now have evidence of CLL clonal proliferation ranging from 0.1-1% 
per day (142). CLL cells undergo unregulated cell division in proliferation centres 
also known as pseudofollicules which are demarcated on histopathological 
assessment of the CLL node. Molecular interactions between CLL cells and the 
BM and or LN cells have been implicated in CLL cell survival, proliferation and 
clonal evolution. In LN affected by CLL, cells evade immune destruction and 
proliferate with aid from survival signals acquired from the microenvironment 
which have a function in normal B cell development. BCR activation is enlisted in 
the pathogenic process, along with signals such as CD40 ligand (CD154), BAFF, 
and APRIL (143, 144). Mesenchymal BM stromal cells have also been found to be 
protective of CLL cells with contributions from T cells via SDF-1 and CD49d and 
VCAM-1 interactions and from CD68+ nurse-like cells among others (145, 146). 
 Chemokine-ligand regulation of B cell positioning and 
migration 
Cancer cell rehoming and the mechanisms by which it is governed are central to 
tumour spread and clonal expansion. The processes of cytoskeletal protein 
assembly, actin remodelling and integrin formation are amongst a range of 
individual events that precede cellular migration and are tightly regulated by 
chemokine and adhesion molecule interactions. In normal lymphocyte migration, 
selectin and integrin binding of lymphocytes at the vascular endothelium 
initiates lymphocyte rolling, arrest and firm adhesion. Subsequent 
transendothelial migration is triggered by integrin activation and chemokine 
receptor/ ligand binding as the lymphocyte is exposed to local chemokine 
release from the vascular lumen (147). B cell positioning within the LN GC is 
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determined by chemokine surface receptor expression of CXCR4 and CXCR5 and 
secretion of ligands CXCL12, CXCL13 and CCL19/CCL21 by the LN stromal cells. B 
cells migrate along chemokine gradients to the appropriate microanatomical site 
where they mature through phases of SHM and clonal selection on the basis of 
antigen affinity.  
 Chemokine signalling in CLL 
In CLL, the pathophysiological process hijacks the innate properties of normal B 
cells not only to retain the function of recognised surface markers which interact 
with chemokines to regulate migration such as CXCR4 – CXCL12 and CXCR5 – 
CXCL13, but also to utilise the enhanced expression of these markers, 
facilitating increased migration to the secondary lymphoid organs.  
Understanding the regulation of these events offers potential candidates for in 
vitro study of oncogenic signalling: molecules of interest in CLL can be broadly 
categorised as chemokine receptors, adhesion molecules and other 
transmembrane signalling molecules.  
CXCR4 surface molecule function is preserved in CLL cells with high expression 
of CXCR4 on CLL cells in PB and downregulated expression after migration 
underneath a stromal cell layer (148). Also, CXCR5 surface expression is found to 
be present and functional on CLL cells (149). The molecule CD49d, which is the 
a4 component of the a4b1 integrin complex, has been implicated in CLL cell 
migration for some time (150) and its expression has been found to co-segregate 
with prognostic entities that have a tendency for increased migration (107, 151). 
Interestingly, those cells carrying trisomy 12 in association with the poor 
prognostic marker NOTCH1 mutation display further upregulation of integrin 
signalling by way of increased b2 signalling (107). The surface marker CD38 is 
established as a marker of negative prognostic significance and this could be in 
part due to increased BCR signalling and tendency for cellular migration to the 
LN (152). CD44 interaction with its extracellular matrix ligand hyaluronan (HA) 
plays a role in cell positioning within the secondary lymphoid organs to receive 
pro-survival signals, which have been implicated in cell activation, migration and 
tissue retention of CLL cells. Properties of the CLL microenvironment including 
the presence of CCL21 secretion and the strength of CD40-CD40L interactions 
with T cells determine the balance of the equilibrium of CD44-HA binding; CCL21 
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induces motility whereas CD40L stimulation shifts the balance towards tissue 
retention of CLL cells (153). The surface receptor CD62L is implicated in homing 
of CLL cells and is upregulated in cells localised to LN and BM tissue (154). A 
similar pattern of increased expression of MMP9 on cells localised to the LN and 
BM formed the basis of studies of MMP9 in lymphocyte homing and egress. In 
vitro modelling of CLL migration demonstrated an upregulation in MMP9 with 
increased migration under regulation by a4b1 integrin and PI3K/AKT signalling 
(155).  
More recent studies of cellular migration have described surface changes in 
chemokine receptor profile and have derived an emigrant lymphocyte phenotype 
(CXCR4dim/CD5hi) (156). Proliferation studies have established a 2-compartment 
model of CLL with those cells in the PB demonstrating a low proliferation rate 
and those with a higher birth rate being derived from the secondary lymphoid 
tissue. Cells traffic between compartments and display distinct surface 
immunophenotype along with gene expression profile (157). Studies that 
demonstrate the immunophenotypic differences employed deuterium labelling 
of resting and proliferative fractions of CLL cells (158) whereas later work 
examined paired fine needle aspirates and CLL PB samples and used functional 
assays to demonstrate phenotypic differences. An in vitro circulation system of 
migration was utilised to lend further support to the proposed model of 
migration in which the CLL microenvironment exerts a phenotype upon cells 
according to their positioning (156). 
 
1.8 BCR signalling 
CLL cells resident in LN and BM display activation of BCR signalling and this, 
coupled with profound clinical responses elicited by treatment with BCR 
signalling inhibitors, has focused CLL drug development. Therefore the next 
subsections detail the BCR signalling process and the various methods by which 
signalling may be aberrantly active in B cell malignant disease. 
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 BCR signalling pathway 
Further evidence for migratory effects as part of the neoplastic process can be 
derived from recent advances in CLL therapy and the function of inhibitors which 
act downstream of the BCR signalling cascade. It has long been understood that 
the ability of B cells to respond to antigenic binding of BCR molecules is retained 
in CLL but the reliance on differential methods of activation of signalling 
downstream of the BCR varies by B cell malignancy. Both antigen-dependent and 
autonomous BCR signalling are at play in CLL and recruit similar downstream 
effectors in signal mediation which shall be discussed (159). Antigen binding of 
the BCR molecule, through the surface immunoglobulin leads to Iga/b (CD79A/B) 
phosphorylation of tyrosine residues on immune-receptor tyrosine-based 
activation motifs (ITAM) by Src-family kinases, such as LYN, FYN or BLK. Binding 
of tandem Src homology 2 (SH2) domains within the spleen tyrosine kinase (SYK) 
molecule, a non-receptor tyrosine kinase, allows further propagation of the 
signal by recruitment of BLNK to the phosphorylated tyrosine residues. BLNK, the 
B cell linker protein also known as SLP-65, acts as a substrate for SYK to recruit 
proteins such as the enzyme phospholipase C gamma 2 (PLCg2) and TEC family 
kinase Bruton’s tyrosine kinase (BTK) to the signalling complex (Figure 1-4). 
Active PI3K generates phosphatidylinositol (3,4,5) triphosphate (PIP3) to enable 
membrane recruitment of oncogenic serine/threonine kinase AKT, BTK and 
PLCg2 and permit signal transduction to the nucleus (160). 
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Figure 1-4 BCR signalling pathway 
A diagram to summarise the intracellular molecular interactions downstream of the BCR 
signalling pathway is shown with a focus on the positioning of the mTOR signalling 
complex. 
 BCR signalling in CLL pathogenesis 
Signalling by the pre-BCR complex may be disrupted in malignant 
transformation; evidence for this resides in the ability of the pre-BCR to 
promote the accumulation of lymphocytes which are undergoing maturation and 
light chain rearrangement/restriction. The pre-BCR contains 2 functional IgVH 
µ molecules which associate with precursor light chain molecules and the 
immunoglobulin heterodimer CD79A/CD79B (161). As the pre-B cells develop, 
there is auto-aggregation of pre-BCR molecules on the cell surface and ligand-
independent activation of signalling. Aberrant enhancement of the pre-BCR 
signal may form part of the malignant process, as in precursor B cell leukaemia, 
or may facilitate transformation in the case of mature B cell neoplasms. The 
study of defects in pre-B cell signalling has formed our understanding of the 
cellular origins of CLL and of the earliest events in the neoplastic process. 
Immunophenotyping and transcriptional profiling of CLL samples identified 
mutations which were present in multiple sorted cellular fractions with a focus 
on the progenitor compartment. The mutations which associated most 
frequently in the early compartment included those which were already known 
to feature frequently in CLL pathogenesis, including NOTCH1, XPO1, SF3B1, 
TP53, BRAF and EGR2. The BRAF-MAPK-EGR2 signalling pathway is directly 
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involved in pre-BCR signalling, with BRAF-G2469R responsible for constitutive 
phosphorylation of ERK and activation of EGR2 transcription factor in BaF3 cells. 
These data may be an indication that the individual genetic lesions described  
are responsible for the development of CLL and may be supported by future 
comparisons with the mutation rate in healthy haematopoietic precursors (162). 
To confirm these findings, 2 GFP-expressing constructs were inserted into mouse 
models BRAFwt and BRAF-G469R to show that the mutated construct increased 
endogenous levels of EGR2 by QRT-PCR (EGR2/ABL) and resulted in a 
downstream increase in pERK by Western blot, concluding that BRAF-G469R 
affects B cell differentiation in vivo. After 5 weeks to allow B cell differentiation 
in transplanted mice there was a reduction of B cells in BM in BRAF-mutated 
B220IgM+ cells. EGR2-E356K, a mutant which affects transcription of target 
genes due to impairment of DNA-binding capacity was introduced to 
immunodeficient mice to study the relationship of EGR2 to the BCR signal by 
gene expression analysis. The importance of EGR2 to B cell receptor activation 
was established as EGR2-E356K mutant and BCR activation signatures display 
overlap of 239 differentially regulated genes; 15 of these are downregulated and 
of those overexpressed genes there are 168 identifiable as direct EGR2 targets 
(162).  
Another study traced the origins of CLL-specific cellular defects back to 
haematopoietic precursor cells in the pursuit of the earliest oncogenic events in 
CLL initiation. Firstly, FACS analysis of the BM of patients with CLL was used to 
enumerate cell fractions at each stage of B cell differentiation with the 
discovery of clonal expansion at the pro-B cell stage. Analysis of the 
haematopoietic stem cell (HSC) subpopulations of CLL BM samples did not reveal 
any abnormalities at this stage so the investigation proceeded to evaluate the 
IgVH gene rearrangement status in BM precursors. The purified HSC 
compartment, isolated from CLL patients were found to possess clonal IgVH  gene 
rearrangement however the pro-B cell population exhibited polyclonal 
rearrangement of IgVH  genes, indicating that clonal selection occurs after the 
stage of pro-B cell differentiation and cannot be attributed to CLL-HSCs (163).  
To characterise the CLL-initiating cell population, xenotransplantation 
experiments were performed, transplanting CLL cells purified from the BM or PB 
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of patients into NSG mice. There was failure of engraftment of human CLL in the 
mice, indicating that CLL cells do not possess the engraftment potential of 
normal HSCs, hence the next step was to attempt engraftment of purified CLL-
HSCs. As with the study of human CLL BM, differentiation was skewed toward 
the B cell lineage in the xenotransplanted mice. CD19+ B cells originating from 
CLL-HSCs also co-expressed CD5, an immunophenotypic characteristic of human 
CLL and a feature not present in B cells derived from normal HSCs. Furthermore, 
in mice possessing CD5+ B cells clones there was co-expression of surface IgM, 
CD20 and CD23 with absence of CD10. However, the experimental results from 
the CLL-HSC xenotransplantation should be considered with caution in the 
absence of supportive studies to date (163).  
The study of mouse xenotransplantation models permits study of haematopoiesis 
and generation of clonal populations within normal and healthy cells. When 
contrasted with xenotransplanted B cells derived from normal control HSCs, 
there appear to be normal polyclonal IGH rearrangement from pro-B cells 
derived from both normal HSCs and CLL-HSCs. Notably, mature B cells appear to 
have undergone clonal selection even in the disease-supportive environment of 
the xenogeneic transplant model. In the analysis of mouse xenotransplantation 
models it was revealed that IGH-VDJ combinations of cells derived from CLL-HSC 
differ from the original transplanted disease in their IgVH gene use. Interestingly, 
there appeared to be a predilection for the use of VH1, VH3 and VH4 by the 
disease xenograft. Further study of disease populations was performed by serial 
transplantation experiments confirming that CLL-HSCs are capable of self-
renewal and produce distinct and independently-derived clones. Unlike normal 
HSCs, therefore, CLL-HSCs are able to develop monoclonal or oligoclonal B cell 
disease in vivo, tracing the origins of CLL to the most primitive stage, the self-
renewing HSC (163).  
DNA methylation changes are a feature of CLL and are known to confer 
prognostic information (92) however, another study corroborated the diversity of 
DNA methylation patterns between samples and established that the methylation 
changes are likely to be acquired stochastically by the developing clone and 
their study may contribute to our understanding of clonal evolution. 
Furthermore, these methylation changes appear to be more frequent in genomic 
regions where there is a relative absence of genes and those genomic areas 
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which replicate later, indicating that methylation variations occur as the 
developing clone proliferates, as a function of the error which is inherent to 
cancer cell proliferation. It is interesting to note, therefore, that these changes 
may also be tracked as early on as the HSC compartment (164). 
Mature B cell receptor signalling may be activated by a range of modalities and 
each of these may be exploited by the process of malignant transformation. 
Inherent activation of the BCR pathway was discovered using transfection of TKO 
cells deficient in BLNK/SLP-65 with receptors derived from B cell malignancies 
and a tamoxifen-inducible ERT2-SLP65 fusion protein. Using the artificial system 
designed for in vitro BCR study, it was discovered that BCRs from a range of 
malignancies including multiple myeloma (MM), marginal zone lymphoma (MZL) 
and FL require BCR crosslinking to display activation via calcium flux assays 
whereas CLL-derived BCRs possess autonomous signalling capacity (165). It 
appears that this signalling is HCDR3-dependent, as a separate experiment which 
involved CLL-secreted BCRs did not activate those TKO cells with cell-surface 
BCRs of their own. Therefore, it is believed that autonomous BCR signalling in 
CLL is reliant upon structures intrinsic to the BCR. The role of autonomous BCR 
signalling in more aggressive B cell malignancies such as DLBCL and MALT 
lymphoma appears to be ill-defined at present. Some tumours may display 
antigenic specificity but it is difficult to prove an interaction between antigen 
and BCR to be directly responsible for tumour progression. Other lymphomas and 
their reliance on the antigen-activated BCR signal has been studied in a mouse 
model with forced expression of a BCR with specificity directed to a ubiquitously 
expressed self-antigen. There was an increase in lymphomagenesis with disease 
bearing greater morphological resemblance to CLL than to a MYC-dependent 
lymphoma, reflective of the inherent role of chronic antigen dependent BCR 
activity in CLL (166). 
Behaviour of CLL B cells has been likened to anergic normal B cells and shared 
features in relation to the antigen-binding and processing by B cells have been 
demonstrated. The phenomenon of anergy in B cells is defined by an impaired 
response of cells to BCR stimulation; anergy is exploited by the pathogenic 
process in CLL to promote disease survival. A subset of CLL was characterised by 
expansion of an anergic cell population, which featured constitutive activation 
of ERK1/2 and nuclear factor of activated T cells c1 (NFAT-c1) and which evade 
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apoptosis induction (167). In normal BCR cell receptor signalling, binding of the 
receptor instigates internalisation of the molecule, permitting antigen 
processing via acidified endosomes. It appears that the leukaemic cell 
internalises the BCR molecule more readily than normal B cells and this 
internalisation occurs independently of the CD79b molecule, giving rise to the 
conclusion that BCR-ligand on the CLL cell surface is uncoupled from 
downstream signalling (168).  
To recapitulate, either BCRs may be activated by auto-crosslinking or by 
antigen-triggered interactions however the established awareness of low-level 
“basal” signal, transmitted by the BCR, has been augmented by an appreciation 
of its aberrant deployment in B cell neoplasia. It has been shown that ablation of 
the BCR leads to apoptosis of normal B cells (169) indicating that there is a basal 
signal dependency of all B cells. Furthermore, naïve B cells may signal through 
IgM or IgD molecules, both of which transmit tonic signals via the ITAMs situated 
on the CD79A/CD79B heterodimer (170). The tonic signal is also transmitted via 
the intracytoplasmic tails of the immunoglobulin molecules after class switching 
to IgG or IgE with other qualitative differences in the signal after class 
switching, delineating some of the factors determining the reliance upon IgM 
signalling by B cell malignancies with further work required to appreciate the 
utilisation by either class of molecule in the misappropriation of the tonic BCR 
signal by the neoplastic process. 
 Downstream targets of the BCR 
BCR signal transduction may be modified by downstream signalling molecules 
with the aim of therapeutic targeting being the diminution of signal output in 
malignancies reliant upon the BCR signal. One such target was first identified as 
the underlying cause of congenital immunodeficiency syndrome “Bruton’s 
agammaglobulinaema” with the disrupted target as the Bruton’s tyrosine kinase 
(BTK) gene encoded on chromosome Xq22.1; the protein product of which is 
essential for B lymphocyte production and development. Targeting the 
enzymatic activity of the BTK protein was first attempted using in vivo models of 
autoimmune disease and B cell lymphoma using PCI-32765 or ibrutinib with 
promising clinical responses (171). Using field-specific in vitro and in vivo 
models of human CLL, PCI-32765 was confirmed as an agent with efficacy and 
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selectivity against CLL with their mode of action to be discussed in the next 
section (172).  
The PI3K family of enzymes can be subdivided into three classes according to 
their biological structure and substrate classification and they are known to 
regulate cell growth, differentiation and survival. Phosphoinositide 3-kinases 
(PI3K) are a family of lipid kinases which are involved in the regulation of cell 
growth, differentiation and survival. Class I enzymes, commonly activated by 
cell surface receptors, may be subdivided further into IA and IB. Class IA are 
heterodimers comprising a 110 kDa regulatory domain which are either termed 
a, b, g or d  depending upon the splice variant of their associated 85 kDa 
regulatory domain. Dysregulation of class IA PI3K is the most common to be 
implicated in human disease, including the isoform PI3Kd whose expression is 
restricted to haemopoietic cells and is involved in the pathogenesis of B cell 
malignancies (173). PI3K is possibly plays a less critical role than BTK as a moiety 
in BCR signal transduction because BTK may also function as an adaptor protein, 
modifying any enhanced signalling to originate from the PI3K molecule. The 
positioning of BTK in relation to PI3K may have consequences for the relative 
efficacy of therapeutic targeting of each molecule.  
Spleen tyrosine kinase (SYK), a member of the SYK/ZAP70 family of non-receptor 
tyrosine kinases is positioned proximally, downstream of the BCR signalling 
complex and is found to be disrupted in autoimmune disease and in B cell 
malignancies. The SYK molecule is required for the pre-BCR signal therefore its 
loss of function is associated with failure of B cell development at an early 
stage. Given the dependence of both mature and malignant B cells on normal 
SYK functioning, the prodrug SYK inhibitor fostamatinib (R788) was trialled in 
CLL and B cell lymphomas with displayed preferential targeting of cancer cells in 
vivo (174). Thus, it has been tested more widely in clinical trials however its 
greatest utility has been demonstrated in the therapy of autoimmune disease 
such as rheumatoid arthritis (175).  
 BCR signalling inhibitors and CLL migration 
Ibrutinib, fostamatinib and idelalisib, which target BTK, SYK and 
PI3Kd respectively, all affect CLL cell migration mediated by tissue-specific 
  42 
expression of chemokines and ligands; modulating processes of cellular adhesion, 
transendothelial migration and tissue retention via effects on integrins and 
adhesion molecules (176-178). Normal lymphocyte migration processes have 
been discussed already in 1.7.2. These inhibitors, as well as targeting BCR-
mediated signals, also have effects on microenvironmental signalling out-with 
the BCR signalling pathway. Paracrine secretion of chemokines CCL3 and CCL4 by 
CLL cells is blocked, reducing support from monocyte-derived nurse-like cells 
and accessory T cells (176, 177). Pre-clinical studies of BCR signalling inhibitors 
detail a striking lymphocytosis effect with individual therapies in terms of 
plasma chemokine levels and surface receptor expression. Using primary CLL 
samples De Rooij et al. demonstrated a reduction in signalling via CXCL12, 
CXCL13 and CCL19 upon ibrutinib treatment, with a reduction in adhesion and 
migration of CLL cells (178). In parallel studies of ibrutinib, Ponader et al. 
identified a reduction in migration toward CXCL12 and CXCL13, which inhibited 
CCL3 and CCL4 secretion. Targeting of SYK with fostamatinib also displayed an 
inhibitory effect on CCL3 and CCL4 secretion in primary disease samples, with a 
reduction in homing towards CXCL12 and CXCL13 and a reduction in CLL cell 
adhesion to VCAM-1 (177, 179). Our group investigated the effects of LYN kinase 
inhibition with dasatinib revealing inhibitory effects on the CXCR4-CXCL12 
signalling axis in CLL samples in vitro (180). PI3Kd inhibition with idelalisib 
revealed a downregulation of chemokine levels in vitro, a finding that was 
corroborated by data from patients treated with the drug during clinical trial. 
Chemokine levels in patient plasma samples exhibited a reduction in secretion of 
CCL3, CCL4 and CXCL13 and a concomitant surge in the lymphocyte count in the 
PB (176). 
1.9 Modelling CLL in vivo  
Cellular migration has not only been studied in vitro as summarised in the 
experimental work described above but also in the more physiological 
environment of the murine models of CLL. The array of available murine models 
represents the wide heterogeneity in human disease phenotype and shall be 
discussed with a focus on the model developed in our laboratory and employed 
in experiments described herein. 
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 PKCaKR construct and mouse model 
The PKCaKR mouse model developed in our laboratory utilises a catalytically 
inactive version of the protein kinase Ca (PKCa) molecule to transform murine 
cells, resulting in disease with an aggressive CLL-like phenotype (181). 
Phenotypic characterisation of the PKCaKR mouse model is still in progress for 
this mouse that represents an exciting prospect for the in vivo modelling of CLL 
cell migration (182). On further interrogation of our model the PKCaKR 
expressing cells exhibit activation of ERK-MAPK-mTOR signalling, a basis for the 
proliferative capacity of these cells. The PKCa-KR model expresses 
predominantly unmutated IgVH genes with longer CDR3 regions and an 
upregulation of ZAP-70, all shared features of poor prognostic CLL. The inherent 
downregulation of PKCa is also visible in our CLL patient cohort with elevation of 
PKCbII as a mechanism of disease progression. The PKCaKR construct also 
mediates upregulation of PKCbII; PKCbII has been identified as a downstream 
regulator of the BCR signal and also features in CLL pathogenesis with 
demonstrable increase in its activity in BCR-dependent CLL (183).  
 Other models 
The Tcl-1 mouse model is analogous to poor prognostic CLL and relies on the 
deregulated expression of the oncogene T cell leukaemia/lymphoma 1 (Tcl-1) in 
B lineage cells. Developed as a model for use in drug development, the Tcl-1 
model was shown to express relevant therapeutic targets with demonstrable 
sensitivity to fludarabine (184). The Tcl-1 model requires PKCb for development, 
however deletion of PKCbII leads to an increase in CLL cell survival and PKCbII 
expression was unchanged with our in vitro studies using this model, with a 
downregulation of PKCa.  The Tcl-1 model also expresses predominantly 
unmutated IgVH genes however the absence of ZAP-70 from the model offers 
insight into the distinction between models and potentially is reflective of 
disease onset at a later stage of differentiation than the PKCa-KR model, 
supported by the greater latency of the Tcl-1 model. Other models which have 
been less frequently employed include a 13q14 deletion model which targets the 
region encoding DLEU2/miR15a/16-1; New Zealand Black mice which are 
histopathologically CLL-like but differ in immunophenotype from CLL and the 
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APRIL mouse indolent model that produces a disease phenotypically like CLL but 
without CLL-like effects on survival. Interferon regulatory factor 4 (IRF4) is a 
transcriptional regulator and plays a role in B cell development. As murine CLL is 
derived from B-1 cell populations, an IgVH subset Vh11 unique to B-1 cells may be 
employed in an (IRF4-/-Vh11) knock-in to elicit a CLL-like disease. 
Characterisation of the disease model will aid in understanding its utility as a 
model of human CLL but also has implications for our understanding of the role 
of IRF4 in CLL pathogenesis and the mechanism by which it appears to suppress 
the onset of CLL (185). 
 In vivo models in migration studies 
Pre-clinical data on ibrutinib and fostamatinib in the Tcl-1 model showed in vivo 
effects of an initial increase in lymphocytosis with therapy and a reduction in 
lymphadenopathy although the molecular mechanisms have not been elucidated 
(186, 187). LYN kinase, proximal to BCR signalling, has been targeted using 
dasatinib, and in the Tcl-1 model regulates haematopoietic cell-specific Lyn 
substrate (HS1) cytoskeletal formation, critical to the migration process (188). 
Based on the observation that the GTPase Rho knockout in the Tcl-1 mouse 
model displays a delayed disease onset, further work with this model revealed a 
reduction in homing of cells to the BM with a reduction in interactions with 
CXCL12 and CXCL13 and a reduction in the polarisation of phosphorylated focal 
adhesion kinase (FAK) with defective integrin function (189). 
1.10 mTOR signalling pathway 
 mTOR kinase complexes: structure and function 
Mechanistic target for rapamycin (mTOR) resides in two distinct signalling 
complexes mTORC1 and mTORC2, which integrate growth factor and nutrient 
signals to promote cell survival, growth and proliferation (190). mTORC1 
contains RAPTOR, mLST8, PRAS40 and DEPTOR and mTORC2 contains RICTOR, 
mLST8, mSIN1 and DEPTOR (190-193). Originally defined in yeast (194, 195), the 
250kDa protein kinase is both growth factor- and nutrient-sensitive with respect 
to mTORC1 however the “rapamycin-insensitive” mTORC2 responds only to 
growth factor signals and its existence explains the evident mTOR activity upon 
treatment with rapamycin (196). Positioned downstream of the 
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phosphatidylinositol-3-kinase (PI3K)-mediated signalling, mTOR integrates signals 
from binding of chemokine receptors, such as CXCR4 and CXCR5, and BCR-
mediated signals in addition to the more frequently reported metabolic and 
growth factor responses ((197) & Figure 1-5).  
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Figure 1-5 Diagram of B cell receptor signal transduction cascade with indication of 
relationship to chemokine receptor signalling in normal B cells 
The mTOR kinase complex described earlier is demonstrated with its positioning 
downstream of the extracellular BCR and SDF-1 signals. The mTORC1 and dual mTORC1/2 
inhibitors rapamycin and AZD8055/AZD2014 are displayed with their site of action within the 
mTOR complex shown.  
The tuberous sclerosis (TSC1-TSC2) protein complex acts as an intermediary 
between the PI3K/AKT and mTOR signal, and its phosphorylation by AKT causes 
disassociation of the complex from GTPase Rheb which permits mTOR activation 
(198). Alternatively, in conditions of oxidative stress, hypoxia or starvation, 
mTOR may be inhibited by TSC1/2, activated by the conversion of Rheb-GTP to 
Rheb-GDP by 5’adenosine monophosphate-activated protein kinase (AMPK). 
While mTORC1 phosphorylates p70S6kinase (S6K) and eukaryotic initiation factor 
4E-binding protein 1 (4EBP1) to increase protein synthesis, mTORC2 directly 
phosphorylates AKTS473, enhancing its kinase activity 5–10 fold to promote cell 
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survival and initiate cell cycle (199, 200). Through AKT regulation, mTORC2 is 
considered to play a role in migration, however the precise molecular 
mechanisms have yet to be elucidated (200, 201). The activation of mTORC1 
may be further regulated by localisation of the complex; mTOR is largely 
cytoplasmic but can associate with cellular organelle membranes, affecting its 
ability to phosphorylate S6K1. The functions of mTORC1 involve regulation of 
cellular proliferation, cell size, ribosomal biogenesis and angiogenesis by 
phosphorylation of S6K1 and 4E-BP1, which are directly responsible for mRNA 
translation (202). After mTORC1 activation, S6K1 triggers protein synthesis by 
phosphorylating PDCD4, marking it for degradation with secondary effects of 
binding and preventing elF4A helicase from fulfilling its function in mRNA 
unwinding. S6K1 can also function to dampen signalling via PI3K by inhibition of 
insulin receptor substrate 1 (IRS1) and 2 (IRS2) expression, providing a negative 
feedback loop within the mTORC1 side of the complex, thus explaining the non-
aggressive nature of the hamartomatous tuberous sclerosis syndrome, a product 
of mutations in tsc1/2 (203). Upon phosphorylation by mTORC1, 4E-BP1 is 
released from inhibiting the elongation initiation factor 4E (eIF4E).  
mTORC2 plays a major role in signalling via the PI3K/AKT pathway, through 
phosphorylation and activation of AKT making it of interest as a therapeutic 
target in blocking the AKT signal, as mTORC2 has been demonstrated to be 
necessary for the development of activated PI3K signalling in tumours (204). Of 
note, an inhibitory feedback loop exists between mTORC1 and mTORC2, 
enabling an upregulation in AKT signalling with the removal of the mTORC1 
signal, suggesting a complex regulatory role for mTOR in AKT-dependent 
malignancies (205, 206). 
1.11 mTOR inhibitors 
 mTORC1 inhibitors 
mTOR kinase was discovered by virtue of research gaining an understanding of 
the pharmacological activity of rapamycin (207). Originally discovered in the soil 
of Easter Island and derived from Streptomyces Hygropicus, this macrolide was 
found to possess both immunosuppressive and anti-neoplastic properties (208, 
209). The two mTOR complexes are defined by their differential responses to 
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rapamycin; mTORC1 binds rapamycin allosterically by its association with 
FKBP12 whereas mTORC2 was first thought to be rapamycin-insensitive thus 
making mTORC1 the obvious choice as a drug development target. Thereafter, 
CCI-779 (temsirolimus) and RAD001 (everolimus) which have greater clinical 
tolerability than rapamycin, were developed for clinical use and have been 
trialed as therapies in both solid organ and haematological cancers with some 
efficacy (210-213). In CLL, everolimus elicited similar lymphocyte redistribution 
effects to that of PI3K and BTK inhibitors however overall clinical responses 
were not as promising (213), potentially due the existence of the negative 
feedback loop allowing preservation of AKT signalling in the absence of mTORC1 
signal (205, 206).  
 Dual mTORC1/2 inhibitors 
Dual mTOR inhibitors can be divided into two broad categories (Table 1). Firstly, 
there are small molecules that selectively inhibit both mTORC1 and mTORC2. 
First-in-class drug AZD8055 and its formulation for clinical use AZD2014 
(Vistusertib) is an ATP-competitive inhibitor of mTOR, which selectively blocks 
phosphorylation of mTOR substrates (214). Dual mTOR inhibitors are ATP-
competitive inhibitors and their superior clinical results and depth of mTORC1/2 
inhibition was originally attributed to their ability to inhibit mTORC2 however 
some of their properties may a result of their ability to block rapamycin-
resistant components of mTORC1. Upon inhibition of PRAS40 phosphorylation by 
dual mTOR inhibitors, this protein has enhanced binding of the RAPTOR/mTOR 
complex with resultant inhibition of the mTORC1/4EBP1 signal (215). 
Furthermore, there are differential effects upon cyclin D1 and D3 by rapamycin 
and dual mTOR inhibitors, with a reduction in protein expression of these and an 
increase in p27 with dual mTOR inhibition (216).  
 Dual mTORC1/2 inhibitors with overlapping functions 
Pitfalls with these agents include the development of drug resistance, or the 
existence of alternative activating signals or negative feedback loops. Other 
types of dual mTOR inhibitor aim to overcome the potential deficiencies of 
specific inhibitors and inhibit PI3K signals as well as mTOR (Table 1-4); these 
have the advantage of inhibiting the three proto-oncogenic kinases PI3K, AKT 
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and mTOR, closing some of the feedback loops. Concerns regarding their effects 
on normal non-malignant cells have not prevented their use however overall 
clinical effects have been modest thus far. Compounds such as SAR245409 and 
PF-04691502 fared well in pre-clinical tests in comparison with specific pan-PI3K 
inhibitors in CLL however clinical data is awaited (217, 218).  
Table 1-4 Dual mTOR inhibitors in current clinical trials 
Agents currently under evaluation in clinical trials are indicated; their respective molecular 
target, phase of investigation and disease of study are shown. 
 
 mTOR inhibition in CLL in vitro 
One dedicated study used CXCL12-transwell migration studies to demonstrate 
the ability of PI3K/mTOR inhibitor SAR245409 to reduce chemokine-mediated 
migration (218). Using vascular cell adhesion molecule-1 (VCAM-1) coated plates, 
CLL cells were pre-treated with 1 µM SAR245409, BYL719 (PI3Ka inhibitor), or 
idelalisib, and allowed to migrate towards 100ng/ml CXCL12 through a 
polycarbonate membrane. Relative migration was significantly lower in 
SAR245409-treated cells than untreated control cells (approximately 80% 
compared to 100%) with a lesser effect by idelalisib and no migration 
impairment by BYL719. The transwell assay was utilised again, this time with 200 
ng/mL CXCL12 to assess migration on CLL cells treated with PF-04691502 at a 
dose range of 1.25-2.5 µM to show a significant inhibition of migration by the 
PI3K/mTOR inhibitor (217). To augment the approach to mTOR inhibition 
further, CC-115, mTOR and DNA damage pathway inhibitor, has shown promise 
using in vitro assessment of caspase-dependent cell killing, proliferation and BCR 
signalling in comparison to specific mTOR inhibitor CC-223 and BTK inhibitor CC-
Drug Generic name Inhibitor target Phase Disease
AZD2014 VISTUSERTIB Dual mTOR kinase I-II AST, GBM, HCC, 
Lymphomas
OSI-027 Dual mTOR kinase I AST, Lymphomas
PF-04691502 PI3K-mTOR I-II Breast, Endometrial, AST
SAR245409 VOXTALISIB PI3K-mTOR I-II AST, GBM, Ovarian, Breast
CC-115
CC-223
MLN0128 
(TAK228)
VS-5584
Dual mTOR/DNA-PK
Dual mTOR kinase
Dual mTOR kinase
PI3K-mTOR
I-II
I-II
I-II
I
AST, GBM, AML
NSCLC, NHL, MM
Prostate, thyroid, breast, liver
Metastatic cancer, 
lymphomas
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229 and the compound has progressed further to preliminary clinical testing 
(219). 
1.12 mTOR and cellular migration 
 mTORC1  
To delineate the relative contribution of mTOR complexes to the cellular 
migration process we still refer to evidence from studies utilising rapamycin. The 
regulation of migration by inhibition of S6K1 and 4EBP1 has been shown in a 
variety of cell types, by the administration of rapamycin, to delineate the 
mechanisms by which control is exerted, including formation of the F-actin 
cytoskeleton, extracellular matrix remodelling (e.g. MMP9) focal adhesion 
formation, and Rho GTPase activation all regulated via S6K1 (220-222). 
Furthermore, there is evidence derived from inhibitor studies that support both 
mTORC1 and mTORC2 as regulators of cell adhesion (223). Extracellular matrix 
changes and GTPase activity are also regulated by 4EBP1 with evidence that it 
also regulates VEGF/TGFb levels in a rapamycin-sensitive manner in mouse 
models of solid organ tumours and metastasis (224). Rapamycin appears to exert 
its effect downstream of S6K1 and 4EBP1 via regulation of small GTPase RhoA 
activation (225). 
 mTORC2  
In contrast, mTORC2 mainly modulates the actin cytoskeleton to regulate 
migration (226, 227). Downstream effectors appear to be species and cell-type 
specific. PKA and Ras signalling pathways appear to be pivotal in amoebae (228), 
while, in mammals PKC, PKA signalling and Rac/RhoA are the main regulators of 
mTORC2-mediated migration (229). Studies using amoebae demonstrate that 
TORC2 exerts its influence via AKT and PKA regulation of adenylyl cyclase–based 
production of cyclic AMP (230). In mammalian systems, it appears that mTORC2 
regulates neutrophil chemotaxis by regulation of F-actin polarisation and myosin 
II phosphorylation, again regulated by cAMP production but via PKC in a 
RhoA/ROCK dependent fashion (231). There are also putative mTORC2-
independent effects of RICTOR on migration that have yet to be fully explored 
(232). 
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 Downstream mediators of mTOR kinase and migration 
control 
It is hypothesised that mTORC1/2 inhibitors would also have effects on 
cytoskeletal formation with downstream effects of cAMP production mediated by 
PKC and GTPases and this is supported by studies from a variety of model 
organisms and cell types. Indeed, the first description of the RICTOR homologue 
pianissimo in Dictyostelium discoidieum is as a regulator of chemokine and 
GTPase signals. In the described piaA knock-out model, cells are unresponsive to 
chemokine stimulation or GTPgS activation, defects that are restored with 
constitutive activation of piaA (233). Cytoskeletal regulation was attributed to 
TORC2 in Saccharomyces cerevisiae and amoebae through regulation of the Rho 
GTPase family and downstream mediators including pkc1 (234). In mammalian 
systems, a link between RICTOR and PKCa was established first (227) followed by 
a link between mTORC2 and RhoA family in regulation of neutrophil chemotaxis 
via mechanisms which are independent of actin cytoskeletal reorganisation 
(235). It appears that Rac/cdc42 GTPases are responsible for actin cytoskeleton 
formation and these effects are driven by RICTOR-mediated inhibition of Rho-
GDP dissociation inhibitor 2 (231, 236). 
GTPases are also dysregulated in CLL cell migration, elucidated by two studies 
with a specific focus on Rap1 GTPase and its role. Chemokine-induced 
transendothelial migration has been shown to be defective in CLL and 
pathological B cells lose their chemokine-responsiveness in the disease. GTP-
loading of Rap1 fails due to impaired endosomal recycling to the plasma 
membrane and this has been attributed to defective activation of phospholipase 
D1 and Arf1, its regulator (237). Additionally, chemokine-induced activation of 
integrin clustering fails due to an inability to polar clustering of aLb2 integrin 
which is Rap1-induced. Binding of a4b1, VEGF and chemokine are all needed for 
aLb2 activation, as a result of failure to GTP-load Rap1 in CLL cells (238). 
Studies are ongoing as to the relationship between mTOR signalling and Rap1 
activity.  
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Chapter 2 Materials and methods 
2.1 CLL samples 
Patient CLL samples were provided after requesting informed consent of the 
patients of the Beatson West of Scotland Cancer Centre, for which local research 
ethics committee approval was obtained. Primary CLL cells were removed from 
liquid nitrogen storage and placed in a water bath at 37oC until almost thawed. 
The CLL cell suspension was diluted in DAMP solution (DNAseI 5000U, 1M MgCl2, 
0.155M Trisodium citrate, 20% Human Serum Albumin, Dulbecco’s Phosphate-
buffered saline (PBS)) added dropwise to a total of 10 ml over 10 min. Cells were 
centrifuged at 350 g for 5 min then washed in RPMI-1640 supplemented with 10% 
fetal calf serum and 10mM L-glutamine, 10000 units/ml penicillin and 
streptomycin 10000 µg/ml (hereafter referred to as complete media) then 
centrifuged at 350 g and resuspended in complete media in preparation for use. 
Sample purity was confirmed by FACS evaluation (Figure 2-1). Flow cytometry 
data were acquired using a FACSCantoII flow cytometer (BD Biosciences) using 
the FACS Diva software package. 
 
Figure 2-1 CLL cell purity by FACS analysis 
Representative FACS plot displaying (A) live cell gating for assessment of (B) CD19+ and 
CD5+ cell surface staining using a patient sample which harbours a normal karyotype 
(CLL116).  
 Cell counting using a haemocytometer 
An aliquot of CLL cell suspension was added at a dilution of 1:10 in 1X trypan 
blue solution into a 500 ul Eppendorf. Using a glass haemocytometer (Neubauer), 
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10 µl of the diluted cells was dispersed under the coverslip for viewing at X40 
magnification by microscope (Nikon). A cell count was obtained from the 4 
corner squares and the middle square of the counting chamber. To obtain the 
final count an average count of 5 squares was calculated with this number then 
multiplied by the dilution factor and by a correction factor for the cell chamber 
volume (104), to obtain a final cell count to be expressed per millilitre of original 
cell suspension. 
 Cryopreservation of primary CLL samples 
Cell freezing mix was prepared by adding 10% dimethyl sulfoxide (DMSO) to fetal 
calf serum and used at room temperature. DMSO is used to prevent the 
formation of ice crystals which would destroy the cells during the freezing 
process. Cells were centrifuged at 350 g for 5 min then resuspended in cell 
freezing mix at a concentration of either 50 x 106 or 100 x 106 cells per millilitre 
in individual cryovials (Greiner). The cryovials were placed in a Mr. FrostyTM 
freezing container (Thermo Fisher Scientific) to allow gradual acclimatisation to 
-80oC before eventual storage at -180oC in liquid nitrogen storage tanks. 
 Short-term stimulation with SDF-1 
Cells were rested in 1 ml of media prepared from RPMI-1640, 500 ml stock 
containing 10mM L-glutamine, 50000 units/ml penicillin and streptomycin 50000 
µg/ml and 0.5% Bovine Serum Albumin (BSA) (Sigma-Aldrich Ltd., RPMI/BSA) for 
2 h prior to the experiment. Cells were counted and placed into wells containing 
1 x 106 cells and incubated in the presence or absence of inhibitors at 37 oC for 
30 min. Cells were placed in a waterbath at 37 oC and SDF-1 (Peprotech Ltd.) 
was added at a concentration of 100 ng/ml. Experimental samples were removed 
from the waterbath and the reaction stopped by the addition of 1 ml ice-cold 
PBS at time points 0, 3 and 10 min. 
 Short-term BCR stimulation with aIgM and avidin 
Primary CLL cells were incubated with drug inhibitors at 37oC for 30 min prior to 
BCR stimulation. Cells were transferred to a 1.5 ml Eppendorfs and placed on ice 
with the addition of aIgM (BD Biosciences) at 10 µg/ml. After 20 min, the cells 
were spun at 350 g for 5 min and avidin was added for a final concentration of 
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25 µg/ml. Cells were removed after 1 h and the reaction stopped with ice-cold 
PBS. 
 BCR stimulation with aIgM F(ab’)2 fragments 
Primary CLL cells were incubated in complete medium with drug inhibitors at 
37oC for 30 min prior to BCR stimulation. Soluble F(ab’)2 fragments (Jackson 
ImmunoResearch Laboratories, Inc.) at 10 µg/ml were added to mimic 
continuous antigen exposure of CLL cells and a range of incubations at 37oC were 
performed from 1 h to 48 h in duration. 
2.2 Migration Assays 
 M2-10B4 cell proliferation in culture  
The murine cell line M2-10B4 was found to secrete factors such as SDF-1 which 
may be used in co-culture experiments with human haematopoietic cells in vitro 
(239). A cryovial of M2-10B4 cells was thawed using DAMP as per CLL samples, 
resuspended in complete media and placed in a flask for adherent cell culture in 
an incubator at 37oC. Twice weekly, cells were checked for confluence and 
media was replenished to prevent exhaustion. Once confluent, the media was 
discarded and cells were washed in 5 ml of PBS. Then 1 ml trypsin was added to 
the flask and incubated at room temperature for 5 min, after which cells were 
removed, resuspended in 5 ml complete media and centrifuged at 350 g for 5 
min. The pellet was resuspended again in 5 ml media and according to the 
extent of cell layer confluence, 1-4 ml of this suspension was discarded and 
supplemented with complete media to create a final volume of 10 ml. Cells were 
placed in a fresh flask and returned to an incubator for culture at 37oC. 
 Pseudoemperipolesis 
The pseudoemperipolesis assay exploits the ability of CLL cells to transmigrate 
beneath a cellular layer along a chemokine gradient (148). In preparation, plates 
were coated with rat-tail collagen I (Invitrogen Ltd.) at 3 mg/ml concentration. 
Stromal M2-10B4 cells were placed in a 24-well plate at 1.5 x 105 cells per well 
and incubated at 37oC for 48 h until confluent. On a separate 24-well plate, 
primary CLL cells were plated at 2 x 106/well and were placed under drug 
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conditions: control, 100 nM AZD8055, 300 nM AZD8055, 10 nM rapamycin, 1 µM 
ibrutinib in the presence and absence of B cell receptor stimulation. Each well 
was prepared in duplicate and the plate was incubated for 15 h at 37oC prior to 
the start of the assay. Next, the M2-10B4 cell suspension was removed and CLL 
cells placed on top of the layer of cells in each well then incubated at 37oC for 5 
h. After removal from the incubator, the cell suspension in each well was 
removed and wells were each washed 3 times with PBS to ensure removal of 
non-migrated CLL cells. Stromal cells were then trypsinised and stained using a 
CD45+/CD19+ fluorescent antibody to permit counting by flow cytometer. Cells 
were counted at high flow for 20 sec for each well and a sample of the initial 
CLL cell suspension was enumerated to provide a comparison. Negative controls 
containing empty stroma or CLL cells incubated to migrate for 5 min were 
washed in the same way as other wells and were established as containing 
<0.05% transmigrated cells. 
 Transwell migration assay: primary CLL cell sample 
preparation 
After counting primary CLL cells, 5 x 105 were set aside per condition. Cells were 
rested in RPMI/BSA for 2 h prior to commencement of the assay and 
subsequently placed in drug conditions for 30 min at 37oC as follows: control, 
100 nM AZD8055, 300 nM AZD8055, 10 nM rapamycin, 1 µM ibrutinib. Next, BCR 
stimulation was added using anti-IgM F(ab’)2 fragments for 1 h at 37 oC at a 
concentration of 10 µg/ml.  
 Transwell migration assay: murine PKC-aKR sample 
preparation 
Murine fetal liver cells retrovirally transduced with the PKC-aKR construct (181) 
were prepared in culture over a layer of OP9 cells in Minimum Essential Media 
(MEM) alpha (Thermofisher Scientific). Each media unit (500ml) was 
supplemented with 50 mM HEPES, 5 mM sodium pyruvate, and 10 µg/ml 
gentamicin (HSG) and 1.25 mM 2-mercaptoethanol; 50,000 units of penicillin, 
streptomycin 50000 µg/ml, and 10 mM L-glutamine (2-PG) (Gibco®). Also, 20% 
fetal calf serum was the supplemental nutrient and 10 µg/ml of IL-7 (Peprotech 
EC Ltd, London) was added to promote proliferation. At the same time, control 
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MIEV-empty vector cells were cultured over OP9 cells. After 14 days, aKR and 
MIEV cells were counted and 3 x 105 per condition were set aside. Cells were 
rested in Dulbecco’s Modified Eagle’s Medium (DMEM) (Thermofisher Scientific) 
with 0.5% BSA for 2 h prior to commencement of the assay and subsequently 
placed in drug conditions for 30 min at 37oC as follows: control, 100 nM 
AZD8055, 10 nM rapamycin, 3 µM ibrutinib and 20 µM enzastaurin. Figure 2-2 
confirms that PKC-aKR transduced cells, which are GFP positive, possess cell 
surface positivity for B cell marker, CD19. 
 
Figure 2-2  In vitro culture of PKCa-KR transduced cells 
FACS plot of cells sampled from day 9 in vitro murine PKCa-KR cells in culture. 
Comparison with (A) unstained and cells stained for (B) PE-Cy7 CD19 highlights a discrete 
GFP+CD19+ population indicative of CLL-like disease.  
 Transwell migration assay 
Cells in a volume of 100 µL were transferred to the upper chamber of a 6.5 mm-
diameter, pore diameter 5 µm transwell culture insert (Costar®) and placed 
above 600 µL of media containing 150 ng/ml SDF-1. Each well was performed in 
duplicate with negative control containing media without SDF-1 and a positive 
control with direct insertion of CLL cell suspension to the lower chamber. The 
plate was placed at 37oC to allow transwell migration, and after 4 h the inserts 
were removed and after mixing the wells, 3 x 150 µl aliquots removed from each 
well for enumeration by flow cytometry. Cells were counted at high flow for 20 
sec for each aliquot. 
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 Actin polymerisation by FACS analysis 
CLL cells were counted and 1 x 106 were set aside per condition; cells were 
rested in RPMI-1640/ 0.5% BSA for 2 h prior to 30 min drug incubation at 37oC. 
Cells were placed in a water bath at 37oC and 100 µL samples removed 
immediately prior to and at 15, 60, 300 and 600 sec post-addition of 100 ng/ml 
SDF-1 and placed directly into 250 µL of fixation/ permeabilisation buffer at 4oC 
for 15 min. Each sample was then centrifuged at 350 g for 5 min then washed in 
2 ml perm/wash buffer and then stained with 66 nM Alexa Fluor 488® phalloidin 
antibody (Invitrogen Ltd.) for 10 min at 4oC. Samples were washed and 
centrifuged at 350 g for 5 min then analysed by flow cytometry, measuring 
10,000 events recorded in the FITC (FL1) channel (gated on live cells by 
FSC/SSC).  
2.3 Sodium dodecyl sulphate-polyacrylamide gel 
electrophoresis (SDS-PAGE) and Western blotting 
 Sample preparation 
CLL cells were washed in PBS and the supernatant was aspirated. 1:10 dilution of 
stock of Protease and phosphatase inhibitors (13) were prepared by using 1 
tablet of each to 1 millilitre of ddH2O and allowed to dissolve, to make a 10X 
stock. Thereafter, lysis buffer prepared was from 1% NP-40, 10% glycerol, 20nM 
Tris (pH 7.5) and 137mM NaCl with a 1:10 dilution of protease and phosphatase 
inhibitors and 30µl was added with mixing to each cell pellet, with vortexing 
before and after. The tubes with cells and lysis buffer were placed on ice for 15 
min, then centrifuged at 21000g for 20 min. Samples were stored at -20 oC in 
preparation for use.  
 SDS-PAGE 
Samples were thawed and the protein concentration was estimated using the 
bichinchoninic acid assay (Pierce). Resolving gel was prepared as per protocol 
for a 12% acrylamide gel containing bis-acrylamide, double distilled water 
(ddH2O), 10% sodium dodecyl sulphate (SDS), 0.5M Tris (pH 6.5), 10% ammonium 
persulphate and 1,2-bis(dimethylamino)ethane and allowed to set for 20 min. 
Stacking gel was prepared using the above reagents with the substitution of 1.5M 
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Tris (pH 8.5) and left to set for 30 min with a gel comb in place. Wells were 
washed thoroughly with ddH2O and gels placed in a gel tank (Bio-Rad 
Laboratories) with immersion in running buffer (34.7 mM SDS, 245.6mM Tris, 2M 
glycine, ddH20). Samples were prepared using PBS to supplement sample volume 
with DTT and loading buffer and were denatured using a heated plate for 10 min 
at 70 oC. Samples were loaded alongside a protein ladder (hyperPAGE II, Bioline) 
and electrophoresis commenced using 80 mV for 30 min then 180 mV until 
samples had run to the bottom of the gel. PVDF (polyvinylfluoridine) membranes 
were cut to gel size and prepared by immersion in 100% methanol for 30 sec 
prior to transfer. Gels and membranes were sandwiched between sheets of 1mm 
paper and immersed in transfer buffer (5% NuPAGE transfer buffer (25 mM Bicine 
25 mM Bis-Tris (free base) 1 mM EDTA, pH 7.2), 10% methanol, ddH2O) inside the 
X Cell II blot module (Invitrogen Ltd.) and electrophoresis performed using 30 
mV for 1 h. 
 Western blotting 
Blots were washed in TBS-T (10 mM Tris, 50 mM NaCl, ddH2O, Tween 20 (Sigma-
Aldrich Ltd.)) for 5 min and were blocked in 5% milk for 1 h. Blots were washed 
again for 5 min in TBS-T and primary antibody was added according to 
manufacturer’s instruction, prepared either in 5% BSA or 5% milk. After 
overnight incubation at 4 oC blots were washed 3 x 5 min in TBS-T and secondary 
antibody applied according to the specificity of the primary antibody in use. 
After 1 h incubation at room temperature (RT) blots were washed for a further 3 
x 5 min in TBS-T and treated with 700 µL Millipore chemiluminescent HRP 
substrate with measurement of chemiluminescence using the Molecular Imager® 
Chemi-Doc XRS™ imaging system (Bio-Rad Laboratories) or the Li-Cor Odyssey® 
Fc Imaging System. With the use of fluoresecent secondary antibodies there was 
a 1 h incubation period at room temperature (RT) with 3 x 5 min washes in TBS-T 
prior to measurement of fluorescence using the Li-Cor system. 
 Densitometry analysis  
Images measured by the LiCor system were generated in Image StudioTM software 
with densitometry performed according to the manufacturer’s instructions using 
Image StudioTM Lite v 5.2.5. Where images from a dataset had been generated in 
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2 different types of software (Molecular Imager® Chemi-Doc XRS™ and Li-Cor 
Odyssey® Fc Imaging System) analysis, images were converted to 8-bit tagged 
image file format for analysis using Image J v1.48. 
2.4 Cell staining for flow cytometry analysis 
 Cell viability staining  
After processing of whole blood samples, the success of the isolation process was 
assessed via cell surface marker staining for CLL-specific markers. Prior to use in 
our experiments, primary CLL samples, either fresh or thawed, were assessed for 
cellular viability. Representative FACS plot of staining for FITC/APC-conjugated 
Annexin V and 7-amino-actinomycin D (7AAD) viability markers are shown in 
Figure 2-3.  A stock solution containing Annexin V 5µL, 7AAD 2.5µL (BD 
Biosciences) and 92.5µL Hank’s Balanced Salt Solution (HBSS) (Gibco®) (12.6 mM 
CaCl2, 4.9 mM MgCl2, 4.1 mM MgSO4 53.3 mM KCl 4.4 mM KH2PO4 1379 mM NaCl 
3.36 mM Na2HPO4, 55.5mM Dextrose) per experimental condition was prepared. 
Cells (0.5 -1 x 106/condition) were washed in FACS buffer and 100 µL of the 
antibody solution was added per condition and cells were left in the dark at RT 
for 20 min to allow staining. The antibody-cell binding reaction was quenched 
with 1 ml HBSS and cells were resuspended in 300 µL after washing in 
preparation for flow cytometry. 
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Figure 2-3 Contour FACS plots of fresh primary patient samples 
CLL 159, a patient sample with a normal karyotype after 48 h incubation with (A) non-drug 
control and (B) 100 nM AZD8055. Apoptotic cells are delineated by their positivity for 
Annexin V which binds to phosphatidylserine on the outer leaflet of the plasma membrane. 
Live cells stain Annexin V-7AAD- and are localised to Q3 whereas late apoptotic cells in Q2 
are positive for both markers. 
 Flow cytometry surface antibody staining 
CLL cells (1 x 106/ tube) were washed in HBSS and antibody stock solution was 
prepared using volumes of fluorescent antibody (BD Biosciences) according to 
the manufacturer’s labelled instructions. Stock solution was adjusted using the 
addition of HBSS and aliquots of 20 µL were added per tube with subsequent 
incubation of cells at 4 oC for 15 min. The reaction was quenched with 1 ml of 
FACS buffer and cells were resuspended in 300 µL after washing in preparation 
for flow cytometry. 
2.5 Immunofluorescence staining 
 Slide and sample preparation 
Multispot slides (Hendley, Essex Ltd.) were coated with 0.01% poly-L-lysine for 2 
h at 4 oC, removed and washed twice with PBS. In the preparation of cells for 
stimulation there was 1.5 h prior incubation in RPMI/BSA at 37 oC. Cells at a 
concentration of 3 x 106 /ml were incubated with drug conditions: control, 100 
nM AZD8055, 10 nM rapamycin, 1 µM ibrutinib for 30 min at 37 oC prior to 
placement on slide spots with a further 30 min incubation.  
A B
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 Rap1 activity assay by immunofluorescence staining 
Each drug condition was either left unstimulated or treated with 10 µg/ml EPAC 
agonist 8-(4-Chlorophenylthio)-2’-O-methyladenosine 3’,5’-cyclic 
monophosphate monosodium hydrate (Sigma-Aldrich Ltd.) or 100 ng/ml SDF-1 for 
5 min before removal of cells with a tissue and fixation each with 30 µl 4.2% 
formaldehyde at RT for 10 min. Spots were washed three times with PBS and 
permeabilised with 30 µl 0.5% Triton in PBS for 15 min. A further wash step was 
performed then cells were blocked with 5% BSA/ 0.2% Triton/ 1% ovalbumin for 1 
h at RT. Cells were either individually stained with Rap1 (1:200) (Santa Cruz 
Biotechnology) or co-stained with LAMP-1 (1:20) or EEA-1 (1:100) antibodies for 
endosomal colocalisation (Abcam Plc.) prepared in 5% BSA block and incubated 
in the dark overnight at 4 oC in a moisture-containing chamber. Spots were 
washed twice and incubated with anti-rabbit Alexa Fluor 488® (Invitrogen Ltd.) 
or Rap1 single staining and for colocalisation a combination of anti-rabbit Alexa 
Fluor 594® and anti-mouse secondary Alexa Fluor 488® (Invitrogen Ltd.) at a 
concentration of 1:200 in 5% block for 1-2 h at RT. Slides were then washed 
three times in PBS and allowed almost to air-dry before placement of coverslip 
using ProLongTM Diamond Antifade Mountant with DAPI (Thermo Fisher Scientific) 
and storage of slides in the dark at RT prior to analysis. 
 Actin polymerisation immunofluorescence staining 
Actin cytoskeletal formation was further evaluated by preparation of cells for 
immunofluorescence staining as above but in this case 2% BSA block was used 
and incubated for 30 min with stained with Alexa Fluor 488 phalloidin at 4 oC for 
30 min in the dark. Slides were washed twice in PBS and allowed almost to air-
dry before placement of coverslip using DAPI and storage of slides in the dark 
prior to analysis. 
 Immunofluorescence staining: BCR stimulation technique 
Slides were first coated with 0.01% poly-L-lysine as before but after washing 
with PBS, aIgM or IgGk1 isotype control (BD Biosciences) at a concentration of 10 
µg/ml PBS were added to slide spots and incubated at 4 oC overnight. The 
following day the antibody was removed and slides were blocked with 10% 
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BSA/RPMI for 15 min at 37 oC before continuing with the protocol for 
immunofluorescence staining at the drug incubation step.  
 Fluorescent microscopy 
Images were taken using Zeiss Axio Observer Imager M1 (Carl Zeiss Microscopy, 
LLC, United States) which is a microscope for multi-channel fluorescent 
acquisition. Epifluorescence microscopy illuminates the whole sample at once, 
but detects both in-focus and out-of-focus light which has implications for 
spatial resolution of cellular structures. To permit the use of a microscope 
system as a tool to evaluate colocalisation of two fluorophores, a variety of 
conditions must be met (240). For widefield fluorescent microscopy to be used in 
evaluation of colocalisation, images require deconvolution (240). Deconvolution 
uses data generated by an optical system to localise fluorescence more 
accurately, bringing images from a Z-stack into focus. In the experiments 
described herein,  Z-stack distance was set at 0.55 µm with constant camera 
light exposure duration set in red, green and blue fluorescence channels for 
each spot under comparison. A range from between 8 and 12 images per Z-stack 
were taken using the motorised AxioCam camera and data from each combined 
using AxioVision v4.8.1 deconvolution software.  
 Quantitative analysis of immunofluorescence 
Analysis of high power fluorescent microscope images was conducted using 
CellProfilerTM v2.2.0 software using .JPEG format grayscale images from FITC and 
DAPI channels. A single pipeline was generated to separate analysis by drug and 
BCR stimulation conditions and >200 cells per sample and condition were 
evaluated in each case. Figure 2-4 shows the method of immunofluorescence 
analysis performed using CellProfilerTM software. 
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Figure 2-4 CellProfilerTM analysis of actin polymerisation 
Representative cycles from CellProfilerTM analysis of images of phalloidin staining of 
CLL143 for assessment of actin polymerisation. Microscopic fields are pictured at x 40 
magnification with automatic selection by the software of cell outline, nuclear outline and 
subsequent characterisation of fluorescence of cellular and subcellular structures.   
2.6 GTPase activity assays 
 Rap1 activity assay: sample preparation 
Primary CLL samples were rested in RPMI/BSA for 2 h prior to the experiment. 
Cells at a concentration of 2 x 107 were incubated for 30 min under the 
conditions: control, 100 nM AZD8055, 10 nM rapamycin, 1 µM ibrutinib then with 
or without stimulation using 100 ng/ ml SDF-1 and a separate positive control 
with EPAC agonist at 10 µg/ml for 5 min. To terminate the reaction, 1 ml ice-
cold PBS was added to cells in media and then were spun at 100 g for 5 min. The 
pellet was resuspended and washed in ice-cold PBS for 5 min. After removal of 
PBS conditions were treated with 0.5 ml ice-cold 1 X lysis/binding wash buffer 
(Active Rap1 Detection Kit, Cell Signalling Technology®) and 1mM 
phenylmethanesulfonyl fluoride (PMSF) (Cell Signalling Technology®) with 
vortexing and placement on ice for 5 min. Samples were microcentrifuged at 
16000 g at 4 oC for 15 min and the supernatant was removed for use in the 
immunoprecipitation assay.  
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 Rac1 activity assay: sample preparation 
Primary CLL samples were rested in RPMI/BSA for 2 h prior to the experiment. 
Cells at a concentration of 2 x 107 were incubated for 30 min under the 
conditions: control, 100 nM AZD8055, 10 nM rapamycin, 1 µM ibrutinib then with 
or without stimulation using 100 ng/ml SDF-1 or 10 µg/ml F(ab’)2 for 30 min. To 
terminate the reaction, 1 ml ice-cold PBS was added to cells in media and then 
were spun at 100g for 5 min. The pellet was resuspended and washed in ice-cold 
PBS for 5 min. After removal of PBS conditions were treated with 0.5 ml ice-cold 
1 X lysis/binding wash buffer (Active Rac1 Pull-Down and Detection Kit, 
Thermofisher Scientific) and 1 X protease inhibitors (13) with vortexing and 
placement on ice for 5 min. Samples were microcentrifuged at 16000 g at 4 oC 
for 15 min and the supernatant was removed for use in the immunoprecipitation 
assay.  
 GTPase activity assays: control steps 
As a control for the immunoprecipitation procedure, 500 µl control lysates were 
prepared adding 10 µl 0.5M EDTA pH 8.0 and vortexed and either 5 µl of 10 nM 
GTPgS or 5 µl of 100 mM GDP was added with vortexing. Samples were then 
agitated and placed at 30oC with termination of the reaction after 15 min using 
32 µl of 1M MgCl2. 
 Rac1/Rap1 activity assay 
A spin cup per collection tube was set up with 100 µl of 50% glutathione resin 
added, centrifuging at 6000 g for 30 sec. Flow-through was discarded and 400 µl 
of 1 X lysis/binding/wash buffer was added to each spin cup with resin and after 
gently inverting the tubes, they were centrifuged at 6000 g for 30 sec and with 
flow-through discarded. Then, 20 µg GST-RalGDS-RBD (Active Rap1 Detection 
Kit) or GST-human Pak1-PBD (Active Rac1 Pull-Down and Detection Kit, 
Thermofisher Scientific) beads were added to the spin cup along with 700 µl of 
the cell lysate and after vortexing the spin cup cap was sealed and samples 
agitated at 4oC for 1 h. Samples were again centrifuged at 6000 g for 30 sec and 
spin cups transferred to a new collection tube. Two wash steps were performed, 
each with 400 µl of 1 X lysis/binding/wash buffer and centrifugation at 6000 g 
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for 30 sec after which a further collection tube was used. Reducing sample 
buffer containing 0.1 M dithiothreitol (DTT) added to 2 X SDS sample buffer to a 
final concentration of 50 mM DTT and 50 µl of buffer was added to each tube 
with vortexing and incubation at RT for 2 min. After centrifuging the tube at 
6000 g for 2 min, spin cups were removed and discarded and eluted samples 
were heated at 95oC for 5 min.  
 Western blot: Rap1 activity assay 
Western blot analysis was performed as described previously and after transfer, 
PVDF membrane was washed with 25 ml TBS for 5 min at RT then blocked with 
25 ml TBS containing 0.1% Tween-20 (T-BST) and 5% BSA for 1 h at RT. Wash step 
was performed 3 times for 5 min with T-BST and membrane incubated with Rap1 
rabbit antibody in T-BST overnight at 4 oC. After removal of primary antibody 3 x 
wash steps were performed and the membrane was incubated for 1 h with anti-
rabbit antibody in TBS-T with 5% milk, then washed x 3 and developed as above.  
 Western blot: Rac1 activity assay 
Western blot and transfer was performed as for Rap1 activity assay with block 
for 1 h using 25 ml TBS containing T-BST and 3% BSA at RT. Wash step was 
performed for 5 min with T-BST and membrane incubated with anti-Rac1 mouse 
antibody in T-BST with 3% BSA and 0.1% NaN3 overnight at 4 oC. After removal of 
primary antibody 5 x wash steps were performed and the membrane was 
incubated for 1 h with anti-mouse antibody in TBS-T with 5% milk, then washed x 
5 and developed as above.  
 GTPase assays: loading controls 
To obtain an assessment of the total protein levels obtained by cell lysis of each 
drug and stimulation condition, the eluate from the immunoprecipitation step 
was retained and stored at -20oC. Once Western blot for active GTPase levels 
was performed, a second blot using the retained eluate was also performed and 
probed for total GTPase level (Rac1/Rap1) and a separate housekeeping protein 
such as GAPDH (241). The protocol for Western blot was performed as for active 
GTPase levels. 
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2.7 Statistical analysis 
Data were analysed using Microsoft® Excel and a statistical software package 
(GraphPad v6 Software Inc., La Jolla, CA, USA) to perform a range of tests 
including the paired student’s t-test and in each case to test goodness-of-fit, 
Kolgomorov-Smirnov test of normality were employed to generate K2 for groups 
of samples. Where samples did not fit a normal distribution, non-parametric 
tests such as the Mann-Whitney U-test were used. P values were assigned the 
symbol * to indicate statistical significance where * is representative of p < 0.05 
and p > 0.01, ** of p < 0.01 and p > 0.001, *** of p < 0.001 and p > 0.0001 and **** 
of p < 0.0001. Flow cytometry data were analysed using the FlowJo software 
package (Tree Star, Inc., Ashland, OR, USA). 
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Chapter 3 Molecular effects of mTOR inhibition 
on CLL cell migration in vitro  
3.1 Introduction  
The mechanisms underlying the lymphocyte redistribution effect demonstrated 
by BCR signalling inhibitors including mTOR inhibitors are worthy of study, 
initially in confirmation of this phenomenon as a bona fide means of drug effect. 
Based upon the relative absence of any apoptotic effect by BCR signalling 
inhibitors, it was speculated that the effects of microenvironmental 
displacement with subsequent loss of survival signals by CLL cells was for the 
most part responsible for the clinical activity of such drugs (242). The molecular 
processes and the downstream molecular signalling output of such drugs were 
not immediately apparent thus triggering intensive study as to the molecular 
control of migration. From already existing data, we have identified mTOR 
kinase as a target of interest however its study, in tandem with the examination 
of the effects of existing BCR signalling inhibitors, may yield information as to 
the differential mechanisms of each. Furthermore, the use of in vitro techniques 
to investigate the molecular effects of mTOR inhibitors may elucidate novel 
therapeutic targets. 
AZD8055 is a novel, ATP-competitive inhibitor of mTOR signalling which binds 
the active site of mTOR kinase (214). Not only does it differ in its capacity for 
dual mTOR inhibition as opposed to mTORC1 inhibition alone, but, unlike the 
allosteric inhibitor rapamycin it is a direct inhibitor, binding to the mTOR kinase 
protein itself. Rapamycin is an allosteric inhibitor of mTOR; allosteric regulation 
is where an effector binds at a distant allosteric site which exerts functional 
regulation. Rapamycin binds FKBP12 and the resultant complex inhibits mTORC1 
activity (243). AZD8055 is orally administered when applied in vivo with a 
maximum tolerated dose of 90 mg, administered twice daily, thus we elected to 
use concentration ranges from 30 - 300 nM for in vitro experiments. AZD8055 has 
an IC50 of 0.8 nM and its selectivity for mTOR kinase complexes has been 
confirmed in vitro (214). The clinical grade analogue of AZD8055, AZD2014 has 
an almost identical chemical structure but has greater oral bioavailability than 
AZD8055 due to its lower rate of hepatic metabolism (244). However, for in vitro 
testing we have selected AZD8055 as it was the original version of the compound 
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and is in widespread use for in vitro experimentation (244). Rapamycin is a 
highly potent allosteric inhibitor of mTORC1 with effectiveness at low 
concentration levels therefore I elected to use concentration ranges from 0.1 nM 
to 10 nM (207).  
  CLL cell viability 
Our initial approach was to conduct cell viability studies to provide an overall 
assessment of the performance of mTOR inhibitors. This section focuses on the 
optimisation of our experimental approach followed by the study of short and 
long-term incubation with drug inhibitors, with in vitro BCR and chemokine-
ligand stimulation to simulate the tissue microenvironment.  
Cell viability was tested using both fresh and thawed primary CLL cells. Cells 
were cryopreserved either using histopaque which enriches for B cells or using 
RosetteSepTM which employs a negative selection method utilising crosslinking of 
cells which bind to specific cell surface markers to red blood cells, with 
separation via a density gradient such that B cells are separated from all other 
leukocytes as they do not possess the target markers, using the technique as 
described by Laprevotte et al. (245).  
The effects of cryopreservation and thawing on cell viability are long-established 
and an applicable immunology study of peripheral blood mononuclear cell 
recovery demonstrated a range of cell sample viability from 1 - 96% on thawing 
of 54 samples from cryopreservation. The median cell viability was 70% which 
provided early evidence in identification of the threshold for adequate recovery 
of lymphocyte function, as assessed by cellular proliferation assays (246). 
Techniques in cell cryopreservation have developed since the earliest studies 
and the introduction of DNase treatment to cell thawing procedures has reduced 
the incidence of cell clumping, which leads to reduced cell recovery and may 
lead to alterations in cell function and phenotype (247). Advances in 
cryopreservation methodology may thus improve the range of samples to retain 
viability and function, increasing the availability of samples for experimental 
use. According to their availability, fresh CLL samples were preferred as their 
baseline viability was generally greater than for those samples which had 
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undergone the cryopreservation and thawing process. A representative fresh 
patient sample shown in Figure 3-1 displays a 50 % reduction in cell viability (Q3) 
and a significant increase in apoptosis (Q2) at 48 h incubation. To account for 
differences in cellular recovery, viability studies were performed on a mixture of 
both fresh and thawed samples.  
 
Figure 3-1 Comparison by FACS analysis of fresh and thawed CLL cell viability 
Annexin V/7AAD staining after 48 h incubation of patient sample CLL12 taken either fresh 
(A) or thawed (B). FACS plots are size gated for comparison of viability markers. 
  Serial FCS dilution experiment – optimisation of media 
Apart from the BCR and SDF-1 signalling axes already described in 1.7 and 1.8, 
mTOR is activated by growth factor signals and is nutrient-responsive (248), 
therefore we investigated a range of media serum dilutions for use in our 
experiments. CLL samples were incubated for 48 h in a range of serum 
concentrations from 0 – 10 % with determination of cellular viability level by 
staining and flow cytometry for Annexin V and 7AAD. The cell viability was 
determined for a range of samples with variation in viability shown in Figure 3-2 
A. Figure 3-2 B displays individual viability results for each serum concentration 
demonstrating the rising trend to maximal or near-maximal viability represented 
by the 10 % FCS incubations for each sample. Normalised viability was calculated 
for a sample set extended from that in Figure 3-2 A to include CLL with a normal 
karyotype in Figure 3-2 C with control value set at the viability for those samples 
incubated in 10% FCS. Individual raw values for the dataset in Figure 3-2 C and 
their distribution are plotted on the axes for Figure 3-2 D. In Figure 3-3 A&B 
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there is demonstration of an AZD8055 or rapamycin-dependent dose-dependent 
trend in inhibition with increasing media serum concentration. With AZD8055 
(Figure 3-3 C) there is a significant reduction in normalised cell viability which is 
greatest at the 10 % FCS concentration, however with rapamycin (Figure 3-3 D) 
these figures represent only a trend which correlates with serum concentration. 
 
Figure 3-2 CLL cell viability across a range of serum concentrations 
Cell viability studies over 48 h of patient samples across a distribution of prognostic 
markers with individual serum concentrations shown (A, n=5), also, demonstration of mean 
and SEM combining a range of serum concentrations (B, n=7). Percentage of viable cells 
was calculated using flow cytometry measurement of Annexin V/ 7AAD. Mean cell viability 
with SEM for individual serum concentrations is demonstrated for 7 samples in (C) with 
these data presented after normalisation in (D). 
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Figure 3-3 Effects of mTOR inhibition on CLL cell viability with variation in serum 
concentration 
CLL samples were rested in their respective serum concentrations for 2 h then treated for 
48 h with AZD8055 (A&C) and rapamycin (B&D). Normalised data values (A&B) including 
mean and SEM are shown. *=p≤0.05; **=p≤0.01; ***=p≤0.001; ****=p≤0.0001. 
The experiments to investigate the role of media serum concentration were 
extended to incorporate mTOR inhibitors to provide data on the effects of mTOR 
inhibition on CLL cells in combination with a range of serum concentrations, to 
inform our later experiments. Figure 3-5 displays the effects on primary CLL 
samples of a range of AZD8055 concentrations from 0 – 300 nM (A) and rapamycin 
0 – 10 nM (B) with 48 h incubation at each drug concentration after suspension in 
their respective FCS concentrations. Figure 3-5 C demonstrates the significant 
dose-related reduction in CLL cell viability with AZD8055 which is most 
prominent at the 10% FCS concentration at 48 h. The experiment was extended 
to 96 h (Figure 3-5), where similar patterns of drug effect persist with both 
AZD8055 (A) and rapamycin (B).  
The effects of CLL cell suspension in 10 % serum display the greatest effects on 
cell survival with the addition of mTOR inhibitors, with significance shown at 48 
and 96 h incubation with both AZD8055 at all concentrations from 30 nM - 300 
nM and rapamycin 0.1 nM. It may be that the greater effect at the higher serum 
concentration may be a result of greater protein phosphatase activity at low 
serum concentrations. Phosphatases may remove the inhibitory effect of the 
drugs at low serum concentrations with the experiments performed at higher 
serum concentration demonstrating a greater effect of mTOR inhibition.  
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There is an appreciable but low rate of apoptosis upon treatment with AZD8055 
or rapamycin (Figure 3-4). Rates of apoptosis appear to be dose-related for both 
drugs and although their overall ability to induce apoptosis is low, there is a 
significant increase in apoptosis with an increased FCS concentration from 2 to 5 
% and from 2 to 10% with 300 nM AZD8055 and from 2 to 10% at 100 nM AZD8055. 
These findings confirm that the serum concentration of 10% is optimal for 
experimental evaluation of the effects of mTOR inhibitors on CLL cells in vitro 
thus media containing 10% FCS was selected for use in further experiments.  
Increasing concentrations of AZD8055 and rapamycin show an incremental 
impact on survival over 48 h and 96 h of CLL cells in vitro. Figure 3-5 establishes 
decrease in viability with increasing concentration of (A) AZD8055 on CLL cell 
viability over both time points; the effects upon rapamycin treatment are lesser 
(B).  
 
Figure 3-4 Effects of mTOR inhibition and FCS concentration on CLL cell apoptosis 
Cells were prepared in their respective serum concentrations for 2 h then treated with 
mTOR inhibitors for 48 h. Apoptosis was determined by FACS analysis for Annexin V and 
7AAD staining. Quadrant Q2 defines the late apoptotic cell populations and percentages of 
each sample (n=7) were normalised to 1 with mean and SEM displayed for (A) AZD8055 and 
(B) rapamycin. *=p≤0.05; **=p≤0.01; ***=p≤0.001; ****=p≤0.0001. 
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Figure 3-5 Effects of mTOR inhibition on CLL cell viability at 48 and 96 h 
CLL cell viability is compared between samples incubated with increasing doses of (A) 
AZD8055 and (B) rapamycin at 10 % FCS concentration. Data are normalised with mean and 
SEM shown for each drug concentration (n=7). *=p≤0.05; **=p≤0.01; ***=p≤0.001; 
****=p≤0.0001.  
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  Impact of mTOR inhibition on CLL cell viability with SDF-1 
stimulation  
SDF-1 is produced in a tightly regulated manner by BM stroma and cells of the 
LN, a feature which is hijacked by the malignant process in CLL. The spatial 
regulation of SDF-1 and consequent concentration gradient of the ligand which 
results is responsible for cellular survival as well as being implicated in CLL 
migration. The application of SDF-1 to CLL experimentation in vitro exploits the 
cell surface overexpression of its receptor, CXCR4, by CLL cells (148) and FACS 
plots of viability experiments are shown in Figure 3-6.  
Our initial approach was to incubate cells for 48 h with inhibitors and 100 ng/ml 
SDF-1 although this approach was found to be flawed as serum starvation could 
not be employed over this duration, limiting the size of SDF-1 effect that could 
be demonstrated. Figure 3-6 demonstrates non-significant inhibition of 48 h 
viability with AZD8055 at 300 nM and rapamycin 10 nM with only moderate 
effects of SDF-1 on CLL cell viability being demonstrable. The CXCR4/CXCL12 
axis has been studied with specific reference to its effects on mTORC1 substrate 
p70S6K, indicating that the optimal time point for study of SDF-1 reactions is 
significantly earlier than 48 h, most likely due to exhaustion of the cellular 
reaction to the chemokine (249). The reaction appears to plateau by 30 min and 
is approaching termination by 1 h, giving a framework on which to base further 
experiments. As it has been discussed previously, mTOR kinase is activated by 
range of signals with many of these being of key importance to cellular 
metabolism. Furthermore, the mTOR signalling pathway has been shown to 
signal downstream of CXCL12 in regulation of cellular migration of T cells (250), 
whilst the influence of CXCL12 on CLL cell migration remains relatively 
underexplored. Therefore, our revised approach was to expose primary CLL cells 
to a period of serum starvation prior to our experiments involving SDF-1, aiming 
to enhance the demonstration of SDF-1 stimulation effects, other than viability 
effects, with our study to be limited to a shorter duration of exposure to 
chemokine as in section 3.2.5. 
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Figure 3-6 CLL cell viability effects of long term SDF-1 incubation 
Normal karyotype CLL patient sample CLL126 was incubated with 100 ng /ml SDF-1 (B) for 
48 h and viability was compared with an unstimulated sample (A). Normalised mean and 
SEM viability effects of mTOR inhibition and +/- SDF-1 stimulation are also shown (C & D). 
CLL cells were incubated for 30 min with mTOR inhibitors then treated with SDF-1 for 48 h. 
Viability was determined by FACS calculation of percentage viable cells of on CLL samples 
(n=10) over (C) 48 h and (D) 96 h with drug conditions: 1 = NDC, 2 = AZD8055 300 nM and 3 = 
Rapamycin 10 nM. 
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  Optimisation of F(ab’)2 vs anti-IgM and effects on viability 
The effects of BCR stimulation on the microenvironment in CLL may be modelled 
in vitro using various methods, either by soluble or bound anti-IgM or by use of 
F(ab’)2 fragment stimulation. Data relating to chemokine expression of CLL cells 
have yielded contrasting results and some of these differences have been 
attributed to the utilisation of varying methods of BCR stimulation; either 
immobilised or soluble and through F(ab’)2 fragment stimulation or anti-IgM 
stimulation, with BCR cross-linking (251, 252). There has been support in the 
published literature for either method however the apparent differences in 
response of CLL cell to the variations in BCR stimulation methodology led the 
authors of one study to comment that there is “no standardized (sic) method of 
BCR stimulation” (253). With the aim of providing clarity over the issue of BCR 
stimulation, there has been dedicated study of each method in parallel by 
Rombout et al (254). The type of stimulation utilised, whether soluble or 
immobilised anti-IgM, was shown to have differential effects on CLL cell mRNA 
and protein expression of genes related to a BCR-activation signature with some 
differential effects on 48 h – 72 h cell survival (254). However, in this study, 
there appeared to be no significant differences elicited between anti-IgM or 
F(ab’)2 fragment stimulation. My work incorporates the use of soluble BCR 
stimulation, either anti-IgM stimulation with the addition of avidin crosslinking, 
or F(ab’)2 fragment stimulation. Where possible I have performed comparisons 
between these methods using the same patient sample to confirm my findings. 
To investigate the short-term effects of BCR stimulation, I performed a series of 
experiments, each conducted over 24 h, to examine the effects of mTOR 
inhibition and BCR stimulation on cell viability and apoptotic regulators. Figure 
3-7 indicates minimal difference in the effects of BCR stimulation by various 
methods when conducted over 1 h as compared with 24 h. Figure 3-8 indicates 
that the 48 h stimulation effects of either F(ab’)2 fragment stimulation or anti-
IgM stimulation promote a significant improvement in viability when compared 
with unstimulated cells or anti-IgM stimulation alone.    
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Figure 3-7 Modality of BCR stimulation and effects on short-term CLL cell viability 
Cellular viability studies of CLL57 (normal karyotype CLL) by FACS at 1 h incubation with 
(A) no stimulation (B) 10 µg/ml anti-IgM antibody (C) 10 µg/ml anti-IgM antibody for 20 min, 
then washing, then then 25 µg/ml avidin and (D) 10 µg/ml F(ab’)2 fragments. Conditions were 
extended for 24 h shown in (E) no stimulation (F) 10 µg/ml anti-IgM antibody (G) 10 µg/ml 
anti-IgM antibody for 20 min, then washing, then 25 µg/ml avidin and (H) 10 µg/ml F(ab’)2 
fragments. 
 
 
 
Figure 3-8 Long-term CLL cell viability effects of BCR stimulation 
FACS plots to compare viability of cells from a normal karyotype CLL sample (CLL126) 
when incubated at 37oC for 48 h with either (A) no stimulation (B) 10 µg/ml F(ab’)2 fragments 
(C) 10 µg/ml anti-IgM antibody and (D) 10 µg/ml anti-IgM antibody for 20 min, then washing, 
then 25 µg/ml avidin. 
A B C D
E F G H
A B
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  Effects of mTOR inhibition and BCR stimulation on CLL 
viability 
BCR stimulation is one of the key survival signals received by CLL cells in the 
disease microenvironment and the well-documented effects of BCR stimulation 
in vitro are exploited in our experimental strategy (254). To mimic this aspect of 
the CLL cell microenvironment, we stimulated the CLL cells by ligating the BCR, 
with either F(ab’)2 fragments or biotinylated anti-IgM crosslinked with avidin and 
incubated the cells for 48 and 96 h. Preliminary experiments were conducted to 
show a limited effect of shorter durations of mTOR inhibition upon CLL viability 
in the presence and absence of BCR stimulation. Figure 3-9 shows the BCR 
stimulation effects at 24 h incubation on a single CLL sample, with and without 
dual mTOR inhibition using AZD8055.  
 
Figure 3-9 Short-term viability effects of dual mTOR inhibition with BCR stimulation 
Cellular viability studies of CLL77 (normal karyotype CLL) by FACS at 24 h incubation with 
the conditions: (A) untreated control (B) 10 µg/ml anti-IgM stimulation for 20 min with 
washing of CLL samples followed by 25 µg/ml avidin crosslinking (C) AZD8055 100 nM 
alone (D) AZD8055 100 nM and subsequent 10 µg/ml anti-IgM stimulation for 20 min with 
washing of CLL samples followed by 25 µg/ml avidin crosslinking. 
Figure 3-10 illustrates the significant reductions in cell viability seen upon 
treatment of CLL cells with mTOR inhibitors in the presence or absence of BCR 
stimulation. For drug treatment, CLL cells were pre-treated for 30 min with 
mTOR inhibitors, as indicated. CLL cell viability is reduced by both AZD8055 and 
rapamycin over 48 h (A) and 96 h (B) incubation periods. Dual mTORC-1/2 
inhibition offers a more robust impact on CLL cell viability over that of mTORC-1 
A B
C D
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inhibition in vitro, even after accounting for the effects of BCR stimulation. The 
addition of F(ab’)2 and anti-IgM stimulation enhanced the effect of drug 
inhibitors at 48 h and 96 h, as did crosslinking with avidin to a lesser degree. 
However, the overall effects of crosslinking with avidin were to increase relative 
viability of CLL cells at both 48 h and 96 h, when compared with unstimulated 
cells and those stimulated with anti-IgM alone, although this did not reach 
significance. The concentrations of 300 nM AZD8055 and 10 nM rapamycin are 
the highest doses that we have used and in these experiments they were used 
with the aim of achieving maximal mTOR inhibition for these initial experiments. 
However, our concentration range was extended to include a clinically 
attainable concentration of 100 nM with concurrent assessment of viability 
effects of ibrutinib at 1 µM. Figure 3-11 displays the effects of BCR stimulation 
on untreated CLL cells (A) with a significant increase in viability with the 
addition of either F(ab’)2 or anti-IgM stimulation with avidin crosslinking. The 
effects of BCR stimulation are evaluated in the context of drug conditions, and 
with data normalisation with significance demonstrated in the AZD8055 300 nM 
condition, also the rapamycin and ibrutinib conditions (Figure 3-11 B). There was 
a significant reduction in cellular viability with AZD8055 at both concentrations 
in the presence and absence of BCR stimulation, as with both rapamycin and 
ibrutinib (Figure 3-11 C). 
 
Figure 3-10 Effects of long term BCR stimulation and mTOR inhibition on CLL cell viability 
Impact of mTOR inhibition and method of BCR, either 10 µg / ml F(ab’)2 stimulation or 10 µg / 
ml anti-IgM alone or with 25 µg / ml avidin crosslinking, on cellular viability for CLL samples 
at (A) 48 h incubation and (B) 96 h incubation. Drug conditions are denoted: 1 = NDC (Non-
drug control), 2 = AZD8055 300 nM and 3 = Rapamycin 10 nM. FACS analysis of Annexin V 
and 7AAD staining were used to calculate percentage viability with mean +/- SEM values as 
shown (n = 8). *=p≤0.05; **=p≤0.01; ***=p≤0.001; ****=p≤0.0001. 
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Figure 3-11 Cell viability over 48 h drug incubation with mTOR inhibitors 
Evaluation of percentage of viable untreated cells as determined by FACS evaluation 
reveals significant effects of BCR stimulation (A) which persist in the presence of drug 
conditions (B). Normalised percentage cell viability is inhibited significantly over 48 h by 
AZD8055 (AZD), rapamycin (RAPA) and ibrutinib (IB) when compared with the non-drug 
control (NDC), an effect which is overcome by the addition of BCR stimulation (C). Mean +/- 
SEM data are shown (n=23). *=p≤0.05; **=p≤0.01; ***=p≤0.001; ****=p≤0.0001. 
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  Impact of BCR stimulation on pro- and anti-apoptotic 
proteins 
Changes in the expression of pro- and anti-apoptotic proteins after 48 h 
stimulation in the presence or absence of drug treatment are shown (Figure 
3-12). The expression of BCL-2 which is fundamental to CLL pathogenesis 
remains constant, whereas MCL-1 levels are modulated with AZD8055 and 
ibrutinib treatment (Figure 3-12 A). The addition of BCR stimulation serves to 
increase MCL-1 levels which may be abrogated by AZD8055 and ibrutinib and to a 
lesser extent, rapamycin. At 48 h BCR incubation there is an upregulation in the 
Bim 15 kDa isoform with the addition of AZD8055 and ibrutinib; BimL levels also 
appear to be downregulated with BCR stimulation (Figure 3-12 B). There appears 
to be a relative enhancement of the BimEL level with AZD8055 and ibrutinib in 
the BCR stimulated cells however BimS levels appear relatively unchanged 
(Figure 3-12 B). These blots confirm that GTPase Rap1 and Rac1 levels are 
relatively unchanged over 48 h mTOR inhibition with or without BCR stimulation 
which shall be discussed further in Chapter 5 (Figure 3-12 A&C). Changes in 
overall protein levels of GTPase protein families are therefore not an 
anticipated feature of drug inhibition, but were studied nevertheless, to confirm 
consistent overall protein levels. The levels of BCL-xL are upregulated by BCR 
stimulation and there are inhibitory effects with AZD8055, and ibrutinib and 
rapamycin in the presence of BCR stimulation, to a lesser extent. Once loading 
correction has been applied, the trend to significance in BCL-xL level changes 
persist with AZD8055 inhibition in the presence of BCR stimulation. Poly (ADP-
ribose) polymerase (PARP) levels and relative size of cleaved and uncleaved 
fractions are indicative of pro-apoptotic activity by the drug inhibitors. Figure 
3-12 B demonstrates induction of apoptosis by AZD8055 as assessed by the 
relatively increased quantity of PARP cleavage product when compared with the 
uncleaved protein. These effects persist with BCR stimulation, with a relatively 
smaller proportion of cleaved PARP with both rapamycin and ibrutinib. The 
viability effects of short-term BCR stimulation by FACS as shown in Figure 3-10 
are supported by Western blot experiments, studying apoptotic regulators. 
Figure 3-13 shows the less pronounced effects of mTOR inhibition on markers 
such as MCL-1 and PARP over 24 h. 
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Figure 3-12 Long-term effects of mTOR inhibition on apoptotic proteins 
Western blot for protein levels of apoptotic regulators and effectors at 48 h incubation with 
demonstrated effects of non-drug control (NDC), 100 nM AZD8055 (AZD), 10 nM rapamycin 
(RAPA) and 1 µM ibrutinib (IB) +/- BCR stimulation in primary CLL samples (A) CLL157 (11q 
deletion) (B) CLL18 (11q deletion) and (C) CLL140 (normal karyotype). Western blot 
identification of proteins demonstrated are based upon estimated molecular weights: MCL-1 
(40 kDa), BCL-XL (30 kDa), BCL-2 (26 kDa), Rac1 (21 kDa), GAPDH (36 kDa), PARP uncleaved 
(116 kDa) and cleaved (89 kDa), BimEL (23 kDa), BimL (15 kDa) and BimS (12 kDa) and Rap1 
(23 kDa).   
 
Figure 3-13 Short-term effects of mTOR inhibition on apoptotic proteins 
CLL143, a CLL sample known to harbour an 11q deletion, was treated with incubation with 
control (NDC), 100 nM AZD8055 (AZD), 10 nM rapamycin (RAPA) and ibrutinib 1 µM (IB) for 
30 min, +/- BCR stimulation for 24 h, demonstrating the effects of mTOR inhibitors and 
ibrutinib on apoptotic regulators at this time point. 
Densitometry analysis was performed on combined results from Western blotting 
of individual CLL patients for apoptotic regulators at 48 h incubation with drug 
inhibitors in the presence or absence of BCR stimulation. The blots were 
analysed using Image Studio software as all long-term BCR stimulation images 
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were generated using the Li-Cor system. Figure 3-14 demonstrates the 
significant inhibition of anti-apoptotic MCL-1 protein by AZD8055 in cells which 
have been stimulated via the BCR. There are inhibitory effects of rapamycin and 
ibrutinib on MCL-1 however these are not statistically significant. The pro-
survival BCL-2 family member BCL-xL also displayed significant inhibitory effects 
by AZD8055 in BCR-stimulated cells compared with untreated control (Figure 
3-15). Densitometry of cleaved PARP levels as shown in Figure 3-16 demonstrate 
the apoptotic effects of AZD8055 and ibrutinib in Figure 3-16 A&B with 
consistent effects after controlling for protein loading. With the addition of BCR 
stimulation, both AZD8055 and ibrutinib display apoptotic effects. Rapamycin 
also exhibits some apoptotic activity in the experiments using 4 samples in the 
context of BCR stimulation alone (Figure 3-16 B). Densitometry values could be 
obtained for Western blot from two samples probed for Rac1 and one sample for 
Rap1 GTPase, each demonstrating minimal changes in GTPase levels with mTOR 
inhibition in the presence and absence of BCR stimulation (Figure 3-17 A&B).  
 
Figure 3-14 Densitometry analysis of MCL-1 expression by Western blot 
Densitometry values of mean and SEM MCL-1 levels with the effects of non-drug control 
(NDC), AZD8055 100 nM (AZD), rapamycin 10 nM (RAPA) and ibrutinib 1 µM (IB) +/- BCR 
stimulation (A) and with loading correction applied (B) (n=6). Statistical comparison is 
performed using the paired Student’s t test. *=p≤0.05; **=p≤0.01; ***=p≤0.001; 
****=p≤0.0001.  
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Figure 3-15 Densitometry analysis of BCL-xL expression by Western blot 
Normalised mean and SEM BCL-xL levels with the effects of non-drug control (NDC), 
AZD8055 100 nM (AZD), rapamycin 10 nM (RAPA) and ibrutinib 1 µM (IB) +/- BCR stimulation 
(A) and with loading correction applied (B) (n=5). Statistical comparison is performed using 
the paired Student’s t test. *=p≤0.05; **=p≤0.01; ***=p≤0.001; ****=p≤0.0001. 
 
Figure 3-16 Densitometry analysis of cleaved PARP expression by Western blot 
Normalised mean and SEM cleaved PARP levels are shown and the relative effects of non-
drug control (NDC), AZD8055 100 nM (AZD), rapamycin 10 nM (RAPA) and ibrutinib 1 µM (IB) 
+/- BCR stimulation (A). Once loading correction has been applied, the effects of mTOR 
inhibitors persists (B) (n=4).  
 
Figure 3-17 Densitometry analysis of GTPase protein expression by Western blot 
Total mean Rac1 (A, n=2) and Rap1 (B, n=1) levels are shown with relative effects of non-
drug control (NDC), AZD8055 100 nM (AZD), rapamycin 10 nM (RAPA) and ibrutinib 1 µM (IB) 
+/- BCR stimulation. Rac1 and Rap1 levels are displayed with correction for protein loading. 
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3.2 Protein expression of chemokine receptor and 
adhesion markers 
As the chemokine receptor and adhesion molecule profile of cells in our CLL cell 
bank has not been studied, the surface expression of CXCR4, CXCR5, CD62L, 
CD44, CD11a, CD38 and CD49d markers were determined in freshly isolated CLL 
samples. CXCR4 and CXCR5 are responsible for migration along a chemokine 
gradient to the BM and LN niches and CD62L and CD44 are responsible for CLL 
cell positioning within the microenvironment (148, 149, 153, 154). CD11a is an 
adhesion molecule found in the early stages of CLL (148, 149, 153, 154, 255). 
CD38 and CD49d are independent negative prognostic risk parameters and form 
part of macromolecular complexes required for CLL cell homing (152, 256). 
We found a wide range of variability in the expression of markers between CLL 
samples (Figure 3-18) and CXCR4, CD62L and CD44 were selected for further 
study in view of their consistent elevation. CXCR5 was selected, although less 
highly expressed, for its importance in migration and in view of the existing data 
with this molecule (149). CD38 and CD49d antibodies stained with low mean 
fluorescence in most samples and although we explored alternative antibodies, 
no significant increase in mean fluorescence was noted with these antibodies.   
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Figure 3-18 Flow cytometry analysis of fluorescence by antibody bound to cell surface 
adhesion markers 
CLL samples were incubated with antibody to CD11a, CD44, CD38, CD62L, CXCR4, CXCR5 
and CD49d with known functions in cell adhesion and migration. After 20 min, cells were 
washed and resuspended in HBSS to allow FACS analysis of fluorescence intensities. 
CLL18 and CLL139 are samples with 11p deletion, CLL12 has 13q deletion, CLL32 has 6p 
deletion and CLL140 has trisomy 12 chromosomal abnormality. All other samples possess a 
normal karyotype. 
  Short-term response of chemokine and adhesion molecule 
expression to BCR stimulation by flow cytometry 
To facilitate selection of patient samples for use in migration studies discussed 
in chapter 4, we measured surface expression of key proteins CXCR4, CXCR5 and 
CD62L by fluorescent antibody staining in primary CLL samples after 1 h BCR 
stimulation, mirroring the transwell assay design. Data shown in Figure 3-19 
support a reduction in CXCR4 and CD62L in response to BCR stimulation, 
consistent with existing published data, and only minimal responses of CXCR5 
(252). Further analysis of 1 h BCR responses with stratification of samples by 
type of BCR stimulation, either F(ab’)2 stimulation or anti-IgM with avidin 
crosslinking, demonstrated that CD62L levels were significantly reduced with 
F(ab’)2 stimulation (Figure 3-20 A&B). The effects of cryopreservation and 
thawing on cellular surface marker expression have been examined with minor 
differences to be observed in the percentage expression of CLL phenotypic 
markers in comparison with that of fresh CLL cells (257). To account for 
differences in protein levels with cellular recovery, cell surface marker 
expression studies were performed on both fresh and thawed samples from the 
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same patient wherever possible, to confirm my findings. Further analysis with 
sample stratification by fresh and thawed sample sources displayed similar 
trends within these subgroups (Figure 3-20 C&D). 
Chemokine receptor responses to short-term BCR-stimulation were re-grouped 
by prognostic categories, either by disease karyotype (Figure 3-21) or by non-
receptor tyrosine kinase, ZAP70 expression (Figure 3-22) to determine whether 
surface expression was altered in distinct prognostic subsets. Trends to 
reduction in chemokine and adhesion marker surface levels were maintained 
even with the low sample number represented in some subgroups. The trends to 
reduction in surface expression of both CXCR4 and CD62L featured both in 
negative prognostic subgroups (17p deletion, 11q deletion, ZAP70 positive) and 
normal karyotype/ZAP70 negative groups alike. Statistical analyses were 
performed between samples grouped by prognostic parameters with no 
demonstrable significance in any of the subgroups.  
 
Figure 3-19 Impact of BCR stimulation on chemokine receptor and adhesion molecule cell 
surface profile 
Mean fluorescence intensity measured for CXCR4 (n=11), CXCR5 (n=4) and CD62L (n=11) 
for a range of CLL samples, treated for 1 h with either F(ab’)2 stimulation or a-IgM with 
avidin crosslinking prior to antibody staining. *=p≤0.05; **=p≤0.01; ***=p≤0.001; 
****=p≤0.0001. 
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Figure 3-20 Chemokine receptor and adhesion molecule levels by BCR stimulation and 
sample type 
Mean fluorescence intensity measured for CXCR4, CXCR5 and CD62L for a range of CLL 
samples, treated for 1 h with (A, n=8) F(ab’)2 stimulation (B, n=6) a-IgM with avidin 
crosslinking with samples stimulated with either type of BCR stimulation but stratified as to 
whether they were used (C, n=5) fresh or (D, n=7) thawed. *=p≤0.05; **=p≤0.01; ***=p≤0.001; 
****=p≤0.0001. 
 
Figure 3-21 Chemokine receptor and adhesion molecule levels by sample karyotype 
Mean fluorescence intensity measured for CXCR4, CXCR5 and CD62L for a range of CLL 
samples (n=11), with samples characterised by (A) either 17p or 11q deletion (n=5) or (B) 
normal karyotype (n=6). *=p≤0.05; **=p≤0.01; ***=p≤0.001; ****=p≤0.0001. 
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Figure 3-22 Chemokine receptor and adhesion molecule levels by sample ZAP70 status0 
Mean fluorescence intensity measured for chemokine receptors CXCR4, CXCR5 and CD62L 
for a range of CLL samples (n=11), with samples characterised by (A) ZAP70 positive (n=9) 
(B) ZAP70 negative (n=2) prognostic marker status.  
The cell markers CXCR4, CXCR5, CD62L and CD44 were also studied after long-
term incubation with BCR stimulation to distinguish the direct effects of BCR 
stimulation on local signal transduction visible over 1 h from putative effects 
which may be mediated by signal transduction to the cell nucleus with 
consequent alteration of gene expression of surface markers. Consistent with 
existing published data, Figure 3-23 shows a significant reduction in CXCR4 
whereas there was only a trend to reduction in CXCR5, with less pronounced 
changes in CD62L and CD44 (252).  
Over 48 h drug incubation no significant changes on chemokine receptor 
expression were observed in the absence of BCR stimulation (Figure 3-24 A,C&E), 
however with the addition of BCR stimulation (Figure 3-24 B,D&F) there were 
significant changes in CXCR4 (B), indicating that the reduction in chemokine 
receptor levels that are normally seen with BCR were lost upon AZD8055 and 
ibrutinib drug treatment. This may provide an insight into the mechanism of 
action of these drugs, as it is already known that ibrutinib may overcome the 
impact of negative prognostic conditions by negating the component of BCR 
signalling and its contribution to disease survival and evolution, in those clones 
for which upregulated BCR signalling is a prominent feature of the disease 
pathogenesis (258).  
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Figure 3-23 Chemokine receptor and adhesion molecule responses to BCR stimulation 
Cells were incubated for 48 h in the presence or absence of BCR stimulation with sample 
staining with fluorescent antibody to CXCR4 (A) CXCR5 (B) CD62L (C) CD44 (D) (n=18). 
Stained samples were analysed by flow cytometry to quantify relative levels of cell marker 
surface expression. CLL12, 28, 44, (fresh and thawed) 77, 80, 90, 92, 93, 95 (fresh and 
thawed), 106, 113, 118, 138 (fresh and thawed), 139, 140, 142. Samples were grouped for 
additional analysis by method of BCR stimulation however no significant differences were 
observed. *=p≤0.05; **=p≤0.01; ***=p≤0.001; ****=p≤0.0001.  
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Figure 3-24 Long-term effects on cell surface profile with mTOR inhibitors and BCR 
stimulation 
The same CLL samples used in figure 3.24 (n=19) were incubated for 48 h with 30 min prior 
drug inhibition with non-drug control (NDC), 300 nM AZD8055 (AZD), 10 nM rapamycin 
(RAPA), 1 µM ibrutinib (IB). Graphs show mean fluorescence intensity (MFI) by FACS 
analysis for CXCR4 (A & B) CXCR5 (C & D) CD62L (E & F). Graphs A, C & E represent 
unstimulated cells with drug conditions only whereas graphs B, D & F represent samples 
exposed to BCR stimulation for 48 h. *=p≤0.05; **=p≤0.01; ***=p≤0.001; ****=p≤0.0001. 
  Promotion of LN-emigrant phenotype with the addition of 
SDF-1 
It is known that CLL surface immunophenotype varies according to cellular 
positioning, either in migration towards or away from the LN niche (156). We 
performed experiments to assess the in vitro effects of chemokine ligand on cell 
surface immunophenotype, in the presence or absence of inhibitors.   
Three patient samples, CLL3, CLL44 and CLL122 were incubated for 48 h after 
pre-treatment with inhibitors. Although no effects on cell viability could be 
demonstrated after 48 h incubation with SDF-1, the conditions were replicated 
as for the viability experiments to assess CXCR4 and CD5 expression by FACS. An 
example of the effect of SDF-1 on untreated CLL cells harbouring a LN emigrant 
phenotype (CXCR4dimCD5hi) is displayed (Figure 3-25).  A significant increase in 
the percentage of CXCR4dimCD5hi cells was observed with untreated, 300 nM 
AZD8055 or 1 µM ibrutinib-treated cells with the addition of SDF-1. Relative 
proportions of CXCR4dimCD5hi cells were compared in the SDF-1-treated 
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conditions, demonstrating significant inhibition of these cells by 100 nM 
AZD8055, but only a trend to significance with ibrutinib and rapamycin (Figure 
3-26).  
 
Figure 3-25 Changes in CLL cell surface phenotype with long-term SDF-1 stimulation 
Flow cytometry analysis of patient sample CLL44, a normal karyotype CLL sample after 48 h 
incubation and staining for CD5 and CXCR4 (A) NDC (B) NDC + 100 ng/ml SDF-1.  
 
Figure 3-26 “LN emigrant” phenotyped CLL cells and changes with SDF-1 stimulation 
Flow cytometry quantification of CXCR4dimCD5hi cells expressed as a proportion of all live 
cells after gating on CD19+. Cells were placed in drug conditions: Non-drug control (NDC), 
100 nM and 300 nM AZD8055 (AZD), 10 nM rapamycin (RAPA), 1 µM ibrutinib (IB) for 48 h +/- 
100 ng/ml SDF-1 (n=3). *=p≤0.05; **=p≤0.01; ***=p≤0.001; ****=p≤0.0001.  
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 In vivo ibrutinib – CLL120 
Study of the lymphocyte-redistribution phenomenon was extended to in vivo 
examination of lymphocyte response and chemokine effects in a BCR-signalling-
inhibitor-naive patient with 17p deletion CLL on initiation of ibrutinib 
monotherapy. Figure 3-27 outlines the effects of ibrutinib administered at a 
daily dose of 420 mg, commencing at day 0 with serial peripheral blood sampling 
performed up to 3 months following the initiation of therapy. There is an early 
rise in surface CXCR4 levels with a second, larger, peak in CXCR4 levels which 
corresponds to a minor rise in the lymphocyte count which tails off along with 
the lymphocytosis (Figure 3-27 B). Other chemokine receptors more closely map 
the second peak of lymphocytosis whereas there are no rises alongside the initial 
lymphocyte peak count (Figure 3-27 C-G). The cell surface marker trends should 
be interpreted with caution given the single sample represented by these data 
and given the minor overall changes in lymphocyte count compared with many 
other samples however it appears that in this patient sample the CXCR4 level 
changes appear to precede the lymphocyte redistribution effects which may 
occur with ibrutinib therapy and after the drop in lymphocyte count, cells 
appear to have a low CXCR4 level, more in keeping with a LN emigrant 
phenotype. Other cell surface marker changes occur after the rise in lymphocyte 
count which may reflect a role in relation to the ongoing effect of ibrutinib once 
the lymphocyte redistribution has occurred, possibly reflecting a role in the 
prevention of LN re-entry by the evacuated CLL cells, rendering cells susceptible 
to a method of cell death resembling anoikis (259).  
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Figure 3-27 Changes in cell surface profile and lymphocyte count with ibrutinib therapy in 
vivo 
Samples from patient CLL120 at the point of commencing ibrutinib with distribution over 
time of measurements of (A) peripheral blood lymphocytes and mean fluorescence intensity 
of chemokines and adhesion molecules by FACS staining for (B) CXCR4 (C) CXCR5 (D) 
CD62L (E) CD44 (F) CD38 (G) CD11a. 
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  Short-term response of mTOR kinase substrate to BCR 
stimulation by protein expression 
The effects of mTOR inhibitors in vitro may be monitored by study of their 
specific effects on mTORC1 and mTORC2 substrates and their impact on protein 
phosphorylation status. Figure 3-28 displays representative blots of the impact 
of BCR stimulation and mTOR inhibition on mTOR substrates after 1 h 
stimulation. BCR stimulation acts to increase phosphorylation levels of mTOR 
substrates such as AKTS473 and S6S235/236 as shown in Figure 3-28. With mTOR 
inhibition by AZD8055 there is a reduction in the AKTS473 phosphorylation 
consistent with mTORC2 inhibition which was not observed with rapamycin. 
Indeed, in the patient sample shown (CLL149), which was found to harbour a 17p 
deletion, there appears to be an elevation in AKTS473 phosphorylation upon 
rapamycin treatment, suggesting the release of a negative feedback loop upon 
inhibition of mTORC1 only (Figure 3-28 B). Ibrutinib treatment reduced AKT 
phosphorylation as previously reported (186). The positioning of mTORC2, 
targeted by AZD8055 specifically, downstream of BTK, were delineated by 
Western blot for Rictor phosphorylation. The S6K target Rictor, a component of 
the mTORC2 kinase complex, is phosphorylated at threonine 1135 upon 
stimulation of BCR for 1 h. The inhibitory effects of AZD8055 on RictorThr1135 
phosphorylation are visible most clearly with the addition of BCR stimulation 
whereas there are minimal effects of rapamycin and of ibrutinib (Figure 3-28 A).  
The mTORC1-specific effects were studied using p4EBP1 as an indicator and pS6 
as, although not a direct target it is phosphorylated by protein S6K which is a 
direct target of mTORC1. The limited availability of a suitable antibody for S6K 
led us to the preference for blotting for pS6 instead. Phosphorylation of the 
eukaryotic translation initiation factor protein target, 4EBP1Thr37/46, is reduced 
with dual mTORC1/2 inhibition but is less affected by rapamycin whereas pS6 is 
targeted by rapamycin. Ibrutinib has inhibitory effects on both mTORC1 
substrates, pS6 and p4EBP1. To delineate the mechanisms of mTORC1/2 
inhibition in CLL we studied FOXO1 phosphorylation status after 1 h BCR 
stimulation in our samples. Forkhead box protein 01 (FOXO1) is a transcription 
factor which is modulated/inhibited by the signalling output of mTORC2 in B 
cells. This places FOXO1 downstream of the AKT signal, with its inhibition by AKT 
being conferred by phosphorylation at threonine residue 24 (260). At 1 h BCR 
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stimulation, a reduction in FoxO1T24 phosphorylation is observed with AZD8055 
and ibrutinib treatment (Figure 3-28 B), indicative of mediation of the FOXO1 
signal by mTOR and in support of the tumour suppressor functions of FOXO1 in 
CLL.  
 
Figure 3-28 Protein expression effects of mTOR inhibitors with short-term BCR stimulation 
Western blot images are obtained from protein lysates of patient sample (A) CLL159 (normal 
karyotype CLL) and (B) CLL149 which is known to harbour a 17p deletion to demonstrate 
the effects of 1 h BCR stimulation and non-drug control (NDC), AZD8055 100 nM (AZD), 
rapamycin 10 nM (RAPA) and ibrutinib 1 µM (IB) +/- BCR stimulation on mTOR substrates. 
Expected molecular weight of mTOR and its effectors are as follows: Rictor 200 kDa, FOXO1 
78-82 kDa, AKT 60 kDa, S6 32 kDa, 4EBP1 15-20 kDa. GAPDH is predicted at 36 kDa.  
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Effects of AZD8055 and ibrutinib on the BCR-stimulated AKTS473 phosphorylation 
signal were highly significant and there was also a strongly significant effect on 
untreated BCR-stimulated cells (Figure 3-29 A). The effects on AKTS473 
phosphorylation persisted despite correction for protein loading, with significant 
inhibition by both AZD8055 and ibrutinib with the addition of BCR-stimulation 
(Figure 3-30 A). Densitometry analysis of 4EBP1Thr37/46 revealed significant 
inhibition by AZD8055-alone with and without the addition of BCR stimulation 
which persisted when adjusted for protein loading, as assessed by GAPDH levels 
(Figure 3-29 B & Figure 3-30 B). Analysis of S6S235/236 revealed significant effects 
of rapamycin and ibrutinib in the presence of BCR-stimulation using the 
measured protein expression (Figure 3-29 C). A significant rise in the S6S235/236 
signal could be demonstrated with the addition of BCR stimulation and after 
correction for protein loading there was a significant inhibitory effect by 
AZD8055 and ibrutinib upon stimulation with BCR (Figure 3-30 C). Densitometry 
analysis of FOXO1T24 revealed non-significant decreases in FOXO1T24 
phosphorylation with AZD8055 and once loading control correction is applied 
there is an increase in FOXO1T24 signal with rapamycin, relative to the signal 
generated in untreated control conditions (Figure 3-29 D & Figure 3-30 D).  
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Figure 3-29 Short-term BCR stimulation and mTOR inhibition densitometry analysis 
Densitometry analysis of Western blot for mTOR substrates (A) AKTS473 (n=7) (B) 
4EBP1Thr37/46 (n=7) (C) S6S235/236 (n=5) (D) FOXO1T24 (n=5) following 30 min drug pre-treatment 
with either non-drug control (NDC), 100 nM AZD8055 (AZD), 10 nM rapamycin (RAPA) or 1 
µM ibrutinib (IB) and subsequent 1 h BCR stimulation. *=p≤0.05; **=p≤0.01; ***=p≤0.001; 
****=p≤0.0001. 
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Figure 3-30 Short-term BCR stimulation and mTOR inhibition densitometry analysis with 
loading correction 
Densitometry analysis of Western blot for mTOR substrates with GAPDH correction 
expressed as a density ratio for substrates: (A) AKTS473 (n=7) (B) 4EBP1Thr37/46 (n=7) (C) 
S6S235/236 (n=5) (D) FOXO1T24 (n=5) following 30 min drug pre-treatment with either non-drug 
control (NDC), 100 nM AZD8055 (AZD), 10 nM rapamycin (RAPA) or 1 µM ibrutinib (IB) and 
subsequent 1 h BCR stimulation. *=p≤0.05; **=p≤0.01; ***=p≤0.001; ****=p≤0.0001.  
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  Effects of SDF-1 stimulation on mTOR activity 
The effects of inhibitors on mTOR substrates after 30 min SDF-1 stimulation of 
CLL cells are shown (Figure 3-31). As expected, SDF-1 increased the 
phosphorylation of mTORC1 downstream substrates S6S235/236 and RictorT1135, and 
mTORC2 downstream substrates AKTS473 and FOXO1, while 4EBP1T37/46  
phosphorylation was not elevated, as assessed by Western blotting. 
Phosphorylation of AKTS473 is targeted by AZD8055 and ibrutinib whereas this is 
relatively unaffected by rapamycin, indicative of mTORC2 inhibition (Figure 3-31 
A). Confirmation of mTORC2 inhibition by AZD8055 and delineation of its effects 
as downstream of ibrutinib’s target are shown with differential phosphorylation 
status of RictorT1135 in the presence of AZD8055 as opposed to ibrutinib (Figure 
3-31 A). The inhibition of mTOR kinase activity using phosphorylation of 
4EBP1T37/46 as a marker of mTORC1 effects is visible in Figure 3-31 B where 
activity is reduced with dual mTORC1/2 inhibition but is relatively spared by 
rapamycin. There is inhibition of S6S235/236 by both rapamycin and AZD8055, 
visible in Figure 3-31 A&B, reflective of the differential inhibitory effects on S6K 
and 4EBP1 phosphorylation by rapamycin. Ibrutinib has inhibitory effects on 
phosphorylation of both mTORC1 substrates, S6 and 4EBP1 however FOXO1 
appears relatively unaffected by drug inhibitors under SDF-1 stimulation (Figure 
3-31 B).  
Phosphorylation of FOXO1 by AKT is an inhibitory event in transcriptional 
regulation of its targets, so an increase in its phosphorylation levels correlates 
with the increase in PI3K/mTOR/AKT signalling activity induced by BCR and SDF-
1 stimulation. As increased phosphorylation can sometimes equate to a 
reduction in the tumour suppressor activity of FOXO1 in CLL, inhibition of 
phosphorylation by AZD8055 and rapamycin may represent their therapeutic 
activity. Further work is required to delineate whether FOXO1 phosphorylation is 
the underlying method of functional control or whether regulation of nuclear 
translocation is the mainstay of FOXO1 activity regulation.  
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Figure 3-31 Protein expression effects of mTOR inhibitors with short-term SDF-1 stimulation 
Western blot images are obtained from protein lysates of patient sample (A) CLL152 (normal 
karyotype CLL) and (B) CLL143 which is known to harbour an 11q deletion to demonstrate 
the effects of 30 min SDF-1 stimulation and non-drug control (NDC), AZD8055 100 nM (AZD), 
rapamycin 10 nM (RAPA) and ibrutinib 1 µM (IB) on mTOR substrates. Expected molecular 
weight of mTOR and its effectors are as follows: Rictor 200 kDa, FOXO1 78-82 kDa, AKT 60 
kDa, S6 32 kDa, 4EBP1 15-20 kDa. GAPDH is predicted at 36 kDa.  
Densitometry analysis of AKTS473 revealed an increase in phosphorylation upon 
SDF-1 stimulation compared with untreated controls (Figure 3-32 A). The pattern 
of drug inhibitor effects with AZD8055 were in keeping with the activity against 
mTORC1/2, displaying significant inhibition on AKTS473 phosphorylation, followed 
by effects of ibrutinib with no effect in AKTS473 phosphorylation with rapamycin 
treatment (Figure 3-32 A). An increase in the S6S235/236 signal could be 
demonstrated with the addition of SDF-1 stimulation with an inhibitory effect by 
AZD8055 and ibrutinib on S6S235/236 phosphorylation, where cells were also 
stimulated using SDF-1 (Figure 3-32 B). Densitometry analysis of 4EBP1T37/46 
revealed inhibition by AZD8055 and ibrutinib in the presence and absence of 
SDF-1 stimulation (Figure 3-32 C). Effects upon the phosphorylated FOXO1 signal 
follow the pattern of AKTS473 phosphorylation with relatively small inhibitory 
effects of rapamycin but with most striking effects visible with AZD8055 and 
ibrutinib treatments, exhibited both with and without SDF-1 stimulation.  
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Figure 3-32 Densitometry analysis of protein expression effects of SDF-1 stimulation and 
mTOR inhibition 
Densitometry analysis of Western blot for mTOR substrates with GAPDH correction 
expressed as a density ratio for substrates: (A) AKTS473 (n=6) (B) S6S235/236 (n=4) (C) 
4EBP1T37/46 (n=3) (D) FOXO1T24 (n=3) following 30 min drug pre-treatment, either non-drug 
control (NDC), 100 nM AZD8055 (AZD), 10 nM rapamycin (RAPA) or 1 µM ibrutinib (IB) and 
subsequent 30 min SDF-1 stimulation. *=p≤0.05; **=p≤0.01; ***=p≤0.001; ****=p≤0.0001. 
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3.3 Summary of findings 
The experimental settings were optimised for assessment of the molecular 
effects of mTOR inhibitors using in vitro methods in demonstration of effects on 
primary CLL cell viability over the 48 h time-point. I identified that 10 % FCS as 
the optimal serum concentration for the cellular viability experiments. The 
impact of AZD8055 on viability was greater than that of rapamycin, some of 
which may be attributable to a greater capacity to induce apoptosis, and which 
was greater than that of the control drug, ibrutinib. Effects on cellular markers 
of apoptosis over long-term inhibition with mTOR inhibitors and ibrutinib were 
studied with dual mTOR inhibitor AZD8055 demonstrating greatest impact on 
anti-apoptotic regulators such as BCL-xL and MCL-1. These findings are of 
significance for future work as further exploration of the efficacy of the control 
drug, ibrutinib and its mode of action is required to set the parameters for study 
of novel agents which act via inhibition of the BCR signal. The next chapter 
addresses the functional effects of mTOR inhibition in vitro as an alternative 
means of study of mTOR kinase effects on CLL cell migration. I introduced 
microenvironmental stimuli to my experimental approach, which required 
optimisation of the time-points for use in SDF-1 experiments to amplify the 
viability changes observed with my focus on mTOR inhibition. I examined the 
variability introduced by the combination of using fresh and thawed CLL samples 
in viability and in evaluation of chemokine receptor profiles and found this to be 
a valid approach. I also evaluated methods of BCR stimulation and found that in 
our cells there were no significant differences with the use of either F(ab’)2 
stimulation or anti-IgM with avidin cross-linking, and that these approaches 
could also be combined without confounding my study.  
The chemokine receptor and adhesion molecule profile of CLL cells were 
relatively heterogenous at baseline however the response to BCR stimulation 
could be measured in terms of changes in mean fluorescence intensity by FACS, 
with significant effects on CXCR4 and CD62L to downmodulate their levels with 
short-term exposure to BCR stimulation. Sample populations were stratified by 
well-characterised risk factors for CLL progression and whilst no increase in 
statistical significance was observed, changes persisted in high-risk CLL 
subgroups, highlighting the importance of these findings. The chemokine 
receptor experiments were extended to the 48 h time-point to assess whether 
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the observed changes were transient or could potentially be affected by changes 
at the level of the cell nucleus and gene expression changes. Only the significant 
reduction in CXCR4 levels could be replicated over 48 h which draws attention to 
the pivotal importance of CXCR4 to the migration process in CLL. Inhibitors were 
introduced to the 48 h BCR stimulation experiments with CLL samples exposed to 
BCR stimulation exhibiting significantly higher levels of CXCR4 in AZD8055 and 
ibrutinib conditions. These effects may be interpreted as a drug action to 
overcome the normal response of the cell to BCR stimulation in downmodulation 
of CXCR4. It is possible that these are methods utilised by the CLL cell in 
emigration from the LN.  
CLL cell phenotype changes were explored further by use of CXCR4 and CD5 
surface staining and response of these markers to SDF-1 stimulation. A marked 
increase in CXCR4loCD5hi population was observed with the addition of SDF-1, 
which was reduced by all inhibitors tested and was significantly overcome with 
the addition of AZD8055. It is possible that the response to a chemokine gradient 
is being thwarted in response to mTOR inhibition or BTK inhibition and that by 
these means that CLL cells are expelled into the peripheral blood, away from 
the protective niche which has the highest concentration of chemokine ligand.  
These studies were correlated with the observation of in vivo effects on ibrutinib 
on one of the first patients in our centre to receive the drug. Changes in 
chemokine receptor and adhesion molecule levels were mapped over a 3-month 
period. Again, CXCR4 was identified as a critical component of regulation of 
migration of CLL cells with changes on other markers occurring much later than 
with CXCR4. A caveat exists that these effects were studied in a single patient, 
who was heavily pre-treated with anti-CD52 (alemtuzumab) and experienced 
only modest lymphocyte counts at the peak of the redistribution effect, 
therefore this effect merits study in other ibrutinib recipients.  
Effects of mTOR inhibition on mTOR substrate expression were studied over a 
short-term time point selected at 1 h for BCR stimulation effects and 30 min for 
SDF-1 effects. The dual mTOR inhibitor displayed greatest efficacy of inhibition 
the mTOR kinase and fared favourably when compared with positive control, 
ibrutinib. Further work is required to examine the downstream effects of mTOR 
inhibition which is the focus of chapter 5. 
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Chapter 4 Functional effects of mTOR kinase 
inhibition on CLL cell migration 
4.1 Introduction 
The evaluation of drug inhibitors and their impact on functional assays offers a 
complementary approach to the molecular assays already described as the 
information provided may confirm the impact of molecular changes on cellular 
migration. Functional assays also provide a means of attributing individual 
chemokine ligand and receptor changes to overall changes in migration effects, 
for example the CXCR4-CXCL12 or CXCR5-CXCL13 axes. In some cases, the assays 
offer visualisation of migration effects to provide strong evidence of the direct 
impact of drug inhibitors on cellular events relating to migratory function. 
Normal ymphocyte migration is discussed in 1.7.2, with comparison to CLL 
migration in 1.7.3. Based upon an understanding of the mechanisms which 
regulate migration it may be hypothesised that CLL cells may display variability 
in migration potential, based upon the surface immunophenotype of the CLL cell 
and whether it is peripheral or nodal in origin.  
I used two types of timed migration assay to assess the capacity of our primary 
CLL samples to migrate in vitro. The discovery of stromal-derived factor as a 
growth factor with activity in haematopoietic system development is now 30 
years old and the concept of using CXCL12 or stromal-derived factor (SDF-1) to 
elicit B cell migration in vitro followed, 10 years later (261, 262), with its 
discovery made in the mouse haematopoietic system and with the first 
experiments performed in sorted murine bone marrow cells. These findings led 
to the development the pseudoemperipolesis assay which is the study of 
transmigration of CLL cells beneath a stromal layer to exploit the property of 
upregulated surface expression of CXCR4, a pathognomonic feature of CLL (148). 
The assay developed subsequently utilises the adherent murine cell line M2-
10B4, known for their ability to secrete CXCL12 in a spontaneous and self-
sustaining fashion, along with other haematopoietic growth factors such as stem 
cell factor (239). I did not perform any assay to quantitate CXCL12 production by 
M2-10B4 cells as the secretion of chemokine ligand is an established feature of 
these cells and the production of other, accessory, chemokine ligands by the cell 
line would potentially confound any such analysis. Instead, I controlled the 
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experimental conditions with reference to the cell count of M2-10B4 cells, with 
cell suspension aliquots of equal volume to be used in each experimental plate 
and well.  
The transwell migration assay also utilises SDF-1, this time as an addition to 
serum-starved media placed in wells below a polycarbonate permeable 
membrane, through which CLL cells are able to migrate along a chemokine 
ligand gradient. There are existing data to support the use of the transwell assay 
as a way of measuring the impact of novel therapeutic approaches (176, 186) 
and our group has also published data in the use of the transwell assay (180).   
Actin polymerisation is a tightly regulated cellular function which may be 
deployed in a variety of processes within the cell, including cytokinesis, cellular 
motility and vesicle endocytosis and trafficking. Phalloidin staining, used in our 
approach, is known to bind not only actin filaments but hWASp-VCA and Arp2/3 
which are involved in the stable actin-binding complex. Fluorescent phalloidin 
stabilises actin filaments and allows visualisation of the products of the actin 
polymerisation reaction, providing a cross-sectional approach to the dynamic 
cellular mobilisation processes. The fluorescence intensity from labelled 
phalloidin staining may permit evaluation by either FACS measurement or by 
microscopic imaging of fluorescent cell structures for visual assessment of actin 
localisation and for quantitative analysis.  
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4.2 The effects of mTOR inhibition on CLL cell 
pseudoemperipolesis 
The pseudoemperipolesis phenomenon is observed in Figure 4-1, with bunched 
CLL cells which have transmigrated through and underneath the cellular layer of 
M2-10B4 cells. The foci of CLL cells are visible through the translucent M2-10B4 
cell stroma and with the large stromal cell nuclei visible, dispersed throughout 
the microscopic field. The pseudoemperipolesis experimental protocol was 
optimised for the drug conditions as the initial experimental conditions, each 
performed in duplicate wells with triplicate FACS measurements of each, 
incorporated a 1 h drug incubation period before commencing the 
pseudoemperipolesis stage of the experiment. 
 
Figure 4-1 CLL cell pseudoemperipolesis 
High power (x40) microscopic image of M2-10B4 stromal cell layer with evidence of 
pseudoemperipolesis exhibited by patient sample CLL132 (17p deletion). The arrows 
indicate two groups of CLL cells which have undergone pseudoemperipolesis. 
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Figure 4-2 compares the effect of 1 h incubation with 100 nM AZD8055 on CLL 
cell pseudoemperipolesis with the transmigratory capacity of untreated control 
cells. Consistent with published examples of the assay, the negative control 
level of pseudoemperipolesis was <0.05% however there was no difference 
between drug-treated and untreated cells. These findings led us to adapt our 
approach to incorporate an overnight incubation step to expose CLL cells to drug 
inhibitors demonstrated in Figure 4-2. There is no overall change in 
pseudoemperipolesis at either 100 nM AZD8055 or 1 nM rapamycin when 
compared with the untreated control cells, which may be attributable to the 
limited time period of exposure to the drug inhibitors. Overnight exposure to 
AZD8055 100 nM of CLL cells prior to pseudoemperipolesis reveals a trend to 
significant reduction in migration with the drug, with no clear effects on 
rapamycin. Differential effects of rapamycin may be anticipated however, given 
its potential for upregulation of AKT signalling.  
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Figure 4-2 Effect of duration of drug incubation prior to pseudoemperipolesis experiments 
Raw data comparing mean and SEM pseudoemperipolesis of n=4 samples. CLL cells were 
prepared by 1 h exposure to non-drug control (NDC), AZD8055 100 nM (AZD) and rapamycin 
10 nM (RAPA) then with pseudoemperipolesis conducted over 5 h (A). Extension of the drug 
incubation period to 15 h reveals greater inhibition of pseudoemperipolesis effects by 
AZD8055 after this time point (n=6) (B).  
A potential caveat to extending our incubation period from 1 h to the overnight 
incubation with drug inhibitors and BCR stimulation would be that any drug 
effects may be erroneously attributed to migration effects, rather than CLL cell 
viability effects which may be the actual mechanism of drug activity. However, 
we have already shown that even over 24 h incubation with dual mTOR inhibitor 
AZD8055 there are minimal effects upon CLL cell viability, using viability studies 
(Figure 3-13) and markers of apoptosis (Figure 3-16).  
Next, the influence of BCR stimulation may be examined using the 
pseudoemperipolesis assay shown in Figure 4-3, Figure 4-4 and Figure 4-5. A 
trend to increase in pseudoemperipolesis was observed with the addition of BCR 
stimulation (Figure 4-3); these findings were examined with reference to use of 
F(ab’)2 fragment stimulation (n=8) as opposed to anti-IgM stimulation with avidin 
crosslinking (n=3) and there were found to be no significant differences with BCR 
stimulation in either subgroup (Figure 4-4). Fresh sample use (n=6) when 
compared with thawed sample (n=7) pseudoemperipolesis did not affect 
statistical significance (Figure 4-4). Statistical analysis could not be extended to 
the ZAP70 negative subgroup (n=2) however ZAP70 positivity conferred a 
significant increase in CLL cell pseudoemperipolesis in response to BCR 
stimulation (Figure 4-5).  
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Figure 4-3 BCR stimulation effects on CLL cell pseudoemperipolesis 
Normalised mean and SEM pseudoemperipolesis over 5 h with the effects of the addition of 
BCR stimulation in relation to untreated controls (n=13). Each dot plotted represents the 
average of three FACS measurements for wells which were performed in duplicate and 
fluorescence measurement of cells stained for CD19+ were compared by normalising BCR 
responses to the levels measured for unstimulated, untreated controls.  A trend to increase 
in pseudoemperipolesis was observed with 15 h (overnight) BCR stimulation. 
 
Figure 4-4 BCR stimulation effects on pseudoemperipolesis: subgroup analysis 
Normalised mean and SEM pseudoemperipolesis over 5 h with the effects of the addition of 
BCR stimulation in relation to untreated controls. Samples were stratified by whether they 
were used fresh (A, n=7), thawed (B, n=6) and by method of BCR stimulation, either by anti-
IgM stimulation with avidin crosslinking (C, n=3) or F(ab’)2 fragment stimulation (D). 
 
Figure 4-5 BCR stimulation effects on pseudoemperipolesis: influence of ZAP70 
Normalised mean and SEM pseudoemperipolesis over 5 h with the effects of the addition of 
BCR stimulation in relation to untreated controls of (A) ZAP70 positive (n=9) and (B) ZAP70 
negative samples (n=2). *=p≤0.05; **=p≤0.01; ***=p≤0.001; ****=p≤0.0001. 
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Analysis of the effect of mTOR inhibitors on migration in the presence or 
absence of BCR stimulation (n=3) revealed some samples with amplified 
pseudoemperipolesis effect which skew the combined raw data, however, there 
is a statistically apparent inhibition by 100 nM AZD8055 of pseudoemperipolesis 
(Figure 4-6). With removal of the outliers (classed as those samples exhibiting 5% 
pseudoemperipolesis in the unstimulated non-drug control), there is 
enhancement of statistical significance of the inhibition by AZD8055 100 nM. 
Furthermore, there is a significant increase in pseudoemperipolesis with the 
addition of BCR stimulation in the subset shown in (Figure 4-6 B).     
Normalised data were compared in Figure 4-7 with graphs to display 
unstimulated drug effects (Figure 4-7 A) and those with the addition of BCR 
stimulation (Figure 4-7 B). A significant reduction in pseudoemperipolesis could 
be demonstrated in the BCR-stimulated cells, with the addition of 100 nM 
AZD8055 and ibrutinib 1 µM and with inhibition demonstrated to a greater 
degree by 300 nM AZD8055.   
 
Figure 4-6 Primary CLL sample pseudoemperipolesis: raw data 
Graphs display (A) pseudoemperipolesis effects over 5 h with non-drug control (NDC) or 
dual mTOR inhibitor AZD8055 100nM (AZD) +/- BCR stimulation (A) (n=13). Elimination of 
outliers by GraphPad software allows visualisation of statistical trends (B) (n=9). *=p≤0.05; 
**=p≤0.01; ***=p≤0.001; ****=p≤0.0001. 
As per the experimental protocol, a wash control step was incorporated which 
involves 5 min incubation of M2-10B4 cells with a CLL cell suspension of the 
original cell concentration used at the beginning of the 5 h incubation period. 
The wash step condition is used to assess the stringency of the washing process 
throughout all of the experimental wells and a threshold of 0.05% CLL cells in 
the control well is used to determine the overall success of the washing process. 
On analysis after elimination of samples with a wash control >0.05%, the trends 
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in drug inhibitor effects on pseudoemperipolesis persist. However, the 
significant reduction in migration that was seen with overnight AZD8055 
treatment at 100 nM and 300 nM and ibrutinib 1 µM are lost (Figure 4-8). More 
samples are required to repeat the experiment, in order to confirm the 
significance of the trends of drug inhibitor effects on pseudoemperipolesis. 
Interestingly, rapamycin appears to be less effective in migration inhibition of 
the samples studied, possibly due to loss of negative feedback regulation of the 
mTORC2 signalling complex and unregulated AKT signalling. 
 
Figure 4-7 Primary CLL sample pseudoemperipolesis: normalised data (i) 
Charts display normalised data with the effects of overnight addition of non-drug control 
(NDC), AZD8055 100 nM (AZD), rapamycin 10 nM (RAPA) and ibrutinib 1 µM (IB) prior to 
pseudoemperipolesis over 5 h, shown in (A) (n=13).  The same drug conditions were 
replicated with 30 min pre-treatment with inhibitors, followed by overnight BCR stimulation 
displayed in (B), this time with significant inhibition by AZD8055 at both 100 nM and 300 nM, 
and by ibrutinib 1 µM (n=11). *=p≤0.05; **=p≤0.01; ***=p≤0.001; ****=p≤0.0001. 
 
Figure 4-8 Primary CLL sample pseudoemperipolesis: normalised data (ii) 
Pseudoemperipolesis over 5 h with the effects of overnight addition of non-drug control 
(NDC), AZD8055 100 nM (AZD), rapamycin 10 nM (RAPA) and ibrutinib 1 µM (IB) prior to 
experiments with data shown in (A), with removal of all samples with a wash control CLL 
cell content of >0.05% (n=8).  The same drug conditions were replicated with 30 min pre-
treatment with inhibitors, followed by overnight BCR stimulation displayed in (B) (n=7). 
*=p≤0.05; **=p≤0.01; ***=p≤0.001; ****=p≤0.0001. 
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4.3 The effects of mTOR inhibition on CLL cell transwell 
migration 
 
I show that BCR stimulation follows a trend towards increased primary CLL 
sample transwell migration along a CXCL12 gradient, when compared with the 
unstimulated control (Figure 4-9). The effects of drug conditions upon transwell 
migration followed a similar pattern in the presence and absence of BCR 
stimulation however no significant inhibition of migration was observed (Figure 
4-10 A&B). With the observation that some CLL samples respond negatively to 
BCR stimulation in terms of the percentage of migrated cells, a subset of 
samples were identified to exhibit an increase in migration with BCR stimulation, 
a subgroup termed “BCR responders” which may be contrasted with “non-
responders” (Figure 4-11 A&B). For these 5 patient samples (CLL8, CLL42, CLL90, 
CLL113, CLL116) there is a significant increase in BCR stimulation within the 
drug conditions AZD8055 100 nM and ibrutinib 1 µM. There is a reduction in 
migration with 300 nM AZD8055 although this is not statistically significant 
however the loss of significant increase in BCR stimulation at the higher 
concentration of AZD8055 may represent an increased efficacy to overcome the 
pro-survival stimuli by these samples. Indeed when taking unstimulated and BCR-
stimulated separately as in Figure 4-12, the BCR stimulation conditions reveal 
drug inhibition effects by dual mTOR inhibitor AZD8055 at both concentrations 
(Figure 4-12 B). As shown in both Figure 4-11 and Figure 4-12, there appears to 
be an increase in migration with rapamycin within the “BCR responders” group. 
Overall analysis of the impact of drug exposure revealed no significant 
differences between drug conditions over the 11 samples utilised. More samples 
may be required from a range of prognostic subsets to try to establish the 
effects of the drug inhibitors. Another reason as to why the effects of mTOR 
inhibition could not be demonstrated by transwell migration could be due to the 
procedure used in the SDF-1 experiments described in chapter 3, as the samples 
were pre-treated with a period of serum starvation before the addition of drug 
inhibitors and subsequent BCR stimulation. The period of serum starvation 
creates a limit on the time period over which CLL cells may be exposed to the 
drug inhibitors. Therefore, an overnight drug exposure step could not be 
incorporated into the transwell assay, possibly preventing CLL cells from 
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sufficient exposure time to mTOR inhibition to facilitate changes affecting 
migration.  
 
Figure 4-9 Effects of BCR stimulation on CXCL12 transwell migration of primary CLL 
samples 
Mean and SEM transwell migration of primary CLL samples over 4 h, along a CXCL12 
gradient after 1 h BCR stimulation (n=14).  Data are normalised with individual data points 
each representing duplicate transwells with each transwell cell count being performed in 
triplicate i.e. each data point represents n=6 for an individual sample. 
 
Figure 4-10 Transwell migration of primary CLL samples towards CXCL12 
Mean and SEM of normalised transwell migration of primary CLL samples over 4 h, along a 
CXCL12 gradient after 30 min drug inhibition with non-drug control (NDC), AZD8055 100 nM 
(AZD), rapamycin 10 nM (RAPA) and ibrutinib 1 µM (IB), (A) in the absence and (B) with 
subsequent BCR stimulation for 1 h (n=11).  
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Figure 4-11 Transwell migration analysis by BCR responses 
Normalised mean and SEM of cell counts generated as described previously. Transwell 
migration was conducted towards CXCL12 for 4 h after 30 min treatment with non-drug 
control (NDC), AZD8055 100 nM (AZD), rapamycin 10 nM (RAPA) and ibrutinib 1 µM (IB) and 
1 h BCR stimulation. A subgroup was identified based upon samples responding positively 
to BCR stimulation in the transwell migration assay (A, n=5). The remaining samples which 
were non-responsive to BCR stimulation are shown (B, n=6). *=p≤0.05; **=p≤0.01; 
***=p≤0.001; ****=p≤0.0001. 
 
Figure 4-12 Transwell migration of “BCR responder” subgroup  
Mean and SEM migration of a subgroup generated by isolation of samples responding 
positively to BCR stimulation in the transwell assay (CLL8, 42, 44, 113, 116, n=5). Data are 
normalised after generation of cell counts as described previously, following transwell 
migration towards CXCL12 for 4 h after 30 min treatment with non-drug control (NDC), 
AZD8055 100 nM (AZD), rapamycin 10 nM (RAPA) and ibrutinib 1 µM (IB), (A) without and (B) 
with subsequent BCR stimulation for 1 h. 
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Figure 4-13 Transwell migration of “BCR non-responder” subgroup 
Mean and SEM migration of a subgroup generated by isolation of samples with no response 
to BCR stimulation in the transwell assay (CLL80, 85, 90, 109, 119, 130, n=6). Data are 
normalised after generation of cell counts as described previously (2.2.5), following 
transwell migration towards CXCL12 for 4 h after 30 min treatment with non-drug control 
(NDC), AZD8055 100 nM (AZD), rapamycin 10 nM (RAPA) and ibrutinib 1 µM (IB), (A) without 
and (B) with subsequent BCR stimulation for 1 h. 
Further evaluation of CLL cells and their response to chemokine ligand in the 
transwell migration assay was undertaken using CXCL13 as the stimulus for 
migration (Figure 4-14). Experimental conditions required optimisation as there 
data availability on the use of CXCL13 in transwell assays was limited with no 
specific references to its use in CLL cell migration studies to be found in 
published literature (263, 264). Therefore, a concentration gradient of CXCL13 
was studied from 800 ng/ml to 1 µg/ml with the impact of BCR stimulation using 
F(ab’)2 fragments on levels of migration towards CXCL13 displayed in Figure 
4-14. An increase in chemokine-mediated migration towards CXCL13 was 
observed with the addition of BCR stimulation, although the increase was not 
significant as more samples are required to confirm this trend. 
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Figure 4-14 Effects of BCR stimulation on CXCL13 transwell migration of primary CLL 
samples 
Mean and SEM of normalised transwell migration data of CLL samples along a chemokine 
gradient of 800 ng/ ml (CLL93, n=1) and of 1 µg/ ml CXCL13 (CLL42, 93, 109, n=3).  
4.4 The effects of mTOR inhibition on PKCa-KR cell 
migration 
Based upon the above results, I sought to consolidate the data regarding primary 
CLL sample migration responses, leading to the application of our in vitro-
generated cellular model of CLL to the transwell assay. The biological similarity 
of the PKCa-KR mouse model to CLL in vivo with overlapping cellular 
immunophenotype characteristics with CLL is the basis for the use of our model. 
The PKCa-KR model has features in keeping with poor prognostic disease, with 
reliance upon the BCR signal, making it a useful model for the study of novel 
agents including mTOR inhibitors and BTK inhibitors (182). One such phenotypic 
similarity to CLL is the property of increased cell surface expression of CXCR4 
making PKCa-KR suitable for use in the transwell assay (Figure 4-15). I 
completed the transwell assay which showed strongly significant inhibition of 
migration towards CXCL12 demonstrated by the incubation of PKCaKR cells with 
100 nM AZD8055 and 1 µM ibrutinib, and even greater inhibition by 10 nM 
rapamycin (Figure 4-16).  
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Figure 4-15 Histogram from FACS analysis of MIEV and PKCaKR cells 
Graphs A & C are unstained controls and B & D represent live cells gated on CD19+ and 
stained for CXCR4. Cells are taken from day 9 of culture in vitro with MIEV and PKCaKR 
cells displaying a proportion of cells which stain strongly for CXCR4 in comparison with the 
unstained controls.   
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Figure 4-16 PKCaKR transwell assay migration studies 
PKCaKR transwell assays with 6 technical replicates for each condition, as with the primary 
CLL sample transwells. There were 5 biological replicates combined to demonstrate the 
significant impact of mTOR and BTK inhibition on transwell migration. PKCaKR cells were 
incubated for 30 min with non-drug control (NDC), AZD8055 100 nM (AZD), rapamycin 10 nM 
(RAPA) and ibrutinib 1 µM (IB) with subsequent transwell migration for 4 hours. Effects were 
compared with the transwell migration results for MIEV. *=p≤0.05; **=p≤0.01; ***=p≤0.001; 
****=p≤0.0001.  
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4.5 The effects of mTOR inhibition on actin 
polymerisation  
 Assessment of actin polymerisation by flow cytometry 
The ability to construct the actin cytoskeleton relates directly to cellular 
migration potential, so we employed assays utilising flow cytometry and 
immunofluorescence staining to define how BCR crosslinking, SDF-1 stimulation 
and inhibitors may mediate changes in migration. Actin exists in an equilibrium 
of cellular forms from monomers to different organisational states of actin 
polymerisation. Peptide toxin phalloidin, derived from the fungus amanita 
phalloides was found to stabilise F-actin filament polymers and to stain these 
cell structures with high specificity (265). Therefore, phalloidin may be applied 
in vitro to study actin polymerisation in fixed cells such as our CLL samples and 
when phalloidin is labelled with a fluorophore, mean cellular fluorescence 
intensity, as measured by flow cytometry, may be used as a surrogate marker of 
actin polymerisation (180). After application of phalloidin to a CLL cell 
suspension in vitro, the polymerisation reaction may be studied over a range of 
time points with serial sampling to assess the extent of actin polymerisation, 
with variations in the degree of cytoskeletal formation and pattern over time 
with each sample which remain heterogeneous after data normalisation (Figure 
4-17 A-C). 
Although the limitations of the assay require data analysis to be conducted with 
the use of time as a categorical variable rather than as a continuous variable, 
peak cytoskeletal activation may be studied. Differences in actin polymerisation 
at each time point were compared with significant increase in fluorescence 
intensity, relating to cytoskeletal formation, at the 15 second time point with 
SDF-1 and at 30 and 60 seconds with F(ab’)2 and BCR crosslinking with avidin 
respectively (Figure 4-18 A-C).  
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Figure 4-17 Actin polymerisation assay by individual CLL samples 
Actin polymerisation studies combined (n=9) to demonstrate heterogeneity of CLL sample 
responses to stimuli. Each stimulation was performed on serum-starved, either fresh or 
thawed, CLL cells at 37oC with serial sampling, cell fixation, permeabilisation and phalloidin 
staining. Reactions were triggered by in vitro conditions: (A) 100 ng /ml SDF-1 (B) 10 µg /ml 
F(ab’)2 fragments and (C) 10 µg /ml anti-IgM with 25 µg /ml avidin crosslinking. 
 
 
 
Figure 4-18 Actin polymerisation assay by time point 
Mean and SEM actin polymerisation of both fresh and thawed CLL samples at each 
sampling time point in response to (A) 100 ng /ml SDF-1 (B) 10 µg /ml F(ab’)2 fragments and 
(C) 10 µg /ml anti-IgM with 25 µg /ml avidin crosslinking. Significant increases in actin 
polymerisation may be demonstrated at different time points with each type of stimulus. 
*=p≤0.05; **=p≤0.01; ***=p≤0.001; ****=p≤0.0001. 
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I used FITC-phalloidin for the majority of the actin polymerisation assays to 
mainly to restrict the measurement of fluorescence intensity to single channel to 
reduce the exposure of the data to another variable, however, there are data to 
suggest that the use of different fluorophores may be applied with different 
fluorescence intensity over time (266). Therefore, I explored the use of TRITC 
phalloidin in the actin polymerisation experiments to investigate for differential 
fluorescence intensity of this fluorophore and to optimise the use of the 
rhodamine fluorophore for our immunofluorescence imaging studies. Figure 4-19 
demonstrates the responses to a range of stimuli of a freshly-obtained sample in 
comparison to a thawed sample from the same patient, CLL8. The effects of 
fluorophore on baseline fluorescence intensity levels in the same sample may 
also be observed, with minimal effect as may be observed. Both fresh and 
thawed samples display SDF-1-responsiveness whereas there are minimal effects 
of BCR-stimulation on actin polymerisation responses (Figure 4-20).  
Next, the phenomenon of BCR-responsiveness was explored by subjecting further 
samples to actin polymerisation studies using BCR-stimulation. Figure 4-21 
illustrates the variety of responses to BCR stimulation with CLL80 indicated in 
Figure 4-21 A with a late peak in BCR response in the untreated control condition 
and with greatest elevation in actin polymerisation with the addition of 10 nM 
rapamycin. There appear to be smaller increases with the addition of AZD8055 
100 nM and ibrutinib 1 µM however these contrast with the overall absence of 
response to BCR in all conditions in Figure 4-21 B representing responses of 
sample CLL86. Further evidence of the heterogeneous response to drug 
inhibitors, and in support of the combination of fresh samples with thawed 
samples for analysis is given in Figure 4-22 with (A) demonstrating the responses 
of a fresh sample as opposed to (B) where a different but similarly poor 
prognosis sample is used thawed.  
Actin polymerisation was studied with reference to responses for individual drug 
conditions. With SDF-1 stimulation, no statistically significant effects were 
demonstrated however peak inhibition by mTOR inhibitors and ibrutinib occurred 
at the 30 and 60 second time points (Figure 4-23 A-E). Dual mTOR inhibitor 
AZD8055 inhibited actin polymerisation at 15 and 300 seconds where BCR 
stimulation effects were studied, however at the 15 second time point it 
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increased actin polymerisation with a significant rise at 600 seconds. Rapamycin 
increased actin polymerisation at all time points except at 300 seconds whereas 
ibrutinib was inhibitory at 15 and 300 seconds (Figure 4-24 A-E). 
 
Figure 4-19 CLL8 actin polymerisation: analysis by stimulation 
Actin polymerisation of a single patient sample with SDF-1, anti-IgM stimulation, BCR 
crosslinking or F(ab’)2 fragment stimulation. The sample (A) was obtained as a fresh sample 
and is stained with TRITC phalloidin whereas (B) is from a thawed sample and stained with 
FITC phalloidin.
 
Figure 4-20 CLL8 actin polymerisation: effects of mTOR inhibition 
CLL8 actin polymerisation from serial sampling after the administration of (A) SDF-1 and (B) 
F(ab’)2 fragment stimulation, each with 30 min pre-treatment with drug inhibitors as 
indicated. 
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Figure 4-21 Actin polymerisation in response to BCR stimulation 
Actin polymerisation from serial sampling after the administration of F(ab’)2 fragment 
stimulation with 30 min pre-treatment with drug inhibitors using (A) CLL80, known to 
harbour a 17p deletion and (B) CLL86, known to harbour an 11q deletion. 
 
Figure 4-22 Actin polymerisation in response to SDF-1 stimulation 
Actin polymerisation studies of samples harbouring a 17p deletion with 30 min pre-
treatment with drug inhibitors using (A) fresh (CLL149) or (B) thawed (CLL113). 
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Figure 4-23 Actin polymerisation in response to SDF-1 stimulation 
Mean and SEM of actin polymerisation for non-drug control (NDC) (n=12), 100 nM AZD8055 
(AZD) (n=12), 10 nM rapamycin (RAPA) (n=12), 1 µM ibrutinib (IB) (n=6) at sampling time 
points (A) 15 seconds (B) 30 seconds (C) 60 seconds (D) 300 seconds and (E) 600 seconds.  
 
Figure 4-24 Actin polymerisation in response to BCR stimulation 
Mean and SEM of actin polymerisation for non-drug control (NDC) (n=4), 100 nM AZD8055 
(AZD) (n=4), 10 nM rapamycin (RAPA) (n=4), 1 µM ibrutinib (IB) (n=3) at sampling time points 
(A) 15 seconds (B) 30 seconds (C) 60 seconds (D) 300 seconds and (E) 600 seconds.  
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 Assessment of actin polymerisation by 
immunofluorescence  
Actin polymerisation was also evaluated by fluorescent microscopy and cells 
assessed for changes with drug inhibitors and with BCR or SDF-1 stimulation 
(Figure 4-25, Figure 4-26). Both stimulation conditions displayed evidence of 
spreading of the actin cytoskeleton with no consistent impact of mTOR inhibition 
or BTK inhibition on cell morphology. Cell stimulation effects were studied 
further by quantitation of intensity of cytoplasmic fluorescence using 
CellProfilerTM software and the subtraction method (2.5.6). A range of 
parameters were studied in order to quantitate cytoplasmic spreading, each of 
which should be interpreted with caution in view of the automatic nature of the 
software’s analysis and the inherent deficiencies of assessing a 2-dimensional 
image of a 3-dimensional structure. Parameters such as mean and median 
nuclear: cytoplasmic intensity ratio; mean and median cytoplasmic intensity in 
the FITC channel of cells from individual samples at high power magnification 
were also measured as shown in Figure 4-28 and Figure 4-29. Mean data values 
were calculated from combining over 200 cells from each sample. Data from 
BCR-stimulated cells were compared for 7 samples to show a significant 
reduction in median cytoplasmic fluorescence intensity which may represent the 
increased cytoplasmic spreading seen with BCR stimulation, a phenomenon 
which may be studied in more detail with deconvolution of cellular images 
(Figure 4-27 and Figure 4-28). Images from an exemplary analysis by 
CellProfilerTM software are shown in Figure 2-4, 2.5.6. 
  
128 
 
 
Figure 4-25 Immunofluorescence effects of BCR stimulation on CLL actin polymerisation 
Fluorescent microscopic images of phalloidin staining in response to 30 min treatment with 
non-drug control (NDC), AZD8055 100 nM (AZD), rapamycin 10 nM (RAPA) and ibrutinib 1 
µM (IB) then 1 h BCR stimulation on CLL155, a CLL sample known to harbour an 11q 
deletion (x 100 magnification). 
 
Figure 4-26 Immunofluorescence effects of SDF-1 stimulation on CLL actin polymerisation 
Fluorescent microscopic images of phalloidin staining in response to 30 min treatment with 
non-drug control (NDC), AZD8055 100 nM (AZD), rapamycin 10 nM (RAPA) and ibrutinib 1 
µM (IB) then 1 h SDF-1 stimulation on CLL155 (x 100 magnification). 
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Figure 4-27 BCR stimulation effects on CLL actin polymerisation 
Deconvoluted fluorescent microscopic images of actin polymerisation in response to 1 h 
BCR stimulation with effects of non-drug control (NDC), AZD8055 100 nM (AZD) and 
rapamycin 10 nM (RAPA) on CLL122, a CLL sample known to harbour a 17p deletion (x 100 
magnification). 
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Figure 4-28 Quantitative analysis of immunofluorescence changes with BCR stimulation on 
actin polymerisation 
Graphical representation of median cytoplasmic intensity for >200 cells from samples 
CLL46, 69, 80, 86, 143, 144 and 148, with distribution according to drug condition (non-drug 
control (NDC), AZD8055 100 nM (AZD), rapamycin 10 nM (RAPA) and ibrutinib 1 µM (IB)) and 
presence or absence of 1 h BCR stimulation. *=p≤0.05; **=p≤0.01; ***=p≤0.001; 
****=p≤0.0001. 
 
 
 
Figure 4-29 Quantitative analysis of actin polymerisation nuclear: cytoplasmic ratio changes 
Nuclear: cytoplasmic (N:C) intensity ratio for >200 cells from samples CLL46, 69, 80, 86, 143, 
144 and 148, with distribution according to condition (non-drug control (NDC), AZD8055 100 
nM (AZD), rapamycin 10 nM (RAPA) and ibrutinib 1 µM (IB)) and presence or absence of 1 h 
BCR stimulation. Both mean and median N:C are significantly enhanced by BCR stimulation 
with the prior addition of rapamycin. *=p≤0.05; **=p≤0.01; ***=p≤0.001; ****=p≤0.0001. 
0.00
0.05
0.10
0.15
0.20
M
ED
IA
N
 IN
TE
N
SI
TY
GROUP MEDIANS - CYTO INTENSITY
*
UT AZD RAPA IB UT
BCR
AZD
BCR
RAPA
BCR
IB
BCR
*
M
ed
ia
n 
cy
to
pl
as
m
ic
 in
te
ns
ity
 
UT AZD RAPA IB UT
BCR
AZD
BCR
RAPA
BCR
IB
BCR
M
ed
ia
n
in
te
ns
ity
 ra
tio
(n
or
m
al
is
ed
)
0
1
2
3
4
5 *
131 
4.6 Summary of chapter 
In this chapter I demonstrate evidence of pseudoemperipolesis by CLL cells and 
show that it may be affected by drug inhibitors. These data show support for the 
use of dual mTOR inhibition as a more effective strategy to block 
pseudoemperipolesis than mTORC1 inhibition alone, with a trend to increase in 
this form of migration with the addition of rapamycin. My hypothesis that short-
term exposure to mTOR inhibitors would be insufficient to affect 
pseudoemperipolesis is supported by data to compare 1 h drug inhibition with 
overnight exposure to drugs. I postulate that the underlying reason for the 
requirement for longer drug exposure may be that changes in 
pseudoemperipolesis effected by the mTOR inhibitors occur at the level of the 
cell nucleus. The primary CLL cell transwell migration study findings also suggest 
that the cellular changes which regulate migration and those changes which may 
be targeted by drug inhibitors may occur after longer-term drug exposure 
periods. Drug effects may be mediated at the level of receptor endocytosis and 
endocytic recycling, as changes in short-term cell surface receptor expression, 
or at the level of protein translation to alter the number of adhesion molecules 
being produced and trafficked to the cellular membrane. Further work is 
required to delineate the underlying processes in regulation of these effects in 
primary CLL samples.  It is of note that significant reduction in transwell 
migration could be demonstrated by the addition of mTOR inhibitors to PKCa-KR 
mouse cells in culture over a short incubation time. These differences may 
relate to a differential response of the mouse model to the mTOR inhibitors or 
may be reflective of the heterogeneity present within the CLL samples used.  
I assess functional analysis of mTOR inhibitors by their migratory effects in the 
actin polymerisation assay, however after data analysis, the only significant 
effects demonstrable were exhibited in response to in vitro stimuli; SDF-1 and 
BCR stimulation. There were no consistent responses to mTOR inhibition with 
the actin polymerisation assay, either by FACS or by immunofluorescence. 
Further work to study the responses of GTPases known to regulate migration 
effects via actin cytoskeletal remodelling and which are known to play a role in 
CLL cell chemokine responses will be explored in the next chapter.   
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Chapter 5 Regulation of CLL cell migration by 
small GTPases and the effects of mTOR 
inhibition  
5.1 Introduction 
There are myriad cellular processes involved in regulation of migration signals, 
of which potential candidates for further study include members of the small 
guanosine triphosphatase (GTPase) superfamily; containing 5 subfamilies each 
with multiple members possessing overlapping functions. GTPases all share a 
common feature in that they act as “molecular switches” in signal transduction 
as they cycle between active and inactive forms. The switching process is 
accelerated by regulatory guanine nucleotide exchange factors (GEF) which 
facilitate guanosine diphosphate (GDP) dissociation, Rho GDP dissociation 
inhibitors (Rho-GDI) and GTPase activating proteins (GAP), responsible for GTP 
hydrolysis (Figure 5-1).  
  
Figure 5-1 Diagram of Rap1 GTPase signalling with indication of downstream relationship to 
chemokine receptor and integrin signalling in normal B cells 
Activator of the Rap1 signal 8-pCPT-2′-O-Me-cAMP along with pharmacological PDE4 
inhibitor rolipram are shown. Dual mTORC1/2 inhibitor AZD8055 is displayed with along its 
site of action within the mTOR complex.  
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The originally discovered Ras subfamily and its members were strongly linked 
with oncogenesis, particularly in solid tumours. Rab and Arf subfamilies share 
functions in vesicle trafficking and membrane transport, with the sole Ran 
family member found to have roles in nuclear pore formation and in microtubule 
organisation (267). The Rho family and its members are implicated in actin 
cytoskeletal organisation; Rac1 and cdc42 initiate actin polymerisation through 
Arp2/3 complex activation, via WASp binding. Our experimental approach is 
focused on two GTPases: Rap1 and Rac1 proteins. The Ras family-member Rap1 
has already been investigated in CLL with the regulation of its function found to 
be impaired (237, 238). Experimental strategies for investigation of GTPase 
activation rely upon the ability to delineate active from inactive forms of the 
protein under investigation, given the earlier findings which demonstrate 
consistent protein levels in the presence of drug inhibitions and in vitro 
stimulation. As these methods require a suitable positive control from which to 
assess relative proportions of active and inactive protein I refer to the Rap1 
signalling pathway to look for exogenous means of activating Rap1. 
As pictured in Figure 5-1, the Rap1 signalling axis is reliant upon 
phosphodiesterase (PDE) 4A-mediated generation of cyclic AMP (cAMP) which in 
turn, activates exchange protein directly activated by cAMP (EPAC). 
Pharmacological analogues are available, with their actions being to increase 
cellular activation of EPAC without concomitant increase in PKA activity, a by-
product of PDE inhibition (268) and these EPAC activators may be exploited for 
the in vitro Rap1 activity assay in primary CLL samples. The EPAC activator may 
also be of use in IF assays as although antibodies for either Western blot or IF 
cannot distinguish between active and inactive forms of Rap1, EPAC activation 
may be utilised to promote Rap1 in its active form, to permit study of 
fluorescence pattern and localisation. 
My hypothesis is that mTOR inhibition may block the active form of Rap1 
GTPase, given the downstream location of Rap1 to the chemokine signalling 
pathway. Rap1 activity may also be reduced by ibrutinib, given that BTK is also 
positioned downstream of chemokine signalling pathways (269). There are 
putative effects on localisation of Rap1, based upon studies which show impaired 
endosomal recycling in CLL and one hypothesis is that these defects may 
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potentially be corrected by mTOR inhibition. IF offers a potential method of 
evaluation of protein localisation with co-staining for multiple cellular 
organelles. 
The Rho family of GTPases has functions in actin re-organisation which places it 
central in regulation of cellular processes such as adhesion, cell polarity and 
membrane trafficking. Rac1 has specific functions in lamellipodia formation and 
clathrin-independent endocytosis, in these ways it has responsibility for 
mediation of downstream effects of focal adhesion kinase (FAK). There is 
evidence from in vivo studies of the importance of Rho family GTPases to the 
CLL microenvironment (189), identifying this family as being of interest for 
further study in CLL. Active Rac1 may also be measured by evaluating the 
relative quantities of active and inactive forms of the protein in an experimental 
condition, however there was no available pharmacological activator, therefore 
control conditions were limited to the concentrated samples of G-protein-
activating GTP analogue, guanosine g thio-phosphate (GTPgS) and GDP, which 
were added to positive and negative control cells, respectively.  
5.2 Molecular effects of mTOR inhibition on GTPase 
activity 
Immunoprecipitation assays were performed to explore changes in cellular 
protein levels under a range of drug inhibition and chemokine or BCR stimulation 
conditions.  
 Rap1 by GTPase activity assay 
The initial Rap1 activity experiment using published conditions (237) was 
performed using a fresh CLL95 sample (normal karyotype CLL) and it yielded no 
Western blot signal in the sample conditions, however there was a weak signal in 
the GTPgS positive control lane. Molecular properties of GTPgS include its 
guanosine triphosphate (GTP) analogue function, G protein-activating and non-
hydrolysable state which are exploited by the GTPase activity assay to provide a 
positive control condition. There was also no signal detected in the EPAC 
positive control cells, therefore we elected to include only the GTPgS and GDP 
controls. A representative example of the effects of mTOR inhibitors on Rap1 
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activity is shown upon SDF-1 and BCR stimulation demonstrated, along with 
positive and negative controls (Figure 5-2). There is a clear stimulation of Rap1 
activity upon SDF-1 and BCR stimulation on sample CLL152, with pronounced 
effects of ibrutinib to inhibit Rap1 activity in the presence and absence of with 
either in vitro BCR or SDF-1 stimulation. The inhibition of Rap1 activity by 
AZD8055 is weaker and less consistently displayed, with a mild stimulation in 
Rap1 activity with rapamycin treatment in the presence and absence of SDF-1 or 
BCR ligation. 
 
Figure 5-2 Rap1 activity assay  
CLL152 (2 x 107 cells), a normal karyotype CLL sample was serum-starved for 2 h, treated 
for 30 min with non-drug control (NDC), AZD8055 100 nM (AZD), rapamycin 10 nM (RAPA) 
and ibrutinib 1 µM (IB)  then stimulated with either F(ab’)2 fragment stimulation or SDF-1 for 
30 min followed by immunoprecipitation for active Rap1. Rap1 levels are shown by Western 
blot along with positive and negative controls to confirm the success of the 
immunoprecipitation procedure.  
 Rac1 activity in CLL cells 
The GTPase Rac-1, also involved in migration and its regulation, was found to 
show consistent protein expression levels under drug and stimulation conditions 
used (Figure 5-3), highlighting the need for study of activation status of this 
protein in investigation of the role that GTPases play downstream of mTOR 
signalling.  
  
NDC AZD RAPA IB NDC AZD RAPA IB GTPgS GDP
- - - - + + + +
NDC AZD RAPA IB NDC AZD RAPA IB GTPgS GDP
- - - - + + + + FAB 30 min
SDF-1 30 min
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Figure 5-3 Total Rac1 protein levels after long-term mTOR inhibition and BCR stimulation 
Patient sample CLL18, an 11q deletion patient, was treated for 30 min with non-drug control 
(NDC), AZD8055 100 nM (AZD), rapamycin 10 nM (RAPA) and ibrutinib 1 µM (IB) then 
exposed to 48 h F(ab’)2 fragment stimulation. The Western blot antibody to Rac1 cannot 
distinguish between active and inactive forms of the protein and the overall levels appear as 
unchanged in relation to the untreated control.  
The availability of Rac1 activity assay with beads specific for active Rac1 
allowed me to perform similar experiments as for Rap1 activity. The efficacy of 
the immunoprecipitation process was supported by the results of GTPgS and GDP 
controls and a representative sample result of Rac1 activity in response to either 
SDF-1 or BCR stimulation is shown (Figure 5-4). Inhibitors appear to have little 
effect in the unstimulated samples with no effect of ibrutinib overall. 
Rapamycin inhibits BCR-mediated Rac1 activity and AZD8055 has no effect in the 
sample shown in Figure 5-4. Direct comparison of Rac1 activity in SDF1 and BCR 
stimulated cells on the same Western blot for CLL147 (Figure 5-5) confirmed 
that the overall signal generated by BCR stimulation is greater than that with 
SDF-1 stimulation.  
 
Figure 5-4 Rac1 activity assay of a single normal karyotype CLL sample 
CLL147, a normal karyotype CLL sample was serum-starved for 2 h, pre-treated for 30 min 
with non-drug control (NDC), AZD8055 100 nM (AZD), rapamycin 10 nM (RAPA) and ibrutinib 
1 µM (IB) then stimulated for 30 min with either F(ab’)2 fragment or 30 min SDF-1 followed by 
immunoprecipitation for active Rac1.  
NDC AZD RAPA IB NDC AZD RAPA IB
- - - - + + + +
GAPDH
RAC1
FAB 48 H
NDC AZD RAPA IB NDC AZD RAPA IB
- - - - + + + +
FAB 30 min
SDF-1 30 min
NDC AZD RAPA IB NDC AZD RAPA IB
- - - - + + + +
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Figure 5-5 Comparison of Rac1 activity assay SDF-1 and BCR ligation conditions 
Samples of CLL147 were evaluated for levels of active Rac1 for drug conditions: non-drug 
control (NDC), AZD8055 100 nM (AZD), rapamycin 10 nM (RAPA) and ibrutinib 1 µM (IB). 
Residual lysates from the active Rac1 pull-down assay were run on Western blot to repeat 
earlier findings. 
Although protein concentrations were assumed to be constant at the outset of 
the experiment, based upon the use of equal aliquots of the same cell 
suspension to provide individual drug and stimulation conditions and the use of 
equal sized aliquots of protein lysates in each lane of all Western blots 
performed. Also, based upon Western blot findings shown in 3.1.6 I have shown 
that total GTPase levels are unaffected by drug inhibitors or in vitro stimulation. 
However, additional control conditions were sought to prove that there was no 
change in protein expression of GTPases and that the protein concentration in 
the protein lysates obtained by immunoprecipitation was constant. To do this, I 
extracted eluate from stage of sample exposure to the Rac1 beads and assessed 
total Rac1 content using sample CLL147. The signals in Figure 5-6 exhibit 
consistency between total Rac1 levels and loading control, supportive of earlier 
data to demonstrate consistency in overall Rac1 levels in the presence and 
absence of drug inhibition and stimulation conditions. As the protein 
concentrations were consistent and because original published data in CLL refer 
only to raw data values in relation to GTPase activity, I compared Western blot 
of individual samples using densitometry values for uncorrected Rap1/Rac1 
activity (237, 238). 
NDC AZD RAPA IB NDC AZD RAPA IB
SDF-1
FAB
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+
-
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-
+
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+
+
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+
-
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-
 138 
 
Figure 5-6 Analysis of Rac1 protein expression with drug inhibitors and SDF-1 or BCR 
stimulation 
Patient samples CLL147 lysates were obtained from the pull-down assay for analysis, from 
both SDF-1 and BCR stimulation experiments for drug conditions: non-drug control (NDC), 
AZD8055 100 nM (AZD), rapamycin 10 nM (RAPA) and ibrutinib 1 µM (IB). All inactive and 
non-bound Rac1 and other proteins are eluted during the immunoprecipitation process and 
in the spin column below the filter cup the sample may be collected and maintained at -20oC 
for further analysis. Western blots were probed for total Rac1 protein (T-RAC) and a loading 
control.  
The Rap1 densitometry findings most clearly demonstrate an increased activity 
with the addition of in vitro stimulation conditions (Figure 5-7). Both SDF-1 and 
BCR stimulation increase Rap1 activity, with significance in the SDF-1 
experiments and a trend to significance with the addition of BCR stimulation. 
Ibrutinib blocks Rap1 activity more effectively than mTOR inhibitors, which 
appears to be overcome by SDF-1 stimulation (Figure 5-7 A) but not by BCR 
stimulation (Figure 5-7 B), which may reflect a greater dependence upon BTK for 
transduction of the BCR signal as opposed its role in chemokine signalling. 
Rapamycin appears to have minimal effects upon Rap1 activity with the 
inhibitory effects of AZD8055 displaying a trend to reduction in Rap1 activity in 
the absence of BCR or SDF-1 stimulation, suggesting that AZD8055 inhibition may 
be overcome by the addition of in vitro SDF-1 and BCR stimulation.  
Densitometry of the active Rac1 signal also supports the effects of in vitro BCR 
and SDF-1 stimulation to cause increased Rac1 activity (Figure 5-8 A&B). 
However, there are minimal drug effects under all 3 drug conditions. More 
samples are required to be assessed by Rap1 and Rac1 activity assays, to confirm 
and to establish the effects of drug inhibitors.  
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Figure 5-7 Rap1 activity assay Western blot densitometry  
Raw mean and SEM densitometry values for Rap1 assay with n=4 samples treated for 30 
min with non-drug control (NDC), AZD8055 100 nM (AZD), rapamycin 10 nM (RAPA) and 
ibrutinib 1 µM (IB) followed by 30 min (A) SDF-1 and (B) F(ab’)2 stimulation. *=p≤0.05; 
**=p≤0.01; ***=p≤0.001; ****=p≤0.0001. 
 
 
 
Figure 5-8 Rac1 activity assay Western blot densitometry 
Raw mean and SEM densitometry values for Rac1 activity assay results are also shown with 
30 min exposure to non-drug control (NDC), AZD8055 100 nM (AZD), rapamycin 10 nM 
(RAPA) and ibrutinib 1 µM (IB) then 30 min (A) SDF-1 (n=5) and (B) F(ab’)2 stimulation (n=3). 
 
5.3 Chemokine stimulation effects on fluorescent 
staining for GTPase proteins  
The effects of mTOR inhibition were explored further with an IF assay and 
stimulation techniques developed using signalling pathways shown earlier as 
their basis. Initially, a secondary control step was performed to compare the 
fluorescence of secondary bound to primary antibody and those of non-specific 
secondary antibody binding and fluorescence. Figure 5-9 A displays the unstained 
control cells which are to be contrasted with the raw image of CLL cells with 
Rap1 and LAMP1 co-staining (B).  
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Figure 5-9 Secondary control for Rap1/ LAMP1 co-staining experiment 
CLL132, a sample known to harbour a 17p deletion, was rested overnight in either (A) block 
containing 5% BSA and 0.1% Triton or (B) 1/200 anti-Rap1 rabbit antibody and anti-LAMP1 
mouse antibody both in block, with subsequent exposure for 1 h to red and green 
secondary antibodies. 
Figure 5-1 displays both Rap1 signalling and activation with the inclusion of 
mTOR and its posited role in the cascade and based upon this awareness of Rap1 
signalling, I have validated an assay used in earlier studies (238) that exploits 
the availability of a pharmacological activator of Rap1 signalling EPAC agonist 8-
(4-Chlorophenylthio)-2’-O-methyladenosine 3’,5’-cyclic monophosphate 
monosodium hydrate and changes in distribution of Rap1 upon stimulation. 
Primary CLL cells were stimulated with EPAC agonist or SDF-1, each for 5 min, 
and the cells were then stained for Rap1 protein (238). In keeping with existing 
evidence, CLL is variably responsive to SDF-1 and EPAC agonist with a tendency 
for Rap1 redistribution to the plasma membrane and a more peripheral 
distribution within the cytoplasm in some cells. Figure 5-10 shows a patient 
sample in which there were minimal effects upon redistribution of Rap1 in 
response to SDF-1 and EPAC stimulation. These appearances may be consistent 
with anergic CLL (237). The effects of mTOR inhibitors on Rap1 distribution were 
introduced as experimental conditions (Figure 5-11 and Figure 5-12). There are 
minimal observable effects of mTOR inhibition on the protein distribution of 
Rap1 in this sample whereas there appears to be a redistribution of Rap1 to the 
plasma membrane with both EPAC and SDF-1 stimulation (Figure 5-11 A&D and 
Figure 5-12 A&D). Interestingly, the EPAC-stimulated redistribution effect 
appears to be overcome by both AZD8055 and rapamycin treatment and 
indicated by increased green fluorescence in the DAPI stained region of the cell 
(Figure 5-11 D-F) which may suggest that mTOR inhibition has specific effects to 
inhibit Rap1 activity. In contrast, Figure 5-12 demonstrates the effects of SDF-1 
to redistribute Rap1 protein in the pictured sample (Figure 5-12 A&D), effects 
A B
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which appear unaltered by mTOR inhibition (Figure 5-12 D-F) therefore mTOR 
inhibition does not demonstrably affect Rap1 redistribution in response to 
chemokine in this case.  
 
Figure 5-10 Comparison of effects of SDF-1 and EPAC stimulation on CLL cellular Rap1 
distribution 
CLL138, a sample with a normal karyotype was either (A) untreated (B) exposed to 100 
ng/ml SDF-1 stimulation or (C) exposed to 10 µg/ ml EPAC stimulation for 5 min before cell 
fixation, permeabilisation, blocking steps. Slides were then stained with primary anti-Rap1 
rabbit polyclonal antibody overnight with secondary antibody staining with green 
fluorescence and overnight exposure to DAPI, which stains the nuclear structures.  
 
Figure 5-11 Effects of mTOR inhibition and EPAC stimulation on cellular Rap1 staining 
CLL122, a sample known to have a 17p deletion, was pre-treated with mTOR inhibitors for 
30 min and 10 µg/ml EPAC stimulation for 5 min before cell fixation, permeabilisation, 
blocking steps. Slides were then stained with primary anti-Rap1 rabbit polyclonal antibody 
overnight with secondary antibody staining with green fluorescence and overnight 
exposure to DAPI, which stains the nuclear structures. Experimental conditions are 
indicated by labels: (A) untreated control (B) 100 nM AZD8055 (C) 10 nM Rapamycin (D) 
EPAC stimulation alone (E) 100 nM AZD8055 + EPAC stimulation (F) 10 nM Rapamycin + 
EPAC stimulation. 
A B C
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The impact of SDF-1 stimulation on Rac1 distribution was also demonstrably 
altered in this CLL sample, with peripheral localisation of Rac1 when compared 
with the unstimulated cells (Figure 5-13 A&D). Figure 5-13 also incorporates the 
effects of mTOR inhibition with some cells displaying Rac1 localisation to the 
plasma membrane in both AZD8055 and rapamycin conditions although some 
cells maintain a more diffuse pattern of Rac1 distribution. The effects of 
AZD8055 are more clearly delineated using a different patient sample stained for 
Rac1 protein where there are more cells shown to have a peripheral Rac1 
distribution in the AZD8055 condition when compared with untreated controls as 
demonstrated in Figure 5-14.  
 
 
Figure 5-12 Effects of mTOR inhibition and SDF-1 stimulation on cellular Rap1 staining 
CLL122, a sample known to have a 17p deletion, was pre-treated with mTOR inhibitors for 
30 min and 100 ng/ml SDF-1 stimulation for 5 min before cell fixation, permeabilisation and 
blocking steps. Slides were then stained with primary anti-Rap1 rabbit polyclonal antibody 
overnight with secondary antibody staining with green fluorescence and overnight 
exposure to DAPI, which stains the nuclear structures. Experimental conditions are 
indicated by labels: (A) untreated control (B) 100 nM AZD8055 (C) 10 nM Rapamycin (D) 
SDF-1 stimulation alone (E) 100 nM AZD8055 + SDF-1 stimulation (F) 10 nM Rapamycin + 
SDF-1 stimulation. 
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Figure 5-13 Effects of mTOR inhibition and SDF-1 stimulation on cellular Rac1 staining by IF 
CLL149, a sample known to harbour a 17p deletion, was pre-treated with mTOR inhibitors 
for 30 min and 100 ng/ml SDF-1 stimulation for 5 min before cell fixation, permeabilisation 
and blocking steps. Slides were then stained with primary anti-Rac1 rabbit polyclonal 
antibody overnight with secondary antibody staining with green fluorescence and overnight 
exposure to DAPI, which stains the nuclear structures. Experimental conditions are 
indicated by labels: (A) untreated control (B) 100 nM AZD8055 (C) 10 nM Rapamycin (D) 
SDF-1 stimulation alone (E) 100 nM AZD8055 + SDF-1 stimulation (F) 10 nM Rapamycin + 
SDF-1 stimulation. 
 
Figure 5-14 Effects of AZD8055 upon CLL cellular Rac1 distribution 
CLL143, a sample known to have a 11q deletion, was pre-treated with AZD8055 before cell 
fixation, permeabilisation and blocking steps. Slides were then stained with primary anti-
Rac1 rabbit polyclonal antibody overnight with secondary antibody staining with green 
fluorescence and overnight exposure to DAPI. Experimental conditions are indicated by 
labels: (A) untreated control (B) 100 nM AZD8055. 
 Colocalisation studies with SDF-1 stimulation 
To investigate protein distribution further, colocalisation staining was performed 
for Early Endosomal Antigen-1 (EEA-1) and Lysosomal-Associated Marker Protein-
1 (LAMP-1) together with Rap1 staining. The images show some evidence of 
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colocalisation of EEA1 (Figure 5-15) and LAMP1 (Figure 5-16) endosomal markers 
with Rap1 in CLL143 and give further support to the peripheral redistribution of 
Rap1 in response to SDF-1 and to a lesser extent with EPAC stimulation (Figure 
5-17 A-C). Features which indicate colocalisation include the relative lack of 
Rap1 distribution throughout the cytoplasm and the orange staining of 
cytoplasmic structures, indicative of Rap1/ LAMP1 protein colocalisation.
 
Figure 5-15 CLL cellular Rap1 distribution with co-staining for EEA1 endosomal marker 
CLL149, a sample with an 17p deletion was adhered to slides, then stained with primary 
anti-Rap1 rabbit polyclonal antibody and EEA1 mouse antibody overnight with secondary 
antibody staining Rap1 and EEA1. Slides were then exposed to DAPI overnight. DAPI stains 
nuclei blue and Rap1 protein in (A) stains with red fluorescence whereas EEA1 stains with 
green fluorescence (B). Images from 3 superimposed fluorescence channels are displayed 
(C).  
 
Figure 5-16 CLL cellular Rap1 distribution with co-staining for LAMP1 endosomal marker 
CLL149, a sample with a 17p deletion was adhered to slides, then stained with primary anti-
Rap1 rabbit polyclonal antibody and LAMP1 mouse antibody overnight with secondary 
antibody staining Rap1 and LAMP1. Slides were then exposed to DAPI overnight. Rap1 
protein in (A) stains with red fluorescence whereas LAMP1 stains with green fluorescence 
with nuclear DAPI shown (B). Images from 3 superimposed fluorescence channels are 
displayed (C).  
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Figure 5-17 Comparison of effects of SDF-1 and EPAC stimulation on CLL cellular Rap1 
distribution with co-staining for LAMP1 endosomal marker 
CLL143, a sample with an 11q deletion was either (A) untreated (B) exposed to 100 ng/ml 
SDF-1 stimulation or (C) exposed to 10 µg/ml EPAC stimulation for 5 min before cell fixation, 
permeabilisation and blocking steps. Slides were then stained with primary anti-Rap1 rabbit 
polyclonal antibody and LAMP1 mouse antibody overnight. Rap1 antibody is bound by red 
fluorescent secondary antibody whereas LAMP1 is bound by green fluorescence. Slides 
were then exposed to DAPI overnight. 
 
 BCR stimulation effects on intracellular colocalisation of 
GTPase proteins 
Given the evidence for defective chemokine responsiveness in CLL cells and the 
role of Rap1, we sought to explore the BCR stimulation effects upon Rap1 in 
primary CLL cells (237). An experimental method to integrate BCR stimulation 
into existing IF staining protocols was already established for use by our group. 
Slides were pre-coated with anti-IgM antibody after the poly-L-lysine preparation 
step which was prepared the night before the IF experiment. A blocking step to 
dampen non-specific binding signal is a requirement inherent to any antibody 
binding protocol and following previously tested protocols I blocked slide-bound 
antibody using 30 min incubation with 10% BSA/RPMI media at 37oC. 
Unfortunately, there was repeated contamination of fluorescent images by non-
specific signal which was not eliminated by media filtration. Therefore, the 
blocking step was abbreviated to 15 min which proved effective in removal of 
the non-cellular debris from the microscopic field.   
The effects of BCR stimulation upon Rap1 cellular distribution are shown in 
Figure 5-18 with the effects of the prior addition of mTOR inhibitors and 
ibrutinib also demonstrated. Unlike the SDF-1 stimulation effects, BCR 
stimulation appears to have minimal effect upon Rap1 distribution in the CLL 
samples which were tested, although there does appear to be an elevated 
A B C
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concentration of Rap1 staining at the plasma membrane in BCR stimulated cells. 
Both mTOR inhibitors appear to be localising Rap1 to an intracellular 
compartment, with greater effects of rapamycin in the unstimulated cells 
whereas AZD8055 shows more effects with BCR stimulation. The difficulties 
encountered with ascertaining the effects of mTOR inhibitors on Rap1 
localisation, along with differential responses to BCR stimulation led to the 
evaluation of Rap1 colocalisation. Cellular organelles and their relationship to 
Rap1 staining were studied in the presence and absence of BCR stimulation.  
 
Figure 5-18 Effects of mTOR inhibition and BCR stimulation on cellular Rap1 staining 
CLL122, a sample known to harbour a 17p deletion, was pre-treated with mTOR inhibitors 
for 30 min and added to slides coated either with isotype control or anti-IgM antibody with 
incubation at 37oC for 30 min before cell fixation, permeabilisation and blocking steps. 
Slides were then stained with Rap1 rabbit polyclonal antibody overnight with secondary 
antibody staining with green fluorescence and overnight exposure to DAPI. Experimental 
conditions are indicated by labels: (A) untreated isotype control (B) 100 nM AZD8055 (C) 10 
nM Rapamycin (D) 1 µM Ibrutinib (E) anti-IgM alone (F) 100 nM AZD8055 + BCR stimulation 
(G) 10 nM Rapamycin + BCR stimulation (H) 1 µM Ibrutinib + BCR stimulation. 
First, it was confirmed that BCR stimulation has negligible effects on organelle 
distribution by comparison of LAMP1 staining pattern in the presence and 
absence of BCR stimulation as shown in Figure 5-19 A&B. 
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Figure 5-19 Effects of BCR stimulation on localisation of LAMP1 staining in CLL 
CLL149 was treated with either (A) isotype control or (B) BCR stimulation by prior coating of 
slides with anti-IgM antibody and exposure to slides for 30 min before cell fixation, 
permeabilisation and antibody staining techniques. LAMP1 mouse antibody is indicated by 
green fluorescence with nuclear structures stained in blue. CHANGE FOR EEA1 
In Figure 5-20 there is slightly greater peripheral localisation of the Rap1 with 
BCR stimulation, when a comparison is made between (A) unstimulated controls 
and (B) BCR stimulated cells. Evidence for colocalisation is provided by greater 
overlap of the dual staining as indicated by the orange colour created in (B) but 
not (A), and where present the orange colour is confined largely to the plasma 
membrane. Figure 5-21 displays the same sample, CLL149, stained for Rap1 
alone as a comparison.  
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Figure 5-20 Effects of BCR stimulation on colocalisation of Rap1 with EEA1 staining 
CLL149, a sample known to harbour a 17p deletion, was treated with either (A) isotype 
control or (B) BCR stimulation by prior coating of slides with anti-IgM antibody and 
exposure to slides for 30 min before cell fixation, permeabilisation and antibody staining 
techniques. Rap1 rabbit antibody is stained with secondary antibody with red fluorescence 
and EEA1 mouse antibody is bound by secondary antibody with green fluorescence.  
 
Figure 5-21 Effects of BCR stimulation on localisation of Rap1 
CLL149, a sample known to harbour a 17p deletion, was treated with either (A) isotype 
control or (B) BCR stimulation by prior coating of slides with anti-IgM antibody and 
exposure to slides for 30 min before cell fixation, permeabilisation and antibody staining 
techniques. Rap1 rabbit antibody is stained with secondary antibody with green 
fluorescence. 
Next, I analysed the impact of mTOR inhibition in combination with BCR 
stimulation in another poor prognostic CLL sample (Figure 5-22). There is 
evidence of Rap1 and LAMP1 colocalisation with BCR stimulation as cells stain 
peripherally with both red and green however Rap1 remains distributed 
throughout the cell cytoplasm (Figure 5-22 E-H). There appears to be some 
colocalisation in Figure 5-22 C and to a lesser extent in Figure 5-22 D, which 
suggests that rapamycin or ibrutinib are acting directly to redistribute Rap1 to 
CLL endosomes but not the dual mTOR inhibitor. Further images are required 
from the testing of additional samples to confirm this trend and to explore the 
drug effects further. More data are required due to the heterogeneity of 
responses of the primary CLL samples tested, in order to confirm the patterns 
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shown by IF staining in our cells. Quantitative analysis of colocalisation would be 
desirable to confirm the trends which are visible from the microscopic images. 
 
 
Figure 5-22 Effects of BCR stimulation on colocalisation of Rap1 with LAMP1 staining 
CLL132, a sample known to harbour a 17p deletion, was exposed to 30 min drug pre-
treatment then added to slides previously coated with either isotype control or anti-IgM 
antibody. After 30 min cells were fixed, permeabilised and stained with Rap1 rabbit antibody 
(red) or LAMP1 mouse antibody (green). Experimental conditions are indicated by labels: 
(A) untreated isotype control (B) 100 nM AZD8055 (C) 10 nM Rapamycin (D) 1 µM Ibrutinib 
(E) anti-IgM alone (F) 100 nM AZD8055 + BCR stimulation (G) 10 nM Rapamycin + BCR 
stimulation (H) 1 µM Ibrutinib + BCR stimulation. 
5.4 Summary of chapter 
The regulation of signalling networks is integral to migration control in 
lymphocytes, as discussed in Chapter 1. GTPases both exert control and are 
themselves regulated both spatially and temporally by their associated GAPs and 
GEFs and by factors upstream of these. Rap1 is shown to be enriched at the 
plasma membrane but has dynamic localisation at the membrane in molecular 
complexes and within cellular endosomes (270). Initial evidence was available in 
support of a key role for Rap1 GTPase dysregulation in CLL cells however the 
role of other small GTPases remains unexamined in the disease (237, 238). 
Furthermore, it is known that Rap1 lies downstream of a range of kinase 
signalling pathways including PKC (271) however its relationship to mTOR kinase 
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signalling is not established. I now provide evidence from GTPase activity assays 
in support of a trend towards inhibition of Rap1 activity by mTOR inhibitors with 
the effects of dual mTOR inhibitor AZD8055 being more pronounced than those 
of rapamycin. Rap1 activity appears to be blocked effectively by ibrutinib which 
appears to have the most consistent effects and in relation to its striking clinical 
activity it represents a positive control drug however more data are required to 
confirm the trends. Although chemokine and BCR stimulation effects upon Rac1 
activity could be demonstrated, no consistent drug effects were shown but in 
view of the low sample number and heterogeneity of individual responses this 
highlights an area for further study.  
IF findings were consistent with the existing data to show CLL cell chemokine 
responses acting to redistribute Rap1 to the plasma membrane, a phenomenon 
which is variably present between different CLL samples. There is also some 
evidence of Rap1 redistribution in response to its specific activator, EPAC, to 
which our samples are variably responsive, indicative of the anergic status of 
these cells. Anergy in CLL has been mainly described with reference to its BCR 
responses and is an interesting property from a therapeutic perspective as the 
anergic population may represent a clonal reservoir of immunologically evasive 
cells. Such anergic cells have shown relative resistance to apoptosis, which is 
reversible once the anergy is overcome. The normal cellular responses to 
chemokine do not appear to be overcome by mTOR inhibition in our study 
however there do appear to be effects upon Rap1 activator, EPAC, responses 
which may represent specific mTOR-mediated effects upon Rap1 activity. The 
effects of BCR stimulation upon Rap1 distribution could not be demonstrated by 
Rap1 staining alone but the colocalisation of Rap1 and the endosomal marker, 
LAMP1 could be demonstrated with BCR stimulation. The effects of 
colocalisation of Rap1 and early endosomal marker, EEA1, were shown in 
response to SDF-1 stimulation. The effects of mTOR inhibition upon Rap1 and 
endosome colocalisation require further investigation. As Rac1 is also implicated 
in leukocyte chemotaxis (272) in processes of actin cytoskeletal activation and 
lamellipodia formation, its function and activity may also be spatially regulated. 
Rac1 protein localisation appears to be affected by dual mTOR inhibition, as 
Rac1 appears to be peripherally distributed in the samples studies but this 
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finding requires confirmation and further exploration using colocalisation 
studies.  
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Chapter 6 General Discussion  
 
6.1 Migration control in CLL cells 
The next few sections describe some of the recent research which has been 
undertaken to identify the mechanisms whereby microenvironmental inputs are 
abrogated by novel drug therapies in CLL. During the following sections, along 
with an explanation of the microenvironmental mechanisms, I address my own 
experimental results concurrently to base my explanations in the context of 
recent research findings. 
 Integrin signalling and GTPase regulation 
Integrin signalling has been known to have a regulatory role in CLL migration for 
some time. Studies of both integrin expression and function have been 
performed and the main molecules to be implicated include heterodimers alpha 
4 beta 1 (VLA-4) which binds VCAM-1 and fibronectin, and alpha L beta 2 (LFA-1) 
which binds ICAM. Integrins are responsible for lymphocyte entry into tissue and 
experimentally it was shown that endothelial stimulation enhanced binding of 
CLL cells via the VLA-4 heterodimer (273). Aberrant integrin signalling has been 
found in association with various cytogenetic defects in CLL cells. Firstly, 
deletions at the chromosome 11q locus have been associated with CLL 
presentation with bulky lymphadenopathy (106). An associated reduction in 
levels of functionally relevant adhesion molecules including integrins was 
attributed as the underlying cause of the characteristic clinical features (274). 
The study identified differential CD49d expression as a means of the altered 
disease pathophysiology, however it could not fully explain the integrin defect in 
the context of disease biology. Trisomy 12 has been more recently associated 
with a demonstrable increase in integrin signalling, in particular, LFA-1, VLA-4, 
Mac-1, CD49d and CD11a (107). The changes were modulated by NOTCH1 
expression with mutated NOTCH1 being associated with lower levels of integrin 
signalling than UM-CLL cases. The increased integrin signalling was hypothesised 
to be responsible for increased cell motility and an increased capacity for CLL 
homing, supported with evidence from the disease biology of trisomy 12 cases. It 
was noted that the poorer prognosis attributed to the NOTCH1 mutation could 
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not be explained by increased motility of this subset as NOTCH1 mutation is 
found in association with inhibition of b2 signalling (107).    
The influence of GTPases in regulation of integrin signalling has been examined, 
based upon an awareness of a defective activation of integrin signalling in CLL 
cells. Rap1 GTPase was found to regulate both VLA-4 and LFA-1 and a failure of 
Rap1 GTP-loading was implicated in the impaired activation of integrin in 
response to chemokine-induced activation (238). T cells from CLL cells also 
exhibit impaired integrin activation and the T cell defect is repaired with 
lenalidomide therapy. It was shown that Rho GTPase signalling defects were the 
underlying factor in the impaired LFA-1 activation which gives further definition 
to the role of integrin signalling in the CLL microenvironment (275, 276). The 
original study demonstrated defective actin polymerisation which resulted from 
the described integrin defects and as these were studied independently from 
GTPases in my project these shall be handled separately. 
The role of mTOR signalling in relation to integrin and GTPase signalling was 
explored in Chapter 5 with specific reference to GTPase activity assays in 5.2.1 
and 5.2.2. The trends in Rap1 activity suggest that mTOR inhibition reduced 
active Rap1 signalling and this is concordant with the effects of ibrutinib upon 
the Rap1 signal. Both chemokine and BCR signalling were shown to increase Rap1 
and Rac1 signalling which suggests that the ability of the primary CLL samples 
tested to respond to chemokine and BCR signalling in vitro was unimpaired. 
AZD8055 treatment blocked active GTPase signalling and partially overcame the 
chemokine effects thus placing mTOR downstream of the chemokine signal and 
upstream of the active Rap1/Rac1 signal. The variation in Rap1 chemokine 
responsiveness by IF was explored in 5.3 but no conclusions could be drawn in 
relation to mTOR effects, due to limited sample numbers and the heterogeneity 
of sample responses.   
 Cytoskeletal activation and mTOR signalling  
Cytoskeletal activation was studied in 4.5.1 using the actin polymerisation 
experimental technique. Stimulation of actin polymerisation was observed with 
both SDF-1 and BCR stimulation over a range of samples, each from 
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heterogeneous prognostic categories. There were no clear trends from the 
application of mTOR inhibitors to the assay when multiple samples were 
combined, however rapamycin appeared more often to increase actin 
polymerisation in CLL cells whereas there was a greater tendency to a reduction 
in actin polymerisation with AZD8055 or ibrutinib. Further work is required to 
determine the role of mTOR inhibition in regulation of the cellular cytoskeletal 
framework and its activation.   
6.2 Advances in the understanding of CLL migration and 
microenvironment 
The experimental findings outlined in chapters 3, 4 and 5 may be taken together 
with recent advances in the understanding of the CLL microenvironment. It 
appears that many novel therapies act to deprive CLL cells of the survival signals 
they may acquire in the LN and BM microenvironment, facilitating a potential 
“death by neglect” or anoikis (259). Taking the microenvironmental signals each 
in turn, I shall outline what I perceive to be the microenvironmental interactions 
of greatest interest in the recent study and application of therapeutic activity 
into within CLL research.  
 CXCR4-CXCL12 axis 
Trafficking between lymphoid microenvironments has a pivotal role in CLL 
survival and growth. Our understanding of the CLL microenvironment is critical 
to our understanding of disease pathogenesis and we know that the normal 
germinal centre in secondary lymphoid tissue is distinctive from CLL germinal 
centres. Tissue homing of CLL cells is regulated by expression of chemokine 
receptors on CLL cells and it has been shown that peripheral blood CLL cells 
express increased CXCR4 and CXCR5 with these receptors being downregulated 
by receptor-mediated endocytosis (269). We can now define CLL cells which 
have recently exited the lymphoid tissue by their immunophenotype with 
expression of low surface CXCR4 and increased CD5 and it has been shown that 
microenvironmental mesenchymal stem cells (MSCs) (276) express and secrete 
CXCL12 (156). Effects of SDF-1 upon the immunophenotype of primary CLL 
samples were shown in 3.2.2. Primary CLL cells treated with SDF-1 for 48 h 
exhibiting a surface immunophenotype shift from CXCR4hiCD5dim to a 
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predominantly CXCR4dimCD5hi profile. The effects of SDF-1 upon CLL cells in vitro 
were similar in the presence of both mTOR inhibitors and of ibrutinib and 
appeared to be diminished.   
The ability of CLL cells to respond to secreted CXCL12 has been explored in vitro 
using stromal cells lines but also using human MSCs using chemotaxis models 
whereby chemotaxis could be induced and then blocked using anti-CXCR4 
antibody (277). Evidence for the effects of the CXCR4-CXCL12 in regulation of 
CLL cell migration can be obtained from the effects of ibrutinib in cell 
redistribution where peripheral blood lymphocytes display differential 
immunophenotype from LN-originated CLL cells, and ibrutinib is shown to block 
CLL cell chemotaxis (178, 186). My data confirm these effects in 4.2 and 4.3 
with transwell and pseudoemperipolesis assays. The effects of AZD8055 to 
inhibit pseudoemperipolesis mirror those of ibrutinib, supportive of AZD8055 as 
another agent to act via lymphocyte redistribution. The data from the transwell 
migration assay demonstrate similar trends between AZD8055 and ibrutinib 
however the sample size in the ibrutinib condition was small. The effects of 
AZD8055 in comparison to control appear to be more marked over a longer term 
drug incubation phase. In consideration of the basis for the AZD8055 effects, it 
may be that differences in the timescale of drug effects are representative of 
drug activity at different loci within the CLL cell.  
Our primary CLL cell transwell migration study findings also suggest that the 
cellular changes which regulate migration, and those changes which may be 
targeted by drug inhibitors, may occur after longer-term drug exposure periods. 
There were less pronounced effects of AZD8055 demonstrated by the transwell 
assay compared with those observed in the pseudoemperipolesis assay. All 
migration assay results must also be taken into consideration alongside my data 
shown in 3.2.5 which appears to conflict with the idea that AZD8055-mediated 
effects are mediated over long-term timescales, as a 30 min drug pre-treatment 
phase followed by 30 min SDF-1 exposure exhibits effects upon mTOR substrates 
and may overcome SDF-1 elicited effects upon mTOR substrates in addition.  
Rapamycin does not inhibit migration to the same extent in either the 
pseudoemperipolesis or transwell migration assays compared with AZD8055. It is 
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known that rapamycin has an ability to regulate cellular migration which is a 
4EBP1 and S6K1- dependent function (278). However, mTORC1 has fewer 
functions in cellular migration and when rapamycin therapy has been shown to 
inhibit migration it has been in settings of prolonged exposure to the drug which 
may elicit mTORC2 inhibition in addition to mTORC1 blockade (279). Thus, 
rapamycin effects on migration in the context of my migration assays are 
minimal by comparison with those of AZD8055 and ibrutinib. 
In consideration of any apparent conflict of my experimental findings it is 
helpful to consider the experimental designs each in turn. Whilst the migration 
assays may each be affected by differential effects upon CLL cell survival, I have 
already analysed the survival effects of the drug inhibitors over these timescales 
and found the contribution of apoptotic effects to be minimal. However, the 
fact that changes in mTOR substrate levels can appear over such short time-
scales indicate that the initiation of the intracellular events which lead 
ultimately to changes in CXCR4 and CD62L surface expression caused by mTOR 
substrates are early events. Effects upon migration in response to AZD8055 must 
therefore be considered as later events, as the overnight effects of the drug 
were more pronounced, and may be initiated by earlier changes in mTOR 
substrate levels. Drug effects may be mediated at the level of receptor 
endocytosis and endocytic recycling, manifesting as changes in short-term cell 
surface receptor expression, or at the level of protein translation to alter the 
number of adhesion molecules being produced and trafficked to the cellular 
membrane. It has already been shown that SDF-1 alone may trigger CXCR4 
receptor endocytosis in CLL cells in a dose-dependent fashion (148) and it may 
be that with a longer drug incubation pre-phase that AZD8055 may accentuate 
this response, whereas the time-scale for demonstration of these effects with 
the transwell assay may be insufficient.  
Pseudoemperipolesis and transwell assays performed in parallel with drug 
incubation studies and concomitant measurement of cell surface CXCR4 levels by 
flow cytometry could provide corroborative evidence for alterations in cell 
surface expression of CXCR4 via receptor endocytosis as the means of drug 
effect. 
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 T cells and the tumour cell niche 
T cells play an instrumental role in the CLL microenvironment as evidenced by 
IHC co-staining where serial section analysis of pseudo-follicles revealed co-
segregation of CD3 and Ki67 staining regions (280). Indeed it has been shown 
that BCR stimulation leads to production of CCL3-secreting T cells which 
implicates T cells as a feature of progressive CLL disease conditions (281). In 
other studies, the existence of a “BCR-activation” signature within the CLL 
microenvironment was identified whereby genes implicated in chemotaxis such 
as CCL3 and CCL4 displayed an increased expression level in the CLL LN and in 
NLC co-culture conditions in association with gene expression phenotyping which 
was consistent with BCR signalling activity (157). It has become apparent that 
CCL3 and CLL4 secretion are one of myriad ways that T cells engage in 
microenvironmental crosstalk. On further examination, it appears that CCL3 and 
CCL4 protein secretion is inducible in CLL NLC co-culture settings after BCR 
stimulation, a phenomenon which is differentially activated by IgM but not IgD 
signalling (282). Also IgM production leads to a selective reduction in protein 
expression of BCL-6, a known tumour repressor, whereas IgD stimulation does 
not. 
Dependence on one or other molecular isotype for individual patient disease 
biology may explain some of the differences in response in migration assays and 
may be one underlying cause of the generation of a BCR response subgroup as 
shown in 4.3. As described earlier, the transwell migration study which utilised 
CXCL12 to create a chemokine ligand gradient showed significant migration 
responses to BCR stimulation. However, the significant effects were only 
demonstrated after identification of a subgroup of CLL samples which responded 
positively to BCR stimulation. Analysis of the basis for inter-sample variations 
revealed that the majority of transwell experiments were performed after 
stimulation with F(ab’)2 fragments rather than by anti-IgM stimulation with 
avidin crosslinking, negating the likelihood of method of BCR stimulation as the 
underlying cause of differential responses. Next, we referred to the traditional 
definitions of prognostic risk category, i.e. CLL karyotype and ZAP70 status. No 
common features are shared by the 5 samples listed above, apart from ZAP70 
positivity although ZAP70 positivity and “BCR response” are not mutually 
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exclusive. Further experiments to examine the significance of ZAP70 positive 
status on migration potential are required to explore this possibility. Another 
more basic feature of CLL biology may be at play for as previously discussed, 
both IgM and IgD are functionally expressed in CLL however I have limited my 
experiments to use of anti-IgM without the use of anti-IgD, based upon the 
experience of our group (180). However, stimulation of the CLL BCR via IgM and 
via IgD have been compared by Haerzschel et al. to show differential migratory 
responses of CLL according to the target molecule (283). Cells stimulated via 
anti-IgD retained the ability to migrate in the context of chemotaxis assay 
findings, whereas stimulation via IgM affected CLL cells to reduce migratory 
potential. 
As already discussed, CCL3 protein expression varies in the CLL 
microenvironment however it has also been CCL3 staining density correlates with 
staining for T cell markers in the CLL LN and it is variation in the localisation of 
CCL3 secretion which may regulate the trafficking of CLL cells within these 
structures (284). Evidence for CCL3 and CCL4 as biomarkers of BCR-signal 
mediated migration effects come from the drug trials of ibrutinib and idelalisib, 
BCR signalling inhibitors, which act downstream of the BCR and display 
pronounced effects upon levels of these chemokines (186). As with many 
pathogenic processes in CLL the chemokine effects are reflective of underlying 
normal lymphocyte biology as normal GC B cells engage in competition for T cell 
help via CCL3 and CCL4. 
 IL4R-IL4 axis 
Recent study has shown the IL4R-IL4 axis to play a pivotal part in the CLL 
microenvironment. Disruption of IL4R-IL4 by ibrutinib therapy predisposes UM-
CLL to destruction as they show greater dependence upon this 
microenvironmental input. IL4 a is key survival factor which predisposes to a 
reduction in CLL cell surface CXCR4 levels and it enhances levels and function of 
surface membrane IgM, particularly in UM-CLL. Ibrutinib blocks IL4 secreted by T 
cells, leading to a lymphocytosis in M-CLL and increased cell death in UM-CLL. B 
cell survival in UM-CLL, promoted by T cells, may be blocked by pre-treatment 
of those T cells with ibrutinib and is attenuated similarly by the addition of IL4-
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neutralising antibodies. Extension of the culture conditions to M-CLL subsets did 
not have any effect upon the survival of B cells, lending further support to the 
specificity of the IL4 axis in its UM-CLL effects. As a result of the co-culture 
conditions of T cells with ibrutinib, expression of sIL4R and pSTAT6 were also 
diminished (285).  
The loss of IL-4 expression with ibrutinib therapy leads to a reduction in IL4R 
signalling in both UM-CLL and M-CLL. Furthermore, ex vivo analysis of ibrutinib-
treated CLL patients displayed a B cell lymphocytosis and T lymphocytosis in 
ibrutinib therapy in UM-CLL but less so with M-CLL.  
Further study revealed that T cells are impaired after ibrutinib therapy with a 
significant reduction in IL-4 production, manifesting in a reduction of T cell 
proliferation upon stimulation. The effects of ibrutinib were examined using 
mouse xenograft experiments into which patient samples were transplanted, 
each of whom were treated for 24 h with ibrutinib (n = 3 for each patient 
sample). The mice were then sacrificed and CD3+ T cells obtained from 
xenografts derived from ibrutinib-treated patients were found to be unable to 
home to the spleen upon secondary transplantation. Furthermore, IL4R was 
present at reduced levels in UM-CLL and M-CLL patients treated with ibrutinib. 
The dysfunctional CXCR4 signalling induced by ibrutinib therapy of CLL B cells 
leads to a loss of phosphoCXCR4 and a greater inhibition of its activity in UM-CLL 
as opposed to M-CLL, as these cells fail to respond to SDF-1 (269). 
Ibrutinib also causes a reduction in BCL-2 levels in CLL cells which is a more 
pronounced effect when observed in UM-CLL over M-CLL clones (286). There is a 
consequent reduction in CLL B cell survival in tissue niches as a result of the 
BCL-2 effects particularly in UM-CLL cases.  
In summary, ibrutinib causes a dual loss in environmental prosurvival signals; it 
causes a reduction in IL4 production by T cells and subsequent blocking of IL4-
ILR4 axis with a reduced cell survival because of BCL-2 reduction leading to 
vulnerability of UM-CLL B cells which die in tissue niches (286).  
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These findings relate to my experimental results as the overwhelming majority 
of my samples in the pseudoemperipolesis assay were representative of CLL with 
high ZAP70 expression which is concordant with UM-CLL. As it is shown by the 
data demonstrated in 4.2, correlation between ZAP70 positive/UM-CLL and the 
BCR effects in the pseudoemperipolesis assay may be understood in terms of IL-4 
changes. Also, as shown by my pseudoemperipolesis findings, there was 
concordance between ibrutinib and AZD8055 in their effects upon BCR-
stimulated pseudoemperipolesis levels suggestive that the dual mTOR inhibitor 
AZD8055 may also act in this way. There were minimal effects of rapamycin 
upon migration in the pseudoemperipolesis, both in the presence and absence of 
BCR stimulation. As both ibrutinib and AZD8055 inhibit the mTOR signal 
effectively whereas rapamycin is directed at mTORC1, differential drug 
responses in the migration studies may be ascribed to mTORC2-mediated 
effects. However, a notable study of migration using endothelial cells was 
supportive of the ability of rapamycin to inhibit mTORC2 using downstream 
markers of mTORC2 inhibition. Indeed, rapamycin was shown to alter GTPase 
signalling and subsequently inhibited cytoskeletal activation in the endothelial 
cell experiments. Therefore it may be that a more prolonged exposure of CLL 
cells to rapamycin would elicit effects upon migration in the assays described in 
this project (279). 
 BCR signalling 
BCR stimulation impacts CXCR4 surface expression although there has been some 
debate regarding the direction of effect as there are apparently conflicting 
reports (252, 253). Initial reports described that BCR ligation caused 
downregulation of CLL cell CXCR4 and CD62L levels on the cell surface and my 
data in 3.2.1 are supportive of these effects. However, an almost simultaneous 
report observed the opposite phenomenon: BCR ligation led to an increase in 
surface CXCR4 and these discrepancies are attributed to variation in the 
modality of BCR ligation and cell type studied however the same conclusions 
were drawn from each study, that long-term BCR ligation causes induction of an 
adhesive phenotype in CLL cells.  
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The mechanisms which underpin the reduction in sCXCR4 expression and changes 
in CXCR4 signalling have been studied with respect to functional responses of 
CLL cells in response to ibrutinib (269). I have shown that changes in sCXCR4 as 
mediated by anti-IgM responses are inhibited by mTOR inhibitor AZD8055 and 
ibrutinib but not by rapamycin (3.2.1). On further exploration of the ibrutinib 
mechanism of activity, functional changes are mediated by phosphorylation of 
CXCR4 at Serine 339 with downstream inhibition of the pathway at the level of 
the BTK protein after ligand binding (269). Further detail regarding the 
mechanism of ibrutinib activity involved another study with a focus on 
migration, utilising heavy water labelling of CLL cells prior to ibrutinib therapy 
to study their birth and death rates (287). Patients drank deuterated water with 
subsequent measurement of labelled CLL cell percentage. It was found that once 
the CLL cells reach a plateau there is a continuous proliferation rate and where 
one would expect a reduction in the percentage of CLL cells due to dilution 
effects, a plateau occurs when the birth rate is abrogated with a concomitant 
increase in the CLL death rate. Ibrutinib therefore inhibits proliferation and 
accelerates CLL cell death in two ways; firstly by death of BCR signal-dependent 
cells and by deprivation of CLL cells from other tissue survival signals.  
The migration effects of ibrutinib were explored in my data in 3.2.3 with study 
of the in vivo effects of ibrutinib in a single patient. Whilst any effects from a 
single patient study must be interpreted with caution, there are trends in 
chemokine receptor surface expression which implicate CXCR4 surface changes 
as some of the initial means of cell redistribution. In 3.2.1, the CXCR4 surface 
changes that occur on the context of BCR stimulation occur both with ibrutinib 
and AZD8055 over the same timescale, indicating that parallels may be drawn 
with AZD8055 and ibrutinib as to the potential effects of AZD8055 in vivo. 
Exploration of the role of AZD8055 in vivo is beyond the scope of this project but 
support for its in vivo application is offered by these findings. 
The mechanism underlying the BCR-mediated effects upon CLL cell surface 
marker expression may be understood further by the BCR effects upon miRNAs 
and may more likely relate to BCR-mediated changes over long-term incubation 
such as were shown in 3.1.6. MiRNAs mediate regulation of BCR and 
microenvironmental interactions (288). From the initial finding that miR15-16 is 
 162 
integral to CLL pathogenesis, to the increased awareness of the function of 
miRNAs in participation in negative feedback loops, the details of the functional 
significance of miRNAs have not yet been worked out. As already stated, miRNAs 
are short complementary binding sequences which regulate stability of protein 
translation and individual sequences can regulate between 10 to greater than 
100 miRNAs. CLL may exhibit both negative and positive BCR regulation and 
there is evidence that malignant cells may be dependent upon the BCR signal 
from both in vitro studies and clinical data regarding BTK inhibitors (289). From 
exome and genome profiling studies there are no specific BCR mutations 
responsible for CLL pathogenesis however it may be that non-coding RNAs are 
involved.  
Microenvironmental interactions affect miRNA expression as shown in studies of 
recent LN emigrant CLL cells which were sorted by CXCR4 and CD5 levels (290). 
CXCR4lo CD5hi cells have low SHIP1 levels which correlates with a higher BCR 
signalling propensity and it has been identified that miR155 is a relevant 
regulator of SHIP1 as in CLL cells with higher levels of SHIP1 correlating with 
miR155 inhibition. In the CD40L co-culture setting there is an upregulation of 
miR155 and a downregulation of SHIP1. Other signals such as BAFF ligand confer 
a similar phenotype to CD40L, which is likely to originate from either follicular 
dendritic cells or stromal cells. Evidence from ibrutinib studies confirms that 
effects upon miRNAs relate to treatment response as miR155 is demonstrably 
reduced over time with ibrutinib therapy; it is known that higher miR155 levels 
over time confer shorter OS duration (291). Therapeutic targeting of miRNAs 
therefore offers an attractive opportunity to exploit the important role that is 
played in by miRNAs in CLL pathogenesis.  
BCR signalling effects may be relayed to the cell nucleus in addition to the 
immediate effects at the plasma membrane and at the cytoplasmic level. A 
family of transcriptional regulators, Forkhead box O (FOXO) proteins, are known 
to have signalling interactions with mTOR kinase and are responsible for signal 
transduction to the cell nucleus. There 4 mammalian FOXO family members with 
FOXO1 being the first to be identified and found to be located on chromosome 
13 in humans. It was originally implicated in the biology of rhabdomysarcoma 
with the t(2;13) translocation as part of the oncogenic process in the disease 
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(292). FOXO4 was next to be discovered and has been implicated in acute 
leukaemias, in particular, those leukaemias found to contain MLL gene 
rearrangements. It is of note that FOXO3 shares high homology with FOXO1 
whereas FOXO6, the most recently discovered family-member is also the most 
distinct (293).  
Some of the earliest information in relation to FOXO regulation by came from a 
study where three phosphorylation sites were identified which AKT may bind 
FOXO1; T24, S256 and S319, thus regulating its transcriptional effects (260). The 
mechanistic aspects of FOXO activation by AKT are complex and not fully 
understood. Both nuclear and cytoplasmic pools of FOXO proteins are present, 
and dependent upon the cell and specific isoform of FOXO there may be 
phosphorylation by AKT in either location (260). However much of the nuclear 
FOXO may be found without phosphorylation at the AKT sites. Phosphorylation of 
FOXO serves as a docking site for 14-3-3 protein binding and this mediates the 
effects upon FOXO DNA binding in inhibition of transcription by facilitating its 
degradation. Therefore, FOXO proteins act downstream of the mTOR signal 
offering a means of transcriptional regulation which may be modulated by mTOR 
inhibition.  
In sections 3.2.4 and 3.2.5, I have demonstrated by Western blot for protein 
levels of FOXO1 that it may be upregulated by either form of stimulation and 
with the addition of short-term BCR stimulation, phosphorylation levels of the 
FOXO1 transcription factor follow the pattern of mTORC2 substrate AKTS473 with 
demonstrably reduced levels in the presence of either AZD8055 or ibrutinib. 
However, further work is required to confirm that the effects shown over 1 h 
BCR stimulation may be related to changes in nuclear FOXO1 phosphorylation 
and not cytoplasmic levels of FOXO1 which may offer an insight into the spatial 
and temporal regulation of FOXO1. 
 Myeloid compartment and CLL progression  
The myeloid cellular contribution to the CLL microenvironment is derived from 
BM progenitors which are able to modulate lymphoid cell responses whereby 
immature myeloid derived cells promote differentiation of lymphoid cells. 
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Evidence from in vitro co-culture experiments demonstrate the survival support 
from myeloid derived cells given to CLL cells to prevent apoptosis even at low 
myeloid cell proportions. As previously described, monocytes which harbour TAM 
phenotypes exist to influence the tumour microenvironment (294, 295) and in 
CLL it is apparent that the leukaemic cells induce a TAM phenotype via 
chemokine production. There is also evidence that myeloid cells are 
immunosuppressive in CLL with evidence from clinical cases that display 
downregulation of immune regulatory genes from gene expression profiling.  
The myeloid cell compartment has been examined experimentally in the EµTCL-
1 mouse model which was first analysed for its myeloid component by removing 
splenocytes and injecting them into immature wild-type syngeneic mice, known 
as the adoptive transfer (AT) model. The AT model facilitates study of the 
influence of CLL upon the myeloid microenvironment as CLL-induced changes 
may be compared and contrasted. The AT model also permits study of the 
immune effects and effects upon disease development of myeloid cell depletion 
(296). Cytokine antibody arrays of the AT model display an overlap between 174 
human and 144 murine cytokines elevated expression of many similar proteins in 
serum of individuals with inflammatory disease when compared with controls. 
Monocyte distribution control as a means of disease pathogenesis has been 
studied with an accumulation of patrolling monocytes as opposed to 
inflammatory monocytes with respect to Ly6C or CD43 status in mice affected by 
CLL. Peritoneal macrophages in the TCL-1 mouse model display a skew towards a 
TAM-like phenotype and monocytes from the same model have both an 
inflammatory and immunosuppressive phenotype.  
Factors such as TREM-1 and PD-L1 have been implicated in the regulation of the 
inflammatory myeloid phenotype and these findings were explored further using 
the TCL-1 AT model (297). The development of CLL was studied over 3 weeks in 
mice treated with antagonists of PD1 or PD-L1 with the effect of slowing the 
onset of CLL without curing the disease in this model. It appears that PD-L1 
blockade controls inflammation and restores myeloid and T cell effector 
dysfunction in CLL, laying the foundation for the use of such checkpoint 
inhibitors in clinical practice. Another strategy was to exploit the myeloid 
effects of sodium clodronate in the CLL mouse model with effects to deplete the 
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myeloid compartment resulting in attenuated CLL development, also controlling 
inflammation and restoring myeloid and T cell effector dysfunction in CLL (298).  
CLL exosomes are known to influence the microenvironmental cross-talk with 
monocytes in CLL (299). On further study of the basis for the tumour-supportive 
phenotype in the myeloid cells, exosomes were isolated from CLL cell culture 
supernatant and these were applied to monocytes. Purification of exosomes was 
undertaken from plasma or cell lines and ultracentrifugation to pellet 
extracellular vesicles. Then nanoparticle tracking of labelled exosomes could be 
performed with uptake of MEC-1 cell exosomes in myeloid cells or to murine cell 
line J774 cells to be visualised by immunofluorescence (300). Small RNA 
sequencing of CLL exosomes and comparison with MEC-1 cells revealed up to 200 
sequences which were enriched in CLL. The regions of enriched RNA were non-
coding in nature and were described as “y4RNA”, appearing to induce PD-L1 in 
monocytes and macrophages and causing an increase in inflammatory cytokines. 
It appears that the response to hY4 RNAs is TLR7-dependent. A TLR7-knockout 
mouse to which exosomes or yRNAs were applied demonstrated that the 
upregulation of PD-L1 was lost in these mice. The effects of chloroquine were 
also to decrease exosome-mediated effects upon TLR7 and also showed 
attenuated disease development in the AT model (300).  
Another CLL exosome purification study monitored the  accumulation of labelled 
exosomes in CLL cytoplasm which were associated  with a concomitant reduction 
in CCR2, an increase in PD-L1 and in monocyte production of CCL2, CCL4 and IL-
6 (301). Using IF imaging and flow cytometry it is also possible to show that 
exosomes may be stimulated by the BCR signal (302), with activated B cells 
being able to produce exosomes which are blocked by ibrutinib. 
 Mesenchymal stem cells in the BM microenvironment 
A greater understanding of the centrality of the CLL microenvironment to 
disease pathogenesis has formed the basis for many of the recent advances in 
CLL therapeutics and alongside this there has been an increased appreciation for 
CLL as a clonal entity with competing subclones, each with variation in genetic 
composition (137). Much of the research focus has been on the BCR signalling 
 166 
pathway and its contribution to the CLL microenvironment, particularly with the 
development of specific inhibitors of the pathway. Indeed, it has become 
apparent that active participants in the constitution of CLL microenvironment 
comprises more than the cells of haemopoietic origin and that the MSC offer 
disease-defining interactions in their molecular interaction in the instance of 
incipient CLL. Genes regulated by MSC interactions with an importance for CLL 
pathogenesis include those relating to the PI3K signalling pathway, cellular 
metabolic and adhesion pathways such as XIAP, MCL-1 and BCL-2 (303).  
Evidence for the protective effects of the microenvironment upon CLL cells 
originates from study of the cells in the peripheral circulation to show increased 
Bim, indicative of their tendency for programmed cell death. BM resident CLL 
cells, however, demonstrate a significant reduction in Bim levels. Also, in 
stromal cell co-culture, CLL cells demonstrate increased BCL-2 and increased 
BCL2A1, both of which offer relative resistance to BCL-2 inhibition in vitro. 
When MSC are cultured in vitro with CLL there is an increased proportion of 
CD38-positive CLL cells which may represent a predilection for these cells to 
home and bind to MSC cells in the in vivo setting (105). MSCs within the CLL 
microenvironment also play a key role in protecting the CLL cells from oxidative 
stress and subsequent apoptosis and this reliance upon oxidative phosphorylation 
CLL may be exploited therapeutically (304). In turn, CLL cells appear to exert an 
influence upon MSC cell signalling with an increase in levels of AKT and PI3K 
activity. Evidence from other diseases such as lymphoma and solid tumour-
associated fibroblasts suggest an upregulated signal via the NFkB pathway as a 
basis for these effects. 
A recent study of microenvironmental interactions downstream of chemokine 
signalling has revealed PIM kinases as one of the mediators of these signals 
(305). PIM kinases are a family of serine/threonine kinases which play a role in 
cellular processes of cell cycle initiation, apoptosis and DNA damage repair 
pathways among others. Levels of PIM kinases have been shown to be inducible 
under conditions of hypoxic stress and act in mediation of drug resistance, a 
phenomenon first observed in pancreatic ductal adenocarcinoma (306). However 
it has now been shown that PIM kinases may be targeted in CLL under conditions 
which mimic the hypoxic tumour environment and that strategies which combine 
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PIM kinase inhibition with the effects of PI3K inhibition may offer efficacy in 
vitro (307). The concept of targeting the aspects of the microenvironmental 
conditions which are known to be conducive to disease development and 
progression may be explored as a potential therapeutic strategy in CLL. The use 
of mTOR inhibitors in combination with current novel therapies which are 
already available for routine use may be applied in some cases of CLL. As the 
mTOR signal regulates the metabolic pathways of the cell it is thought that this 
may be why mTOR is so routinely dysregulated in oncogenesis. Therefore, mTOR 
inhibition may be applied as a means of depriving the tumour cell of nutrient 
and metabolic signals which may enhance disease progression, thereby attacking 
the malignant cells on two fronts. 
The TCL-1 CLL mouse model has also offered further insights into the 
microenvironmental MSC contribution as the introduction of PKCb gene knockout 
attenuates disease development when co-cultured with stromal cells, in relation 
to wild-type PKCb TCL-1 models (308). It seems therefore that the MSC 
contribution is dependent upon cell-cell contact and further investigation has 
implicated Notch ligand which appears also to be constitutionally expressed 
upon the MSC cell surface, as well as on CLL cells. Evidence for the importance 
of Notch in MSCs, and Notch2 in particular, comes from NestinGFP+ mice which 
are neural cells which are expressed to retain a “stemness” capacity for study of 
differentiation in these lineages. It appears that Notch activates the promoter in 
these cells and in the small population of MSCs which these mice (309).  
Further study of Notch2 function in MSCs from Notch2-deficient floxed mice 
indicate that Notch2 is largely responsible for repression of other genes and 
those which are upregulated fall into categories of collagen formation or 
inflammatory response-mediators. Interestingly, somatic mutations which are 
known drivers of disease in CLL are often found to affect the Wnt/b-catenin 
signalling pathway by its aberrant activation. However, a robust increase in b-
catenin within CLL cells may be exerted by culture of CLL cells on a layer of 
MSCs and this finding has been confirmed through IF studies to display increased 
b-catenin expression. From the use of CRISPR-Cas9 gene editing studies it was 
found that the elimination of Notch2 expression in MSC cells leads to a 
stabilisation of b-catenin through GSK3b binding. Therefore, therapeutic 
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approaches to target the Wnt signal may offer cytotoxic effects in CLL and may 
represent an indirect approach to target stromal Notch2 activity within the 
microenvironment. A range of approaches to target components of the disease 
microenvironment have already been discussed earlier in this chapter and 
include BTK inhibition to target the fibronectin – VCAM1 interaction, AMD3100 to 
target the CXCL12-CXCR4 axis sodium clodronate and checkpoint inhibitors, 
however other approaches which target the stromal cells associated with CLL 
cells may include Nox-A12 which inhibits migration of CLL cells via CXCL12 
inhibition and permit CLL chemo-sensitisation (310). Furthermore, the 
immunomodulatory effects of lenalidomide may be applied to the CLL disease 
milieu with efficacy against CLL in vivo (311). 
6.3 Advances in CLL pathogenesis 
The next section is intended to summarise the latest advances in the 
understanding of CLL biology with a focus on discoveries made in relation to the 
underlying pathogenic process.  
 Clonal evolution in CLL 
Whole exome sequencing was applied to 149 cases of CLL for study of disease 
clones, intra-tumoural heterogeneity and the factors associated with disease 
response to therapy and subsequent disease progression (138). Such sequencing 
studies serve to demonstrate the properties of CLL as a clonal disease within 
which clonal evolution occurs as a key feature of disease progression. The 
awareness of the existence of clones in CLL has been present for some time 
however until recently, the significance of the existence of disease clones was 
not clear. Features of CLL which make it amenable for study of clonal evolution 
include the relative slow-growing nature of the malignant cell population and as 
any changes may progress slowly over time. Therefore there is a greater chance 
of capturing a cross-section of the clonal populations when the disease is 
undertaking population shifts. Furthermore, the relative ease of sampling 
patients with CLL means that aliquots of blood may be sampled and stored for 
later analysis at disease progression. At stages of progression, novel genetic 
changes may be searched for within historical serial samples to identify their 
presence at very low levels.  
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Given the limitations of FISH evaluation in detection of somatic mutations in 
CLL, whole exome sequencing was used on 160 CLL cases and normal pairs; the 
CLL samples were selected to reflect the range of clinical features that occur in 
CLL  (312). Twenty putative CLL cancer genes were detected at an increased 
rate with 9 (in bold) potential CLL driver mutations: TP53, ATM, MYD88, SF3B1, 
NOTCH1, DDX3X, ZMYM3, FBXW7, XPO1, CHD2, POT1, NRAS, KRAS, BCOR, EGR2, 
MED12, RIPK1, SAMHD1, ITPKB, HIST1H1E. There were also 5 cytogenetic 
aberrations implicated in the cohort studied each of which are well-established 
contributors to CLL biology; deletions of 8p, 11q, 13q and 17p were found in 
addition to trisomy 12. All mutations or cytogenetic defects were found to be 
involved in a limited range of intracellular signalling pathways each of which 
play a role in CLL biology, these were DNA/ cell cycle regulation, Notch 
signalling, Wnt signalling, RNA processing/splicing and inflammatory pathways. 
Of note, increased age and UM IgVH  heavy chain status were associated with an 
increased number of subclonal mutations and the rate of such mutations 
increased with CLL therapy. Mutations were stratified by their clonal or 
subclonal status and temporal ordering of mutations was then inferred. Evolution 
patterns with chemotherapy were then studied and the negative prognostic 
influence of subclonal driver mutations was identified. These findings lay the 
basis for targeted therapies directed at subclonal driver mutations to prevent 
the expansion of such subclone, and may help to guide sequencing of available 
therapies with the knowledge of the evolutionary process of the disease (138). 
 Functional evaluation of somatic mutations contributing to 
CLL  
Recent study has focused on the role of key recurrent somatic mutations in CLL 
as we seek to understand how specific mutations lead to disease progression. As 
an example, SF3B1 is known as the catalytic core of the spliceosome and 
mutations affecting this gene independently predicts poor prognosis (138). To 
improve understanding of the contribution of SF3B1 to CLL development and 
progression, investigative strategies were employed to integrate transcriptome 
and functional analysis; gene set enrichment analysis identified multiple CLL 
pathways as being affected by mutation of SF3B1 and downstream signal 
alterations (313). Notch pathway activation was discovered in association with 
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mutation of SF3B1 by the study of overexpression of wild-type and mutated 
SF3B1 in multiple isogenic cell lines.  
Notch signalling has been implicated in CLL cell migration and survival and is 
constitutively activated in the pathogenic process (116, 118). It was also 
discovered that subtle changes in DNA telomerase and in-frame deletion in DVL2 
is associated with SF3B1 mutation and can inhibit Notch signalling in vivo. DVL2 
is a Dishevelled protein family member; such proteins are implicated in the Wnt 
signalling pathway and are upregulated in multiple malignant diseases (73). 
Altered DVL2 is present in CLL with associated mutation of SF3B1 and it 
modulates the Notch signalling pathway but does not appear to affect Wnt 
signalling in progressive CLL. Furthermore, study of activating coding and non-
coding mutations in CLL have led to the conclusion that somatic mutations are 
only one mechanism of genetic alteration in CLL and a range of changes occur 
including subclonal somatic copy number alterations and subclonal somatic 
single nucleotide variations, epigenetic changes, miRNAs and non-coding region 
affecting splice variants (313, 314). 
Further study of the role of SF3B1 in CLL was undertaken with generation of a 
mouse line with conditional expression of SF3B1-K700E mutation. The mouse 
model was generated by CD19+-cre+/+ crossed with SF3B1flox/+ mice and produced 
equivalent levels of protein between wild-type and mutant mice. The model 
gave evidence of oncogene-induced cellular senescence with SF3B1-K700E and a 
PCR array revealed 84 cellular senescence-associated genes. All such genes were 
upregulated in the mutant B cells, and 18 demonstrated a significant increase in 
expression. Of note, there was no evidence of leukaemia by B cell profiling over 
a 1 month period in the studied mice to aid with the conclusion that SF3B1 is 
predominantly a subclonal event, however cellular senescence appeared to be 
overturned in the mice with the combination of monoclonal B220+CD5+ cell 
infiltration in BM and spleen (313). Other work on CLL genetics has been 
conducted to address how somatic mutations contribute to natural progression 
of CLL, with a particular focus on genetic features of CLL with a poor prognostic 
phenotype. Based upon the described findings we appear to be moving towards a 
more comprehensive understanding of the genetic characteristics of CLL and are 
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now shifting focus to a review of somatic mutations to identify their critical 
oncogenic effects to determine the risk of individual defects (313). 
 Complex karyotype as a negative prognostic marker in CLL 
Genomic complexity has been discovered as an independent predictor of a 
negative prognosis in CLL. Complex karyotype in CLL has been defined as the 
presence of 3 or more karyotypic abnormalities (315). Studies with venetoclax 
have demonstrated a poorer PFS in patients harbouring a complex karyotype and 
was an indicator of progressive disease (316).  A complication of the study of 
genomic complexity has been a lack of standardisation of methods for its 
evaluation. Some studies employ lipopolysaccharide-stimulated metaphase 
cytogenetic analysis whereas others use multiple interphase FISH probes with 
whole genome array and whole genome sequencing are also in use. A recent 
study assessed the role of complex karyotype with a focus on FISH and 
lipopolysaccharide-stimulated metaphase cytogenetic analysis which found there 
to be a significant failure rate of the analysis (317). Also, complex karyotype was 
predictive of a negative prognosis independently of 17p deletion. Further studies 
to integrate different methods of chromosomal analysis with each with greater 
numbers of patients may provide a consensus on the role of genomic complexity 
to inform clinical decision-making.  
6.4 BCR signalling inhibitors and other novel therapies: 
clinical trial data updated 
 BTK inhibitors in clinical trial 
There has been a plethora of clinical trials undertaken to explore the use of BTK 
inhibitors since the commencement of my project. I aim to summarise some of 
the trials which have been completed and to outline some of those still in 
operation at the time of writing. The randomised, open-label phase 3 trial, 
RESONATE-2, was initiated to explore the role of ibrutinib in treatment of the 
elderly patients (median age 73) comparing ibrutinib with chlorambucil in 
previously untreated patients with CLL or SLL (318). Ibrutinib offered superior 
responses to chlorambucil across all outcomes with median PFS on ibrutinib not 
reached as opposed to 18.9 months with chlorambucil, and 2-year OS for 
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ibrutinib was 98% compared with 85% for chlorambucil. Interestingly, ibrutinib 
outcome was unaffected by high-risk prognostic features in the cohort of 296 
patients studied, unlike chlorambucil. The HELIOS trial studied the effects of the 
addition of ibrutinib to regimens containing bendamustine and rituximab by 
randomising relapsed/refractory CLL patients to either ibrutinib and BR or 
placebo plus BR with significant benefits of ibrutinib across all progression and 
survival-based outcomes and with an MRD rate of 9% with ibrutinib as opposed to 
2% without. However, the combination of BR and ibrutinib has not been adopted 
into treatment recommendations as cross-trial comparison fails to support the 
superiority of ibrutinib and BR over ibrutinib alone (319).  
Building upon the initial safety and efficacy data (49), there are studies 
underway using acalabrutinib including a phase III study to compare 
acalabrutinib alone, acalabrutinib and obinutuzumab against chlorambucil with 
obinutuzumab in previously untreated elderly patients and those with lower 
performance status (NCT02475681). As chlorambucil and obinutuzumab is 
already a recognised treatment option for this category of patients, the 
performance of acalabrutinib alone and with obinutuzumab will be of great 
interest. There is a phase II trial to study the administration of acalabrutinib for 
those patients that are unsuitable for chemotherapy and received but were 
intolerant of ibrutinib (NCT02717611). The premise upon which acalabrutinib is 
indicated in the study population is that the relative low number of off-target 
effects in comparison with ibrutinib suggest an improved side effect profile and 
increased tolerability (320). Finally, a phase II comparison of ibrutinib and 
acalabrutinib is underway with the intext of demonstrating non-inferiority of 
acalabrutinib in the relapsed/refractory CLL patient (NCT02477696). Study 
outcomes include tolerability measures and there is potential study power to 
demonstrate superiority of acalabrutinib.  
With regard to other BTK inhibitors in current clinical trial, GS-4059 is currently 
in phase I/II studies either alone or in combinations including obinutuzumab, SYK 
inhibitors or idelalisib and early indications are that it has tolerability and 
efficacy (NCT02968563). Indeed, long-term follow up of phase I studies confirms 
the tolerability of GS-4059 (321). SNS-062 is a non-covalent inhibitor of BTK 
which offers a means of inhibiting BTK where there is a C481S mutation. This 
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second generation BTK inhibitor has progressed through phase Ia with combined 
safety and efficacy studies are underway (322). Furthermore, BGB-3111, which is 
a covalent BTK inhibitor, is being studied in phase III comparisons with ibrutinib 
to see if it offers a difference in outcomes from the first-generation BTK 
inhibitor (e.g. NCT03336333).  
Some questions remain: are there any novel agents with greater efficacy either 
alone or in combination when compared to current front-line 
chemoimmunotherapeutic options? Do second generation BTK inhibitors offer 
superior outcomes to ibrutinib in CLL and are there any agents which may 
overcome BTK resistance mutations? Also, are there any other BCR signalling 
inhibitors which offer a safe and efficacious combination with venetoclax? The 
aforementioned and following trials aim to address the outstanding clinical 
problems in CLL. 
 SYK and PI3K inhibitors in clinical trial  
Strategies to target SYK in CLL more recently have focused on an oral, selective 
SYK inhibitor known as GS-9973, or entospletinib. At the time of writing, 
entospletinib had reached phase II studies and may offered as part of a trial 
either to be administered alone or in combination with other drugs such as 
obinutuzumab or idelalisib. Published data support the tolerability and efficacy 
of entospletinib in a population of pre-treated CLL patients (323). Also, dual 
SYK/JAK inhibitors have emerged such as PRT062070 (cerdulatinib) offer dual 
targeting of BCR and IL-4 signalling pathways which was originally shown in vitro 
(324). Interestingly, there has been some success in vitro with the combination 
of cerdulatinib and ibrutinib with specific applications for cases of ibrutinib 
resistance (325). A phase I/IIa dose escalation study of the selective anti-
SYK/JAK agent cerdulatinib in CLL, SLL or NHL is currently in progress 
(NCT01994382). 
The safety and efficacy of duvelisib has now been explored with results 
indicating that duvelisib may be applied in both treatment-naïve and 
relapsed/refractory CLL/SLL populations. Targeting of both PI3Kd and g is 
efficacious and causes minimal adverse effect with only mild elevation in 
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transaminases observed (326). Therefore, duvelisib has been identified as an 
eligible candidate for phase III testing and phase II study has also commenced for 
duvelisib in combination with venetoclax (NCT03534323).  
 mTOR inhibitors in clinical trial 
First-in-human studies have now been performed to show the safety and efficacy 
of AZD2014 in solid tumours (327). At the time of writing, the only active clinical 
trial including a dual mTOR inhibitor is the TORCH study for evaluation of 
AZD2014 alone and with the addition of rituximab for relapsed/refractory DLBCL 
(NCT02752204). The phase II study in DLBCL which includes 36 patients, is 
estimated to complete in April 2019.  
 CAR T cells 
Perhaps the most innovative therapy for haematological malignancies which has 
become clinically available as a treatment of CLL are chimaeric antigen receptor 
(CAR) T cells. A type of immunotherapy, known as adoptive cell transfer (ACT), 
the CAR T cell technology has been in existence for decades but has been 
refined to produce a greater and more sustainable yield of modified T cells for 
application in haematological disease.  
Comprising 3 generations of molecular design, first generation CAR T cells only 
possessed an extracellular domain which generally takes the form of an antigen 
recognition molecule from the T cell receptor (TCR) or a cell surface receptor 
ligand directed at targets such as CD19. The intracellular component of the first 
generation molecules was merely an intracellular component of the 
CD3 molecule. Later versions of the molecule possess co-stimulatory domains 
including molecules such as CD28, CD134 and/or CD137 to provide the signal for 
T cell activation. Phase I/II trials show responses of 50 – 90 % overall responses in 
B cell malignancies which have not responded to standard therapies, with a 
curative outcome in some cases studied. The therapeutic approach requires 
harvest of the patient’s T cells for adoptive transfer of the CAR construct. 
Thereafter, cells are expanded in vitro which takes a period of around 4 weeks, 
which may limit its utility in acute leukaemias but poses less difficulty for 
chronic malignancies such as CLL. Issues which may limit its therapeutic 
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application in CLL including the cytokine-release syndrome, which may be 
related to specific construct- or conditioning-related issues. Other complications 
may include B cell aplasia in the case of anti-CD19 CAR T cells, antigen-shedding 
of target cells which may be addressed by dual targeting of malignant cell-
associated antigens and insertional mutagenesis originating from the viral 
vectors used to introduce the construct to the patients’ T cell population. An 
understanding of the frequency of complications of CAR T cells, with the 
subsequent development of technologies to manage these adverse effects, may 
enhance the utility of CAR T cells and other immunotherapies in the treatment 
of haematological malignancies such as CLL (328).  
6.5 Conclusions 
Situated downstream of BCR signalling and exhibiting upregulated activity in CLL 
pathogenesis, the mTOR signalling pathway comprises two inter-linked kinase 
complexes: mTORC1 and mTORC2 (190). Selective mTORC1 therapeutic 
strategies utilising rapalogues have elicited only modest clinical responses with 
potential limitation due to consequential upregulation of AKT signalling. 
Ibrutinib and idelalisib, inhibitors of BCR-mediated signals, elicit a peripheral 
blood lymphocytosis indicative of CLL cell redistribution from the LN and BM 
niche; a characteristic clinical effect of mTORC1 inhibitors. Dual mTORC1/2 
offers a mechanistic advantage over mTORC1 inhibition in closure of the 
mTORC1-mTORC2 negative feedback loop whilst providing an alternative means 
of BCR signal blockade. The aim of this study was to examine the functional and 
molecular impact of mTOR kinase inhibition on BCR- and chemokine-mediated 
CLL migration. Treatment with mTOR inhibitors for patients with CLL is 
supported by the data I have shown with dual mTOR inhibitor AZD8055 exhibiting 
superior efficacy of inhibition of the mTOR kinase complex over rapamycin in 
vitro. There are greater effects of AZD8055 upon CLL cell viability, upon cell 
surface markers which relate to CLL cell migration, there is more significant 
impact upon migration studies and upon downstream markers of migration 
including GTPases. Further work is required to elucidate the differential effects 
of mTOR inhibition upon colocalisation of GTPases and intracellular organelles by 
IF studies. AZD8055 offers greater depth of inhibition of the AKT signal than 
rapamycin thus from my work and that of others in vitro it may be supposed that 
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the effects of AZD8055 to target these molecules and signals in vivo would also 
be greater. The study of the effects of AZD8055 and its clinical analogue, 
AZD2014, are underway in vivo using the mouse model developed in our 
laboratory.  
With a view to potential clinical uses for AZD2014, parallels may be drawn from 
in vitro data for solid tumours and their outcomes. Activity of the dual mTOR 
kinase inhibitor against ovarian cancer and breast cancer has been shown to 
overcome resistance mechanisms in disease models to paclitaxel or hormone 
therapy (329, 330). Studies such as these suggest putative roles for mTOR 
inhibition in targeting disease resistance to other agents or in targeting of 
multiple pathways simultaneously, so as to reduce “escape mechanisms” for the 
pro-survival signals that facilitate CLL progression, such as in the studies of 
cerdulatinib in combination with ibrutinib, for example (325).  
One study which explored the combination of AZD2014 with BCL-2 inhibition by a 
small molecule inhibitor (ABT-737) demonstrated efficacy in combination against 
head and neck squamous cell carcinoma (331). Findings obtained from studies 
such as these may be applied to venetoclax as it is an orally bioavailable agent 
of the same class of ABT-737. However, the study of venetoclax in the treatment 
of acute myeloid leukaemia (AML) may be of greater relevance to CLL 
therapeutics (332). Both BCL-2 and MCL-1 are implicated in AML although the 
only available specific inhibitors are directed at BCL-2. The described study in 
AML focused on the efficacy of venetoclax in the inhibition of BCL-2 but 
demonstrated synergy with conventional chemotherapeutics. The study also 
utilised an AML xenograft model and found that selective targeting of BCL-2 and 
MCL-1 was sufficient to eliminate leukaemia from diseased mice. Therefore, the 
ability of AZD2014 and AZD8055 to inhibit MCL-1 as shown in 3.1.6 identifies the 
dual mTOR inhibitor as a potential agent for therapeutic approaches in 
combination with venetoclax (332). 
In conclusion, I show functional and molecular studies supporting mTOR 
inhibition as a strategy for attenuating downstream BCR signalling. 
Microenvironmental modelling demonstrates similarity between AZD8055 and 
ibrutinib in their effects on CLL cell viability, CXCR4 levels, targeting of mTOR 
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kinase substrates and in changes in transwell migration with the addition of BCR. 
As ibrutinib targets upstream of mTOR activation, AZD8055 may circumvent the 
emerging resistance mutational changes in BTK or PLCg that render ibrutinib 
ineffective in CLL (333, 334).  
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